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Chapter 1
Introduction
Metabolism is one of the key cellular processes that enable life. The metabolic
machinery involves thousands of chemical reactions, enzymes, genes and other
cellular compounds. Seemingly tiny -inborn- errors in this complex machinery
are known to give rise to severe diseases. The complexity of metabolism and
its inseparable relationship with life and disease make it a highly interesting re-
search area. Moreover, it is a broad area. Topics range from more fundamental
studies of metabolic evolution in model organisms on one side, to applied stud-
ies that ultimately focus on curing a particular metabolic disease in humans on
the other side.
Metabolism consists of a cascade of chemical reactions, known as pathways,
in which metabolites are converted into intermediate compounds. In the end,
this process provides the building blocks and the energy for a cell to function,
grow and reproduce. Metabolic reactions rarely occur spontaneously, but re-
quire enzymes to catalyze the reactions. These enzymes are proteins or protein
complexes which are encoded by our genes. Metabolites produced by one re-
action are typically consumed by other reactions. Therefore, metabolism can be
viewed as a network of metabolites that are connected by reactions, and these
reactions in turn are connected to enzymes and genes. A considerable part of
this thesis focuses on computational methods applied to these network models
of metabolism. Figure 1.1b shows a simplified example of a metabolic network
of 7 metabolites connected by 10 reactions.
Some pathways, such as glycolysis and the citric acid cycle have been discov-
ered and unraveled starting halfway the 19th century. They are now classic text-
book biochemistry pathways [154]. However, the development of whole-genome
sequencing techniques in the mid-1990s and the ongoing developments in high-
throughput genetic data acquisition and processing greatly accelerated the dis-
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Figure 1.1: A toy metabolic network and basic computational analysis. a) The
metabolic reaction B + C → 3E (labeled V4) is catalyzed by the enzyme EZ.
This enzyme requires two proteins, encoded by the genes G1 and G2. b) Often,
a metabolite is produced by one reaction and consumed by another, which de-
termines a metabolic reaction network. Nutrients are taken up by the cell (v1,
v2 and v5) for cellular maintenance and growth. Metabolites are also secreted to
the environment (v5). c) This network can be described by a matrix (S) in which
the number of metabolites produced and consumed by each reaction is depicted
(the stoichiometric coefficients). For example reaction V4 requires 1 molecule of
B and 1 of C to produce 3 molecules of D. Assuming a steady-state and bound-
ing the reaction fluxes constrains the feasible flux paths. d) Still, many flux
paths satisfy these constraints. Together, they determine the steady-state solu-
tion space. Flux paths that optimize a biological objective (e.g. maximize growth
or ATP production) can be found by linear programming (green dots). Only spe-
cific flux paths lead to this optimum and therefore this approach narrows the
range of feasible flux paths. Another possibility is sampling the solution space
(red dots) to obtain the ‘most likely’ flux paths.
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covery of novel metabolic genes and enzymes. This enabled the genome-scale
reconstruction of metabolic networks for many organisms, ranging from the bac-
terium Escherichia coli [58] to humans [50, 218]. Nowadays, detailed metabolic
networks [196] and protocols for their reconstruction based on scientific liter-
ature and experimental high-throughput data exist [59, 217, 90]. Importantly,
these network reconstructions provide a biochemically, genetically and genomi-
cally (BIGG) sound model [176, 161]. Moreover, they provide a solid computa-
tional framework that combines network optimization and (omics) data integra-
tion to generate and validate new biological hypotheses.
1.1 The purpose of (metabolic) modeling
Why go through the effort of building models? To better understand the purpose
of models, their advantages and possible applications, I will briefly introduce the
discipline called ‘systems biology’, to which metabolic modeling belongs.
1.1.1 Modeling in systems biology
Without providing a formal definition, systems biology pursues to understand
biological systems by building models of it. A model aims to mimic the system
under study and allows us to make predictions or formulate hypotheses that can
be verified with experiments. Ideally, correct model simulation and predictions
indicate a good understanding of (that part of) the system. In contrast, false
predictions indicate wrong assumptions, a lack of knowledge, modeling errors
or other mistakes. These new insights are used to adapt the model, run new
simulations and predictions until we understand how the system works. Im-
portantly, good models not only capture the biological data observed, but also
correctly predict new relations that could be inferred from the model, but have
not explicitly been used for its construction. In addition, the model can be used
to zoom in to the system in order to obtain a deeper level of understanding.
Another option is to use the model to make predictions in similar organisms
or systems, or connect the model of the studied biological system to those of
related biological (sub)systems.
What is a biological system?
What makes something a system? Well known examples are a computer system,
a car engine or a television. Without providing a formal definition, three things
are required for a functioning system: an input, an output and something that
processes the input and produces the output. In the systems above, an input
3
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can be a key stroke, button push on the remote control or stepping on the gas
pedal. The output is a letter on the screen, a switch of television channel or
an accelerating car. For most purposes, we don’t care about how the system
works; to us it is just a black box. However, this black box processes the input
in a coordinated fashion; many smaller parts ‘cooperate’ in time and space to
process a task and finally provide the output we observe.
Biological systems work in the same basic fashion [61, 185]. For instance, the
growth medium or temperature can be changed or a gene can be knocked-out
(removed). Changing the cell’s environment mainly affects the cellular input,
whereas a gene knock-out affects the functioning of the system itself. In both
cases, the cell responds by regulating other genes and pathways, building other
enzymes and routing metabolic flux through other pathways. This may be ob-
served as a different cellular phenotype, an increased growth rate or the secre-
tion of different metabolites. Understanding why this cellular response happens
and in particular how it is realized by building models that mimic this behavior
is the aim of systems biology in general, and understanding metabolism is the
purpose of metabolic modeling in particular.
1.2 Computational models in biology
There are many modeling formalisms for biological processes [136, 61]. Which
formalism to adopt mainly depends on the process that is modeled, the purpose
of the analysis, the available data and the scope. In this thesis I mainly used
COnstrained Based Reconstructions and Analysis (COBRA) networks to model
metabolism at the genome-scale. COBRA models impose constraints on the
reaction network and are widely adopted to model metabolism at this large
scale. To put this modeling approach in context, I will briefly discuss some
other popular modeling formalisms.
Boolean networks
Boolean networks [112] model active and inactive ‘states’ and logic transitions
between those states. They are often used to model how transcription factors
regulate other genes (which themselves may be transcription factors) in gene
regulatory networks. In this way, they can model a pattern of gene activation
and repression. They do not require a lot of quantitative knowledge, but there-
fore are also largely restricted to modeling qualitative (i.e. ‘active’ vs ‘inactive’)
states.
4
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Kinetic models
In contrast, kinetic models (using differential equations) have successfully been
used to model metabolic processes on a smaller scale, but in greater detail [119,
115]. However, detailed metabolic concentrations and kinetic (enzyme) parame-
ters are also required for these models. This information is often organism- and
condition specific and typically only known for a limited set of reactions. How-
ever, rapid advances in high-throughput omics techniques allow researchers to
obtain the required parameters at an increasingly larger scale, which recently
resulted in a complete kinetic model of the human red blood cell [21]. Despite
these advances, kinetic models are currently mainly used to study the dynamics
in smaller systems. In contrast, constraint-based models study the genome-scale
capabilities of the cell, but in a steady-state. Not surprisingly, there are various
modeling formalisms in between the ‘large-scale and general’ boolean models
and ‘specific and small-scale’ kinetic models.
Petri-nets
Petri-nets consist of places, transitions and tokens. The assignment of tokens
(e.g. metabolites, proteins or genes) to places determine the state (called the
marking) of the network. Places are connected to transitions (interactions or
reactions) and together they determine the system’s behavior. Stochastic- and
colored petri nets are expansions that allow the assignment of probabilities to
(time-delayed) transitions and different values (metabolite concentration, gene
activation level) to the system. Petri nets have successfully been used to model
biological systems such as metabolic- [33, 117] and signaling networks [83, 192].
Bayesian Networks
Bayesian networks (BNs) are probabilistic graphical models in which nodes are
variables and arcs denote directed connections between variables [120]. BNs
model how nodes (e.g. metabolites, proteins or genes) affect connected nodes
using a probabilistic formalism. A BN is a popular and well-established model-
ing formalism to reason under uncertainty. Algorithms to infer networks from
experimental data have contributed to their popularity in computational biology.
An often mentioned downside of the ‘classical BNs’ is that they cannot model
feedback loops, which are common in biological systems such as signaling-,
transcription- and metabolic pathways.
5
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Constraint-based models
Metabolic models (in particular their stoichiometry) are among the most well-
defined models in computational biology. Most metabolic reactions, the en-
zymes catalyzing these reactions and the enzyme coding genes are known from
literature and high-throughput genomic experiments for a large number of or-
ganisms. Although much of this information is known, it is challenging to infer
which reactions are active under varying environmental conditions, such as nu-
trient availability, stress or pathologies. Moreover, for higher order organisms
the metabolic activity is highly dependent on the cell- and tissue type under
study. The COBRA approach aims to deal with this uncertainty by using a com-
putationally efficient, flexible and easy to interpret constraint-based formalism.
In its most general form, the COBRA model imposes two types of constraints
(eq. 1.1). First, it is assumed that the total rate at which a metabolite is produced
equals the rate at which it is consumed. Thus, this mass-balance constraint
assumes a cell to be in a pseudo steady-state, which means there is no net pro-
duction or consumption of metabolites within the cell. However, nutrients can
be taken up from the cell’s environment and metabolites can be secreted when
they are mass-, chemically- and redox balanced. The second constraint limits the
flux capacity and directionality of the reactions in the network. Briefly, this con-
straint does not allow thermodynamically infeasible flux directions and limits
the reaction rate by assuming an upper bound on the enzymatic capacity.
d~x
dt
S~v = 0
vlbj ≤ vj ≤ vubj ,∀j ∈ {1, 2, . . . , n} (1.1)
The number of metabolic molecules that are consumed and produced in
each reaction is called the reaction stoichiometry. The topology of the complete
metabolic network can therefore be defined as the so-called stoichiometric ma-
trix S, consisting of m metabolites (rows) and n reactions (columns). Metabolic
flux can be viewed as a flow or flux path of metabolites through the cell. Typi-
cally, there are (infinitely) many of such paths that satisfy the mass-balance and
flux capacity constraints. More formally, the matrix S is system ofm linear equa-
tions and n unknowns. Since there are many more reactions than metabolites
(n > m), this system is underdetermined and there is no unique (flux) solution,
but rather a convex space of feasible solutions. These concepts are illustrated in
figure 1.1.
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1.3 Biologically relevant flux paths in COBRA networks
A steady-state flux path or flux distribution is a n-dimensional point in the space
of feasible flux distributions. For many organisms, this flux space has hundreds
of dimensions and metabolic modeling pursues to find paths that are likely
to be used by the cell. Therefore, we -often implicitly- pursue to narrow the
hypervolume of this space, which boils down to either adding new constraints,
or ‘tightening’ existing ones [20, 184]. There is a great deal of computational
methods, often combined with experimental data for exactly this purpose. Most
of these methods can be characterized in three broad categories, with overlaps
between them.
1. Direct flux measurement
In theory, a reaction’s flux capacity constrains the allowable flux to its maximum
enzymatic turn-over rate vmax. In practice, this maximum is often unknown and
an arbitrary large value is chosen for many reactions. However, if the reaction
rate is actually measured, the range between the lower- and upper bound for this
reactions rate can be drastically reduced. Unfortunately, direct measurement
of metabolic reaction rates (flux) is currently only feasible for a limited set of
reactions. Most importantly, uptake and secretion rates of nutrients from the
environment are routinely measured. This is especially helpful for modeling
unicellular organisms grown on a single carbon source (e.g. glycerol or glucose)
in the laboratory that excrete a limited set of metabolites (e.g. lactate, ethanol or
acetate). Since the network is assumed to be in steady-state, measuring the major
in- and output fluxes of the cell often greatly reduces the feasible flux paths.
Measurement of intracellular fluxes is more involved and is at this moment only
possible for a small part of the metabolic network.
2. Optimization of a biological objective
A large part of the early success of COBRA models stems from growth rate pre-
dictions for unicellular organisms. The bacterium E. coli for example shows an
exponential growth rate given sufficient nutrients and faster growing bacteria
have evolutionary benefits over slower growing variants. Therefore, it is not
unreasonable to assume that this bacterium tries to maximize its growth rate
given the environmental conditions. Indeed, it has been shown in the laboratory
that E. coli cultured for many generations evolves and adapt its metabolism to-
wards a maximum growth yield in the culture medium [96, 64]. This maximum
growth yield can be predicted from the network model using linear program-
ming. This method, termed Flux Balance Analysis (FBA) [163] is one of the old-
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est and most successful examples of constraint-based modeling of metabolism.
There are many reasonable biological objectives one can think of [200], which
have successfully been tested by applying optimization techniques to metabolic
networks in recent literature.
3. Integration with genome-scale ‘omics’ data
Given the successful applications of metabolic networks in unicellular organisms
it is not surprising that people tried to adapt them to more complex, multicellu-
lar organisms, such as mice and humans. One of the major obstacles for apply-
ing COBRA models and methods to multicellular organisms is that they have no
clear global biological objective function that can easily be optimized. This objec-
tive is highly cell or tissue specific, and even then it is difficult to determine what
such an objective would be and how the objectives of different cells or tissues
are unified in one organism. One notable exception is the modeling of cancer
metabolism, where the maximum growth assumption of a cancer cell has shown
important applications [221, 204, 63]. The advent of high-throughput techniques
such as gene expression micro-arrays, RNA sequencing and mass-spectrometry
made a more data-driven approach also feasible for other cell- and tissue types.
In the last decade, a series of papers have shown successful integration of gene-,
protein- and metabolite data with genome-scale models [135]. Most are driven
by the same basic assumption: genes that are not expressed do not encode pro-
teins (and thus enzymes) and therefore the reactions catalyzed by these enzymes
cannot be active. In contrast, the proteins and enzymes can be present for ex-
pressed genes. Given that a cell dedicates energy to express the genes, it is likely
that it requires the enzymes to be active and therefore most of these metabolic
reactions should be active. Global optimization techniques that maximize flux
through ‘active’ reactions and minimize flux through ‘inactive’ reactions aim to
fit the metabolic state of the cell to the observed data. A similar rationale can be
applied to the metabolites [199]. Although the relation between gene-expression
and flux is not as straightforward as described here, these methods have been
successfully applied to various cell- and tissue types in different organisms.
1.3.1 Applications of metabolic modeling
How can computational models help to address questions about metabolism?
There are many types of computational models used in biology [136] (see sec-
tion 1.2) and many biological processes and systems that can be better under-
stood by modeling them [61]. In this part, I will constrain myself to applications
of constraint-based models of metabolism; the main modeling formalism used
8
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in this thesis.
Bio-engineering COBRA tools have been developed that can pinpoint genes
that should be over-expressed or knocked out in order to increase the yield of
valuable byproducts [155, 116, 213]. These techniques have been applied for
instance in E. coli to increase the yield of succinate [181], lycopene [5], polyatic
acid, lactic acid and the antibiotic actinorhodi [65]. In yeast, metabolic network
models have been used to optimize the production of vanillin [25] and biofuels
such as ethanol [82].
Cancer and other human diseases Metabolic models provided systematic in-
sights into the phenomenon known as the Warburg effect [72, 225, 225, 204],
which is frequently observed in cancer cells. Otto Warburg [229] showed that
cancer cells often favor the use of glycolysis and fermentation pathways rather
than the oxidative pathways that are used in normal cells, even when suffi-
cient oxygen is present. This seems strange, because oxidation provides a much
higher energy yield than fermentation pathways. One hypothesis for this phe-
nomenon is that although the yield is lower, the total production rate can be
higher given a nutrient surplus [221]. Another explanation might be that cancer
cells try to avoid oxidation, because it is related to programmed cell death [221].
Gene expression data has been mapped to human metabolic models, to eluci-
date the pathways that are active in certain cancer cells [103, 101]. By combin-
ing these cancer specific models with optimization algorithms, potential drug
targets could be found that significantly lower the fitness of cancer cells [63].
Metabolic models have been used to predict ‘anti-metabolites’; anti-growth fac-
tors that target metabolites required for cancer cell survival and proliferation [76,
2]. Many more examples exist, where (metabolic) modeling is used to obtain a
better understanding of the complexes processes in cancer, or to guide anti-
cancer drug design [63, 204, 238, 240]. Beyond cancer, metabolic models have
also been used to gain insights in liver disease [141], obesity and diabetes [222]
to name just a few.
Other Another application of metabolic networks is to address evolutionary
questions [96, 239, 166, 167]. Pa´l et al. simulated adaptive evolution of en-
dosymbionts from a common ancestor, by first constraining the uptake medium
to match that of the natural environment of the endosymbiont. Then, evolution
was simulated by computing the impact of randomly selected gene losses on the
organism’s fitness. Genes that did not significantly contribute to the organisms
fitness were iteratively removed in this random fashion, until a minimal set of
essential genes was obtained. Indeed, this predicted minimal set of metabolic
9
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genes had high overlap with the actual set of metabolic genes of these organ-
isms. This shows that genomic evolution can be predicted by simulation on
a metabolic network, using only knowledge of a species ancestor and its nat-
ural environment. Furthermore, it was shown that the minimal gene set not
only depends on the simulated environment, but to a large extent on chance
(i.e. the order and random choice of alternative gene deletions). This explains
why closely related endosymbionts may possess substantially different minimal
metabolic gene sets.
Another study [96] showed that E. coli does not grow at the optimal growth
rate predicted by FBA, on every carbon source. However, after growing E. coli
for 700 generations, its metabolism was adapted to this carbon source, and the
in vivo growth rate closely matched the optimum predicted by FBA.
Two recent studies [158, 80] showed that the metabolic network of E. coli
contains a large number of so called underground reactions or pathways. These
metabolic reactions are not active when the organism grows in its natural envi-
ronment, but can be active when they provide a marked fitness advantage. This
fitness advantage was realized by introducing gene knock-outs [80] or growing
E. coli in a large number of different nutrient sources [158], such that the net-
work of underground reactions could be studied. These studies showed that,
first, adaptive evolution can be explained by the existence of a network of latent
metabolic reactions. Furthermore, knowledge of the network of underground
reactions can be utilized in bioengineering, in order to optimize strains for the
production of valuable metabolites.
Metabolic models for plants have more recently become available. One of
the first metabolic reconstructions in plants was that of the model organism
Arabidopsis thaliana, but models for crops like sugarcane and maize are also avail-
able [174, 149, 162]. Many of the modeling principles and lessons learned from
microbial metabolic modeling have successfully been applied to plants and al-
ready contributed to the understanding of their metabolism. It is highly likely
that such models will have important applications, for instance in understand-
ing plant diseases, increasing yield or engineering of crops that are better suited
to grow in dry environments.
One of the important ‘applications’ of metabolic models, is that they allow
the systematic integration of high-throughput data, such as gene- and protein
expression. Why are certain metabolic genes co-expressed? Which reactions
-and genes- are coupled? How are they regulated? Metabolic modeling can as-
sist in answering these questions. Moreover, models of various related cellular
systems become increasingly more integrated to answer more complex ques-
tions.
10
1.4. Genetic interactions within and beyond metabolism
1.4 Genetic interactions within and beyond metabolism
Metabolic networks provide an integrated view on the functional dependencies
between metabolic enzymes, genes, reactions and metabolites. One particularly
interesting feature of such a model is that perturbations to any of these compo-
nents can be simulated to predict their effect on other components. This idea has
been widely used, for instance in metabolic engineering of bacteria. From the
network, an optimal set of perturbations (e.g. gene deletions) can be computed
in order to maximize the production of valuable byproducts in bacterial meta-
bolism [236, 27]. Another valuable application is the computational discovery
of metabolic vulnerabilities in disease networks. For instance, essential genes
have successfully been discovered in the malaria causing protozoan Plasmodium
falciparum [54], which make them interesting potential drug targets. Metabolic
targets that disrupt tumor metabolism have been identified using a similar ap-
proach, applied to various cancer cell lines [63].
Metabolic networks have a highly robust architecture and are relatively ro-
bust to many single gene deletions. Moreover, important vulnerabilities are not
always visible by using only simple flux simulation on the metabolic network.
By combining the metabolic network topology with genome evolution, Lu et
al. [131] identified a predictive pattern in converging metabolic pathways. It
was shown that the genes involved in the protein complexes of two converging
metabolic pathways (a ‘fan-in motif’) often have a negative genomic interac-
tion. In particular, genomic evolution showed that in this fan-in motif, one of
the two converging reactions was often not active, because the enzyme-coding
genes were not expressed. It was shown that this information can be exploited
in cancer cells, by identifying target genes in the protein complex of the other
converging reaction. Interestingly, this pattern generalized to protein interac-
tions derived from genome evolution beyond the scope of metabolism. The
second part of this thesis focuses on such genetic interactions, either derived
from a computational model, or inferred from genome-wide copy number and
transcription data.
Chapter 4 describes genetic interactions in metabolism that can possibly be
leveraged to target tumor cells. These interactions are derived from a computa-
tional model of metabolism and therefore genetic interactions unrelated to me-
tabolism cannot be detected. Ideally, one would combine computational models
and genome-scale data of these other cellular processes to discover important ge-
netic interactions beyond metabolism. Indeed, computational models for other
cellular processes such as transcription regulation, cell signaling or the cell cycle
exist. However, they are often highly cell- or tissue specific or span a limited
number of genes. Moreover, mapping large-scale genomics data on these mod-
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els is often non-trivial, for example because data needs to be discretized such as
the boolean models described above. Other models, such as kinetic models can
be detailed, but also highly specific to the process and conditions they model.
Therefore, such models often do not generalize well to other conditions, making
them less suitable for integration with other data. Therefore, rather than using a
computational model, functional interactions are directly inferred from the data
in the fifth and sixth chapter of this thesis. A major advantage of this approach
is that it is not limited to any particular domain captured by a computational
model. The major disadvantage is that interactions are derived from a statisti-
cal model, which indicates that a relationship between two genes exists, but in
most cases does not provide a systematic framework that explains why such a
relationship exists.
In chapter 5, we look at genome-wide genetic interactions in humans, with
a special interest in interactions targeting cancer cells. Important concepts for
chapter four and five are the Synthetic Dosage Lethality (SDL, Fig 1.2c) and Syn-
thetic Lethality (SL, Fig 1.2b) respectively. Both concepts indicate an interaction
between two genes that is lethal or detrimental to the cell. A SL is a combined
knock-out of two genes that is lethal to the cell, whereas a single knock-out
is not. A SDL is an interaction that requires one gene to be repressed and the
other one to be (over)active. SLs and SDLs can be derived from a network model
(chapter 4) or inferred from data such as gene-expression data sets (chapter 5).
A last concept explored in this thesis is that of gene co-regulation. Often,
tens or hundreds of proteins are involved in the functioning of a molecular
system or biological pathway. For the system to function, these proteins need
to be present at the same time. Therefore, their genes are regulated in a similar
fashion (co-expression, or co-regulation). Co-regulation can often be observed as
genes with a similar gene-expression pattern in micro-array or RNA-sequencing
data. If a sufficient number of genes that co-regulate in a molecular system are
already identified, novel genes can be predicted from gene-expression data sets.
This is the topic of chapter 6.
1.5 Outline of the thesis
Chapters 2-4 of this thesis are about constraint-based modeling of metabolism.
Imposing the constraints in eq. 1.1 results in a space of feasible flux distributions,
as illustrated in Fig. 1.1d. Chapter 2 and 3 respectively deal with the character-
ization of this space and the aim to reduce this space to the biologically most
relevant flux paths. Chapter 4 exemplifies how computational simulation can be
used to detect and prioritize cancer cell vulnerabilities.
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Figure 1.2: The concept of Synthetic (Dosage) Lethality. a) A cancer cell takes
up nutrients (v1 and v2) and directs metabolic flux to cell growth. b) SL: A
knock-out of the genes G1 and G2, which encode the enzymes catalyzing reac-
tion v7 and v8 blocks both paths required for cell growth, which kills the cell.
Note that a single knock of either gene G1 or G2 is not lethal to the cell, since
in that case not all paths to growth are blocked. c) SDL: the over-expression of
gene G2 routes the metabolic flux away from cell growth (reaction v6). On top of
that, a knock-out of G1 blocks the alternative flux path (v7 → v9) to cell growth.
Instead, the metabolite D is excreted to the environment.
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Chapter 5 and 6 are about genetic interactions (the SL) and co-regulation and
are not limited to metabolism. In chapter 5, a method is described that finds SL
patterns from a large set of genomic data and combines it in an automated
method to select the most promising novel SL candidates. Chapter 6 is about
a webtool that crawls a large amount of gene-expression micro-arrays to find
genes that belong to any molecular system of interest. A short introduction of
every chapter is given in the following paragraphs.
In chapter 2, an improved sampling tool is introduced that samples feasible
flux distributions (n-dimensional points) from this space. By taking samples
from the so called steady-state solution space one can -to some extent- determine
which flux paths are likely and which ones are not. A big challenge is to sam-
ple points uniformly distributed over this space in reasonable time. The uniform
requirement informally states that all possible flux paths should have an equal
chance of being sampled, without biasing towards certain flux paths. As models
get larger, sampling time increases and it becomes harder to obtain uniformly
distributed samples.
Chapter 3 focuses on shrinking the large solution space, in which it is still
unknown which flux paths are utilized by the cell. For many human cells it
is unknown what their metabolic objective is, not to mention how to convert it
into a mathematical objective. Two basic ideas are used in this chapter. First, it
has been observed that organisms living in various environments do not reach
the theoretical maximum growth level, but roughly 60-90% of that. One hy-
pothesis is that a full commitment of a cell’s metabolic machinery to one energy
source greatly affects their ability to switch to other nutrient environments. In
contrast, a slightly smaller commitment largely retains their adaptability [201]
making cells much more robust to possible environmental changes. Second, this
robustness issue is exploited in an algorithm that excludes flux distributions that
severely affect an organisms robustness. Finally, it is used to prioritize experi-
mental measurements that provide maximum information about the flux paths
utilized by the cell.
Chapter 4 is an example of how metabolic networks can be applied in cancer
research. In this chapter FBA is used to find a combination of a highly active
reaction and a near inactive reaction that reduce tumor growth when combined.
These so called Synthetic Dosage Lethality (SDL) pairs were found and ordered
by their predicted degree of lethality. Comparison of the predicted SDL pairs
with gene-expression data from a large cohort of breast- and ovarian cancer
patients demonstrate the ability of the SDL algorithm to predict SDL tumor vul-
nerabilities in silico. Patients with many such SDL pairs exhibit longer cancer
survival times and decreased tumor sizes compared to other patients. Unfor-
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tunately, most patients do not express many of these SDL pairs as cancer cells
select against their expression in order to grow and proliferate.
In this study, I conceived and implemented the computational algorithm
called IDLE, ranked the SDL pairs and performed the tumor size and (cumula-
tive) survival analysis on the breast- and ovarian cancer patients.
In chapter 5, an ensemble-based classifier that predicts synthetic lethal (SL)
interactions from cancer genomic evolution data is described. Here, genome-
wide copy number variation and gene-expression data from a large number of
cancer- and healthy tissue was used. Five patterns of gene loss, co-loss and com-
pensation events were inferred from this data. These five predictive signals were
successfully combined to train a classifier that ranks interactions between pairs
of genes by their likelihood of being lethal to the cancer cell.
Identifying which genes are involved in a molecular system, pathway or
disease is important to understand its function. A number of genes are of-
ten known, but it is unknown whether that information is complete or if other
genes also play a role. The topic of chapter 6 is to identify other genes involved
in or belonging to such a system, given a set of genes known to be active in
that system (called query genes). Novel genes can be identified by observing pat-
terns of gene co-expression in a large number of gene expression micro-arrays.
However, a molecular system is usually not active in all possible cells, tissues or
conditions and therefore not all micro-arrays are equally relevant for the query
system. Micro-arrays in which many of the query genes are expressed seem to
be more important and receive more weight in the webtool than those in which
they are less expressed. This idea had already been introduced and successfully
applied before [10], but an easily accessible webtool that automated this process
was not available yet. Apart from enabling users to find novel candidate genes
that co-express with their query genes, it also contains a database of genes that
strongly co-express with annotated sets of genes. These genes are known from
literature to carry out a common molecular function, are involved in the same
biological pathway or take part in the same cellular component.
In this study, I implemented a part of the webserver and database and pre-
computed the weighted gene co-expression for the terms annotated in the Gene
Ontology, Reactome and KEGG databases. I also performed the comparative
analysis with the other co-expression webtools.
Finally, chapter 7 provides concluding remarks and discusses future perspec-
tives for (metabolic) modeling in biology. Computational models have strongly
increased in size and complexity in the last decade and probably will do so
in the next ones. The creation and validation of computational models has
greatly been facilitated by the introduction of high-throughput experimental
procedures in molecular biology. Likewise, these procedures have generated a
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wealth of data and dramatically increased the demand for computational mod-
els and algorithms that process this data and extract new knowledge to make
better predictions and generate novel hypotheses. There is a strong need for
next-generation models that integrate data from multiple biological phenomena
in order to elucidate their relations and interactions.
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Sampling the solution space of
genome-scale metabolic networks
Constraint-based models of metabolic networks are typically underdetermined, because
they contain more reactions than metabolites. Therefore the solutions to this system do
not consist of unique flux rates for each reaction, but rather a space of possible flux
rates. By uniformly sampling this space, an estimated probability distribution for each
reaction‘s flux in the network can be obtained. However, sampling a high dimensional
network is time-consuming. Furthermore, the constraints imposed on the network give
rise to an irregularly shaped solution space. Therefore more tailored, efficient sampling
methods are needed. We propose an efficient sampling algorithm (called optGpSampler),
which implements the Artificial Centering Hit-and-Run algorithm in a different manner
than the sampling algorithm implemented in the COBRA Toolbox for metabolic network
analysis, here called gpSampler. Results of extensive experiments on different genome-
scale metabolic networks show that optGpSampler is up to 40 times faster than gpSam-
pler. Application of existing convergence diagnostics on small network reconstructions
indicate that optGpSampler converges roughly ten times faster than gpSampler towards
similar sampling distributions. For networks of higher dimension (i.e. containing more
than 500 reactions), we observed significantly better convergence of optGpSampler and
a large deviation between the samples generated by the two algorithms.
This chapter is based on Megchelenbrink W.L., Huynen M.A. and Marchiori E. (2014),
OptGpSampler: An improved tool for uniformly sampling the solution-space of genome-scale metabolic net-
works, published in PLOS ONE. Supplementary material is online available at PLOS ONE.
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2.1 Introduction
Modeling metabolic networks helps to unravel the complex machinery of meta-
bolism within the cell. A classic approach is to model the reaction pathways in
a dynamic fashion, using detailed kinetic data. For genome-scale models, often
involving hundreds or thousands of reactions and metabolites, it is experimen-
tally prohibitive to obtain the kinetic parameters involved. A constraint based
approach has successfully been applied to model and address a wide range of
biological questions in the absence of detailed kinetic data [111, 180]. By using
a steady-state assumption, a first type of constraint dictates that all metabolite
concentrations stay constant over time (mass-balance). A second type of con-
straint limits the flux rate for each reaction (flux-capacity and directionality).
The relation between themmetabolites and n reactions is described in them×n
stoichiometric matrix S. A positive stoichiometric coefficient Si,j means that
the metabolite i is produced by reaction j and a negative entry indicates that
the metabolite is consumed in that reaction. At steady-state, the mass balance
and flux capacity constraints can be formulated as in eq. (2.1) and ineq (2.2)
respectively.
d~x
dt
= S~v = 0 (2.1)
vj,min ≤ vj ≤ vj,max,∀j ∈ {1, 2, . . . , n} (2.2)
where ~x and ~v are vectors of metabolite concentrations and flux rates respec-
tively. Each flux rate vj is bounded by ineq. (2.2). Although in some cases
the bounds are known from experiments, for most reactions this is not the case
and arbitrarily large values are used. Since the matrix S is a system of linear
equations, the constraints in eq. (2.1) and ineq. (2.2) form a bounded convex
space [178], containing all possible values of ~v. A major challenge is to charac-
terize the biologically interesting flux distributions among all alternatives. Since
the stoichiometric matrix is fixed, the remaining possibility is to add additional
constraints or tighten the inequality bounds in ineq. (2.2). This can be done by
incorporating measured flux data, which is often laborious, expensive or diffi-
cult to obtain, even for a small subset of all reactions.
Many constraint-based methods have been proposed to find flux distribu-
tions that are of biological interest. A successful approach is Flux Balance Ana-
lysis (FBA) [224], which introduces a biologically relevant objective function and
uses linear programming to find a flux distribution that optimizes this objective.
FBA proved to be especially useful for cell types with a well-defined objective
function, such as maximum growth for unicellular species. Although FBA has
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successfully been applied to determine possible phenotypes and byproduct se-
cretion in various experimental settings, it is often unable to determine the un-
derlying (internal) flux states [211]. Furthermore, for many objective functions,
a wide range of alternative optima exists [138]. In order to obtain an estimated
probability distribution of attainable flux values for each reaction in the net-
work, methods based on uniform sampling are used. A fast algorithm for this
task is called hit-and-run (HR) [206]. HR collects samples by iteratively choos-
ing a random direction and a random step size in that direction such that the
next point also resides in the solution space. For the irregularly shaped solution
spaces of metabolic networks the Artificial Centering Hit-and-Run (ACHR) al-
gorithm [113] is better suited, because it is tailored to sample in the elongated
directions of the solution space. Partly based on ACHR, the uniform random
sampling procedure known as gpSampler is often used to sample metabolic
networks and implemented in the COnstrained Based Reconstruction and Ana-
lysis (COBRA) Toolbox [195]. Although these algorithms are often referred to as
uniform random samplers, their convergence behavior in the context of genome-
scale metabolic networks has not yet been thoroughly investigated. Besides its
irregular shape, the solution space of genome-scale metabolic networks are of-
ten high-dimensional, containing hundreds to almost a thousand dimensions as
in the human metabolic network reconstruction. Therefore in this paper we in-
vestigate uniform random sampling in the context of metabolic networks. Our
contributions are threefold: (1) we introduce an efficient and effective random
sampling algorithm, which combines the advantages of ACHR and gpSampler;
(2) we propose a new measure to quantify the deviation between samples ob-
tained from two independent sampling runs; (3) we perform a thorough analysis
on five metabolic network models.
2.2 Methods
2.2.1 Uniform random sampling
One of the first attempts to sample the flux states in a metabolic network used
a rejection sampling technique [230]. In rejection sampling, the space of interest
is enclosed by a regular shape, such as a parallelepiped. Samples are drawn
from the uniform distribution over the parallelepiped and rejected if they violate
the constraints for the enclosed space of interest. The nice feature of rejection
sampling is that the samples are uniformly distributed over the enclosed space.
However, fitting a regular shape tightly around the space of interest is hard
and often impossible. This means that in higher dimensions, the volume of
the enclosing shape grows explosively compared to the volume of the shape of
19
Chapter 2. Sampling the solution space of genome-scale metabolic networks
interest [206]. In this case, a very large fraction of the samples have to be rejected,
making rejection sampling an inefficient method for genome-scale models.
The hit-and-run (HR) algorithm [206] mitigates this problem, because it sam-
ples directly from the solution space (figure 2.1). Hit and-run starts from a point
~x0 in the bounded space. It chooses an arbitrary direction ~u1 from the uniform
distribution on the boundary ∂B of the unit sphere in Rn . The distance from
~x0 to the boundary of the solution space in the direction of ~u1 determines the
maximum distance it can travel. An arbitrary step size λ1 is selected in the (neg-
ative) direction of ~u1, such that the sampler does not step out of the constrained
space. The next point ~x2 is determined by traveling distance λ1 in the direction
~u1. By iterating this process, HR generates a chain of consecutive sample points.
The fact that HR uses only the current point to obtain the next sample makes
it a Markov Chain Monte Carlo (MCMC) method [77], which has been shown
to converge towards the target distribution (uniform in our setting). In general,
the constraints in metabolic network models lead to a convex space of irregular
shape, which is elongated for reactions whose flux rates are loosely constrained,
and is narrow for tightly constrained fluxes. A consequence of this phenomenon
is that many sample points are close to the boundary of the solution space. Since
HR chooses a direction ~ui uniformly from all possible directions, this enforces
the sampler to perform small steps, so the next generated point is close to the
previous one. In practice this prevents the sampler to fully explore the rest of the
solution space. ACHR [113] alleviates the problem of getting trapped in regions
close to the boundary because it tries to sample in the elongated directions, thus
making larger steps possible. It iteratively generates samples by using an ‘arti-
ficial’ center of the space, which is empirically estimated at each iteration using
the points sampled so far. ACHR consists of two phases: warm-up and (main)
sampling. In the warm-up phase an arbitrary initial point ~x0 in the solution
space is selected to generate a chain {~x0, ~x0, . . . , ~xW } of W ≥ n points. The
requirement W ≥ n ensures that after the warm-up phase, the set of directions
spans ∂B with probability one [113]. Then the main sampling phase starts from
~xW . By iteratively updating the empirical center and by using a direction from
a randomly chosen previous sampled point to this center, ACHR explores elon-
gated directions of the space. Figure 2.2a illustrates the warm-up and the main
sampling phase of ACHR.
The sequence of ACHR iterates is not a Markov chain, due to the dependence
of directions on prior iterates. Thus the sequence of iterates is not guaranteed
to converge to a uniform distribution [113]. ACHR is at the core of gpSam-
pler [195], a popular sampling algorithm for metabolic network analysis. Figure
2b illustrates how gpSampler works. The highly irregular shape of the solution
space of metabolic networks makes a uniform direction choice on ∂B a poor
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Figure 2.1: Illustration of Hit-and run (HR) sampling. HR starts at the point
~x0 in the solution space S. It chooses a random direction ~u1 and determines
the maximum distance it can travel forwards or backwards in that direction. A
random step size is chosen on the line ~u1 ∈ S. The next point ~x1 is obtained by
traveling λ1 in the direction ~u1. By iterating this process T times, samples are
obtained that are uniformly distributed in the space, when T →∞
choice. Therefore, in order to generate a number of T samples, gpSampler’s
warm-up phase uses linear programming in a two parts procedure. In part (1)
2n warm-up points are generated by consecutively minimizing and maximiz-
ing the flux rate of each reaction. In part (2) the remaining T − 2n warm-up
points are generated by assigning random weights to the fluxes that should
be optimized. The optimal solutions (and thus the warm-up points) for a lin-
ear program reside on the boundary of the constrained space [233]. Often, this
causes the allowed step sizes to become very small, which makes it hard to move
away from the boundary. Therefore, gpSampler uses a linear transformation to
‘pull’ the warm-up points more into the interior of the solution space. Then,
each moved warm-up point is used in the main sampling phase to generate T
separate chains of length k. The user provided step count parameter k deter-
mines the number of ACHR iterates between the starting point ~xW and the end
point ~xW+k of each chain. Finally, the T end points of the chains are returned
as samples.
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C
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Figure 2.2: Conceptual difference between (a) ACHR, (b) gpSampler and (c)
optGpSampler. Warm-up points are depicted as gray rectangles, samples that
are stored as gray circles. Uncolored circles denote points that are visited by
the sampler, but are not stored as a sample. a) The original ACHR algorithm
starts at a point ~x0 and iteratively moves to a next point ~xi = ~xi−1 + λi~ui. One
chain is used, with step count k=1. The chain contains W warm-up points and
T samples. b) GpSampler uses the linear programming procedure described
in the main text to find T warm-up points. Then, each of the warm-up points
is iteratively moved in the space in the same fashion as the ACHR algorithm
in (a), leading to T sampling chains. Each chain of length k returns its end
point as a sample. c) OptGpSampler obtains 2n warm-up points. For each of
the p processors used, a warm-up point is chosen randomly as the initial point
~xj0, with j ∈ {1, 2, . . . , p}. Starting from the warm-up points, new points are
found in the same fashion as for the ACHR algorithm in (a), but now only every
kth point is kept as a sample. Again, the result is T sample points, but now
these have traveled k up to kT/p steps from a warm-up point. Compared to
gpSampler, it uses less but much longer sampling chains.
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2.2.2 optGpSampler: an improved sampling tool for metabolic
networks
We propose to combine a part of the warm-up phase of gpSampler and ACHR.
The resulting algorithm is called optGpSampler (algorithm 1). First, 2n warm-
up points are generated using part (1) of gpSampler’s warm-up procedure by
successively minimizing and maximizing the flux through each reaction. We do
not generate T warm-up points as in gpSampler because running a linear pro-
gram on a large network is much more time-consuming than random sampling.
Moreover, although the weight vector for the linear program is randomly cho-
sen, the constraints in eq. (2.1) and ineq. (2.2) often lead to the same or a similar
optimal solution. This could bias the starting points and directions choice of our
sampler.
The sampling phase of optGpSampler is similar to that of ACHR (figure 2.2c),
but only selects a sample at each k iterates. Furthermore, instead of generating
one chain of consecutive sample points, optGpSampler exploits p processors and
generates p chains in parallel. In practice, the desired number of sample points
T is much larger than the number of available processors p. This makes the
length of the chains generated by optGpSampler a factor of T/p longer than
those generated by gpSampler. We implemented optGpSampler in C++ and
used Armadillo [194], a fast linear algebra library. OpenMP [19] was utilized
to start a separate chain on p processor cores in parallel. Interfaces for Matlab
and Python enable users to easily sample existing models with optGpSampler
or integrate our sampler in new methods.
2.3 Experiments
2.3.1 Datasets
We benchmarked gpSampler and optGpSampler on five publicly available re-
constructions of genome-scale metabolic networks [196]. All reactions and as-
sociated metabolites that could not carry a flux were removed from the models
prior to the sampling. The network size remaining after this preprocessing step,
i.e. the number of m metabolites and n reactions is given between brackets. In
ascending size order, we used E. coli central metabolism (68, 87), C. thermocellum
iSR432 (288, 351), S. cerevisiae iND750 (479, 631), E. coli iAF1260 (1032, 1532) and
H. sapiens recon 1 (1587, 2469).
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2.3.2 Evaluation
We assessed efficiency and quality metrics of gpSampler and optGpSampler.
Efficiency was measured as the algorithms runtime (single core). Quality per-
formance in our context amounts to measure the capability of a sampler to ef-
fectively generate points uniformly distributed in the solution space. Since both
gpSampler and optGpSampler have no theoretical convergence guarantees, we
use two methods: empirical convergence diagnostics and a new method called
xy-deviation.
Empirical convergence diagnostics
Empirical convergence diagnostics are used to test whether the sampled distri-
bution converges towards a stationary one. There is not always good agree-
ment between different convergence diagnostic methods [39]. Therefore we
use the following three convergence diagnostics tests: Gelman and Rubin [74],
Geweke [75] and Heidelberger and Welch (HW) [88]. They are available in the
Convergence Diagnosis and Output Analysis (CODA) toolbox for MCMC [172].
The Gelman and Rubin test is multivariate: it returns a so called R value (with
R ≥ 1.0). R values smaller than 1.2 indicate convergence, with values closer to
1.0 indicating better results. The other two tests are univariate. The Geweke test
returns a z-value for each reaction, with lower values indicating better conver-
gence. The HW test returns whether a sample distribution for a given reaction
converged (value=1) or not (value=0).
xy-deviation
In general, a larger step count provides a sample distribution that is closer to the
target distribution, at the expense of a longer runtime. Therefore, we introduce a
measure called xy-deviation that quantifies how samples generated by sampler
x using a given step count k1 deviate from those generated by sampler y using
a much larger step count k2. Specifically, a small deviation indicates that the
sample distribution generated by sampler x converged empirically to the target
distribution of y. Given samplers x and y, step counts k1 and k2, with k2 very
large (k2=5000 in our experiments), the number c of runs, and the number T of
samples, xy-deviation is computed as follows:
1. Perform c runs of sampler x with step count k1, and c runs of sampler y
with step count k2, where each run generates T samples.
2. Sort the points in each run, producing c sorted chains of points for sampler
x and y: < xjb,i >,< y
j
b,i >, b ∈ {1, 2, . . . , T}, j ∈ {1, 2, . . . n}, i ∈ {1, 2, . . . , c}
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3. For each reaction j, normalize the flux rates: we divide xjb,i (resp. y
j
b,i)
by the difference between the upper and lower bounds of vj : X
j
b,i =
xjb,i
vj,max−vj,min , Y
j
b,i =
yjb,i
vj,max−vj,min , i ∈ {1, 2, . . . , c}, j ∈ {1, 2, . . . , n}, b ∈
{1, 2, . . . , T}
4. Compute the mean chain of the c runs of y:
Y¯ jb =
1
c
∑c
i=1 Y
j
b,i, j ∈ {1, 2, . . . , n}, b ∈ {1, 2, . . . , T}
5. Our assumption is that chains generated by sampler x that converge will
have small deviation from the ‘average-chain’ generated by y. For each re-
action j, we measure such deviation by computing the mean absolute devi-
ation over the chains generated by x from Y¯ jb : D
j = 1cT
∑c
i=1
∑T
b=1 ‖Xjb,i−
Y¯b‖, j ∈ {1, 2, . . . , n}. Our choice to use a mean deviation over the stan-
dard deviation is motivated by the fact that the mean deviation is more
efficient than the standard deviation in the realistic situation where some
of the measurements are in error, and more efficient for distributions other
than perfect normal [79]. Note that the range of Dj is [0,1], and can be ex-
pressed as a percentage, which makes it convenient to compare deviations
across different reactions.
6. Then the xy-deviation over c chains with respect to k1 and k2 is defined as
the average of the reaction deviations:
D¯ =
1
n
n∑
j=1
Dj (2.3)
Small values of xy-deviation indicate convergence of x to y. In the ex-
periments we analyzed self-deviation (xx-deviation) and cross-deviations
(xy-deviation).
2.4 Results
We used the gpSampler implementation in the COBRA toolbox. Results of ex-
tensive experiments are given in supplementary material. Tables S1–S5 in File S1
provide results for all the runtime experiments performed. Figures S1–S6 in File
S1 provide the results of the convergence diagnostic tests and xy-deviation. We
visualized how a small or large xy-deviation translates to a similar or (highly)
dissimilar sample distribution in figures S7–S11 in File S1.
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2.4.1 Efficiency
We sampled all networks four times using T=10, 50 and 100 thousand samples,
with step count k=50. Both gpSampler and optGpSampler were executed in par-
allel mode on an AMD desktop computer using p=4 processor cores in parallel.
Efficiency results (Table 2.1), show that optGpSampler is roughly 6 to 40 times
faster than gpSampler.
2.4.2 Quality
To asses the quality of the results, we performed four independent runs with
each sampler. Each run collected T=50,000 samples and was repeated for six
different step counts; k ∈ {50, 250, 500, 1000, 2500, 5000}. We ran all convergence
diagnostics with the default settings in the CODA package. The convergence
tests results were averaged over the four runs. A univariate test for a sampler
outputs a vector of length n. Significance of the difference between gpSampler
and optGpSampler was assessed by applying the Wilcoxon signed-rank test to
the corresponding vectors. The results for the Gelman and Rubin test indicated
convergence for all experiments, in disagreement with results of the Geweke and
HW tests. The obtained chains were also used to compute the xy-deviation for
the above given step count k1, and k2=5000. All sample chains were compared
by the average of the four chains obtained at the highest step count of k=5000.
Small networks (less than 500 reactions)
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Figure 2.3: Empirical convergence for C. thermocellum iSR432. a) Conver-
gence according to the Geweke diagnostic. b) Convergence according to the
Heidelberger-Welch diagnostic. Convergence for optGpSampler is observed at
approximately 500 steps. For gpSampler, both diagnostics only agree on con-
vergence after k=5000 steps. Notice the higher HW convergence fraction of the
latter at k=50 steps and at k=5000 steps compared to the steps in between.
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Figure 2.4: xy-deviation for C. thermocellum iSR432. xy-deviation from sam-
ples obtained with sampler x at step count k1 to sampler y using k2=5000. a)
Deviation to samples obtained by y=gpSampler. b) Deviation from samples ob-
tained by y=optGpSampler. In both cases optGpSampler converges much faster
to sampler y.
On the E. coli central metabolism network, the Geweke test returned rela-
tively low z-values for both gpSampler and optGpSampler (figure S1 in File S1).
Results of the HW test indicated that optGpSampler converged rapidly, at k=50
step count. Both the Geweke and HW tests showed that gpSampler needs a step
count close to 500 to converge.
Results of xy-self-deviation demonstrate a large deviation of samples gener-
ated by gpSampler with a small step count from those generated with a higher
step count. In general, results showed that optGpSampler with a low step count
generates samples that are both close to those generated using a higher step
count with the same sampler and to those generated by gpSampler with a higher
step count. On the C. thermocellum iSR432 network the HW test showed signifi-
cantly higher convergence rates for optGpSampler (figure 2.3).
Both the Geweke and HW tests showed that optGpSampler converged at step
counts bigger than 1000. The situation for gpSampler is different: the values of
the HW test dropped at step count 250 and then increased significantly when the
step count reached 5000. This indicates two distinct points of convergence, one at
small step count values and one at large values. This behavior can be explained
by the way gpSampler collects its samples. It starts at a warm-up point and
uses k iterates of the ACHR algorithm to obtain a sample point. It repeats this
process, each time starting from a different warm-up point (figure 2.2). These
warm-up points turn out to be close to each other, as a consequence of the
linear programming procedure used. Thus gpSampler often starts the sampling
from the same area of the solutions space. In higher dimensions, a small step
count can prevent gpSampler to ‘travel’ far from the warm-up points. In this
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case the small step count causes gpSampler to show a bias towards the regions
close to the warm-up points and the sampling chain converges towards these
regions. The large xy-deviation shows that the samples collected are different
from those sampled at a higher step count (figure 2.4). The results for gpSampler
at large step count (k=5000 steps) again indicates convergence. In this case the
small xy-deviation indicates that an extended region is covered by the samples.
Since optGpSampler does not restart at a warm-up point, it is better able to
‘escape’ from the regions near the warm-up points because it effectively uses
much longer chains. Therefore, its convergence and xy-deviation results are
better.
Large networks (≥ 500 reactions)
The convergence and results for the S. cerevisiae iND750 (figure S3 in File S1)
and especially the E. coli iAF1260 network (figure 2.5) showed an even more sur-
prising result. For these larger models, the convergence results for gpSampler
declines when the step count is increased. For optGpSampler, we still observed
an increasing convergence performance for the yeast network, although a much
larger step count (k ≥ 2500) was required. The more stable results for the larger
E. coli iAF1260 network could be an effect of the minimum glucose setting of this
network, which significantly reduces the attainable flux states. The xy-deviation
results (figure 2.6) indicate that the samplers give completely different sampling
results. The self-deviation (figure 2.6) reveals a small variability within the four
independent runs for each sampler. This means that both samplers give rela-
tively stable results, and thus that the deviation results observed between the
samplers must be due to the difference between the algorithms. Finally, the re-
sults for the human network reconstruction (figures S5 and S6 in File S1) indicate
that gpSampler converges already at low k. Although we believe that the sample
distributions indeed converged in this case, it seems unlikely that they represent
a uniformly distributed sample. First, the high dimensionality of almost a thou-
sand and the declining results for the Geweke test make this unlikely. Next, the
huge deviation with samples obtained by optGpSampler indicate a non-uniform
distribution, especially since we saw that optGpSampler performs better on the
smaller networks. The convergence results for optGpSampler seem more realis-
tic, with a relatively large z-value and a HW test result that indicates that around
60% of the sampled flux distributions converged.
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Network m n N(S) Time gp Time optGp
E. coli central met 68 87 24 137.16 (± 0.62) 3.6 (± 0.05)
C. therm. iSR432 288 351 70 258.57 (± 0.54) 10.20 (± 0.05)
S. cerev. iND750 479 631 180 496.57 (± 3.07) 21.81 (± 0.04)
E. coli iAF1260 1032 1532 525 1474.01 (± 6.78) 95.78 (± 2.62)
H. sapiens recon1 1587 2469 932 2910.26 (± 43.57) 349.05 (± 0.48)
Table 2.1: Runtimes for the networks analyzed. The number of metabolites and
reactions is denoted by m and n respectively. The dimensionality of the null
space of S, is given by N(S). Time gp (SD) is the mean runtime (seconds) and
standard deviation for sampling T=50,000 points using gpSampler. Time optGp
(SD) denotes the same metrics for optGpSampler. Experiments were performed
on a 16 GB RAM AMD Phenom desktop pc.
Algorithm 1: optGpSampler(S, T , k, p)
Input: S: the solution space; T : sample count; k: step count, p: number of
processors;
Output: P : sequence of T sampled points;
/* Warm-up phase */
1 Generate 2n warm-up points as in part (1) of gpSampler’s warm-up phase;
/* Sampling-phase */
2 P =<>;
3 L = dTk/pe;
4 for i=1 to p do
5 ~x0 = a point randomly chosen from the 2n warm-up points;
6 for j=1 to L do
7 ~xj = point generated from ~xj−1 by performing one iterate of the
ACHR sampling phase;
8 if j mod k == 0 then
9 P =< P , ~xj >;
10 end
11 end
12 end
2.5 Discussion
We proposed a new algorithm for uniform sampling of the steady-state solution
space of metabolic networks. Our algorithm also implements ACHR, but in a
different manner than the state-of the-art sampling method for metabolic net-
works (gpSampler). We compared the runtimes with those of gpSampler, and
showed its superior efficiency. We investigated empirical convergence using dif-
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Figure 2.5: Empirical convergence for E. coli iAF1260. a) Convergence according
to the Geweke diagnostic. b) Convergence according to the Heidelberger-Welch
diagnostic. For both convergence tests, gpSamplers performance deteriorates
when the step count is increased up to k=2500. Especially the good scores at
low values of k seem unrealistic and could indicate convergence towards a non-
uniform distribution. Results for optGpSampler seem more stable and more
reliable.
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Figure 2.6: E. coli iAF1260 xy-deviation from samples obtained with sampler x
at step count k1 to sampler y using k2=5000. a) Deviation to samples obtained
by y=gpSampler. b) Deviation from samples obtained by y=optGpSampler. Self-
deviation (x = y) is small for both samplers, but there is a large cross-deviation
(x 6= y). For this large network, the we do not observe convergence of gpSampler
to the samples obtained by optGpSampler or vice versa as in figure 2.4.
ferent diagnostics and showed faster convergence of optGpSampler on the two
smaller networks studied. Moreover, by using the here introduced xy-deviation
measure we compared the sampled distributions. For smaller networks, the
samples obtained by optGpSampler using a small step count are close to those
obtained with a high step count by both optGpSampler and gpSampler. On three
large networks the convergence performance of gpSampler diminishes when the
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step count increases. We hypothesized that the approach gpSampler takes by
starting each sample chain at a warm-up point, together with the high dimen-
sionality of the solution space restrains its ability to move from the vicinity of
these warm-up points. Because our method continues the ACHR procedure
from the last collected point it effectively uses much larger step counts. There-
fore, optGpSampler is more likely to escape the regions near the warm-up points
leading to a better sampling result. For the larger networks, results showed that
the convergence observed at lower step counts does not reflect a convergence to-
wards the target distribution since the sample distributions deviate significantly
from those generated using a large step count. Therefore, especially larger net-
works should be sampled with a high step count. To the best of our knowl-
edge there is no method to assess whether samples are truly uniformly random
distributed in a convex space of unknown shape. Since the chains generated
by ACHR are not Markov chains, asymptotic convergence guarantees also do
not hold for both gpSampler and optGpSampler. Therefore convergence results
should be interpreted with caution. The accelerated convergence of ACHR to-
wards a uniform distribution was demonstrated by [113] for convex polytopes
of known shape. However it remains uncertain to what extent the samples ob-
tained by ACHR for the irregular solution space of metabolic networks are truly
uniformly distributed. As expected, our experiments indicate that convergence
results deteriorate when the dimensionality of the solution space increases and
that for the large genome-scale metabolic networks using a large step count is
advisable.
We envisage the provided implementation of optGpSampler will be bene-
ficial to constraint-based metabolic network analysis as it provides an efficient
and versatile algorithm for sampling the irregular solution space of metabolic
networks.
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Chapter 3
Estimating metabolic fluxes using
maximum network flexibility
Genome-scale metabolic networks can be modeled in a constraint-based fashion. Reaction
stoichiometry combined with flux capacity constraints determine the space of allowable
reaction rates. This space is often large and a central challenge in metabolic modeling
is finding the biologically most relevant flux distributions. A widely used method is
flux balance analysis (FBA), which optimizes a biologically relevant objective such as
growth or ATP production. Although FBA has proven to be highly useful for predic-
ting growth and byproduct secretion, it cannot predict the intracellular fluxes under all
environmental conditions. Therefore, alternative strategies have been developed to select
flux distributions that are in agreement with experimental “omics” data, or by incorpo-
rating experimental flux measurements. The latter, unfortunately can only be applied
to a limited set of reactions and is currently not feasible at the genome-scale. On the
other hand, it has been observed that micro-organisms favor a suboptimal growth rate,
possibly in exchange for a more “flexible” metabolic network. Instead of dedicating the
internal network state to an optimal growth rate in one condition, a suboptimal growth
rate is used that allows for an easier switch to other nutrient sources. A small decrease
in growth rate is exchanged for a relatively large gain in metabolic capability to adapt to
changing environmental conditions.
Here, we propose Maximum Metabolic Flexibility (MMF) a computational method
that utilizes this observation to find the most probable intracellular flux distributions.
By mapping measured flux data from central metabolism to the genome-scale models
of Escherichia coli and Saccharomyces cerevisiae we show that i) indeed, most of the
This chapter is based on Megchelenbrink W.L. et al. (2015),
Estimating Metabolic Fluxes Using a Maximum Network Flexibility Paradigm, published in PLOS ONE.
Supplementary material is online available at PLOS ONE.
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measured fluxes agree with a high adaptability of the network, ii) this result can be
used to further reduce the space of feasible solutions iii) this reduced space improves the
quantitative predictions made by FBA and contains a significantly larger fraction of the
measured fluxes compared to the flux space that was reduced by a uniform sampling
approach and iv) MMF can be used to select reactions in the network that contribute
most to the steady-state flux space. Constraining the selected reactions improves the
quantitative predictions of FBA considerably more than adding an equal amount of flux
constraints, selected using a more naive approach. Our method can be applied to any
cell type without requiring prior information.
3.1 Introduction
Advances in obtaining quantitative “omics” data have led to the availability of
genome-scale metabolic network reconstructions for many organisms. Success-
ful metabolic modeling examples range from predicting the impact of cell per-
turbation experiments in micro-organisms [176] and in silico yield optimization
of valuable products such as bioethanol [24] to metabolic engineering for drug
synthesis [143] and tumor vulnerability studies in cancer cells [101, 2, 160, 3,
63]. At the heart of these models lies the stoichiometric matrix (S), containingm
metabolites and n reactions. Entry Si,j denotes the stoichiometric coefficient of
metabolite i in reaction j. The allowable flux range vj for reaction j is bounded
by the mass-balance equations (considered at steady-state) and flux capacity
constraints:
d~x
dt
= S~v = 0 (3.1)
vlbj ≤ vj ≤ vubj ,∀j ∈ {1, 2, . . . , n}
where ~x and ~v are vectors denoting the metabolite concentrations and reac-
tion rates respectively. In metabolic networks the reactions typically outnumber
the metabolites, leaving the system of linear equations S underdetermined [20].
This means that there is no unique solution, but rather a convex space of (in-
finitely many) feasible flux distributions [163], known as the steady-state solu-
tion space. Knowledge of the actual flux distribution the organism utilizes is
of great importance for many biological engineering purposes [20, 211], making
reduction of the solution space a central problem in metabolic modeling. Since
the reaction stoichiometry in eq. (3.2) is fixed, reduction of the solution space
can only be achieved by tightening the feasible flux ranges. Methods for reduc-
ing the feasible fluxes to those that are biologically most relevant can be divided
into three main categories.
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i) Computational methods that select flux distributions based on optimiza-
tion of a biologically sound objective such as biomass or ATP yield. Flux Balance
Analysis (FBA) [163, 224] is arguably the most applied technique that has shown
to be accurate in predicting maximum growth [52] and byproduct secretion
rates [223] for micro-organisms. Often, the flux distribution obtained by FBA
is not unique and multiple optima exist. Flux Variability Analysis (FVA) [139]
can be viewed as an extension of FBA that instead of finding a unique flux dis-
tribution computes the minimum and maximum allowable flux through each
reaction while optimizing an objective function. To further reduce the space of
alternative optimal solutions, variants of FBA are used. A method that is of-
ten applied is parsimonious enzyme usage (pFBA) [127]. This technique selects
among the optimal flux distributions the one that minimizes the sum of abso-
lute fluxes, using the rationale that a cell minimizes its enzymatic cost when
alternative optimal flux paths exist. Other methods, tailored to minimize the
enzymatic cost exist [202, 12, 204, 214] but require organism specific parameters
that are not widely available, such as metabolite and enzyme concentrations or
the Gibbs free energy change associated with each reaction.
ii) The most reliable method is direct measurement of the unknown intra-
and extracellular fluxes. Extracellular or boundary reactions such as glucose
and oxygen consumption, together with growth rates and byproduct secretion
rates such as acetate, ethanol and CO2 are measured on a routinely basis. Unfor-
tunately, measuring intracellular fluxes is currently limited by the available ex-
perimental techniques. A successful technique that measures intracellular fluxes
is metabolic flux analysis (MFA) [231, 232, 242]. MFA uses isotopic (C13) labeling
combined with a computational approach to uniquely identify the reaction rates
inside central (carbon) metabolism. A drawback of the MFA method is that it is
currently mainly limited to central metabolism and can therefore not be applied
on the genome-scale.
iii) Computational methods that use other omics sources such as gene- or
protein expression [11, 205, 191, 31, 99]. The basic idea behind most of these
methods is to maximize the agreement between high (low) expression and ac-
tive (inactive) pathways. Although the relation between gene-expression and
metabolic flux is not straightforward and fluxes may not correlate well with the
expression of their enzyme-coding genes [165, 4], this is a method that can be
applied on the genome-scale. Many methods have shown to be highly predic-
tive in a qualitative sense (predicting active versus inactive fluxes), but a recent
review revealed that most are not well-suited for making quantitative flux pre-
dictions [135].
It has been shown that microbes that normally grow in various environments
favor a suboptimal growth in order to keep a metabolic state that allows for an
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easier switch towards other nutrient conditions [60, 201]. Here, we utilize this
trade off between robustness and growth to define a novel algorithm that allows
for selecting flux ranges from the suboptimal growth space that correspond to
maximum metabolic flexibility (MMF) in the network.
We evaluated our method on the genome-scale models of E. coli and S. cere-
visiae and show that measured reaction rates indeed correspond to a high MMF
value within the solution space corresponding to suboptimal growth. This infor-
mation can be used to discard fluxes that would severely affect the organisms’
metabolic robustness and effectively reduces the flux range for each reaction
considered. We compared our method with a uniform sampling approach and
show that MMF provides a smaller prediction error rate when flux ranges are
reduced at a similar cutoff. By applying pFBA after discarding all flux ranges
that violate the MMF paradigm by more than 5%, better quantitative flux esti-
mates are obtained. Finally, we demonstrate that our method selects reactions
that contribute substantially to the uncertainty in the network. Measurement of
the fluxes selected by our method provides a larger reduction and subsequently
better prediction than can be expected from an approach that cannot estimate
these most likely fluxes.
3.2 Materials and method
3.2.1 Computing the total flux range (TFR) distribution
Our method uses the idea that micro-organisms, which can grow in various
environments typically grow at a suboptimal rate on a certain substrate, to fa-
cilitate an easier adaptation to other nutrient sources [60, 201]. Our hypothesis
is therefore that the routing of metabolic fluxes in these micro-organism is such
that they facilitate a substantial growth rate and are furthermore tuned to a
maximal metabolic robustness. To clarify this, we introduce a measure called
the total flux range (TFR). The TFR is the sum of the feasible flux ranges for a
set of n reactions:
∑n
i=1(v
ub
i − vlbi ) and can easily be computed using FVA. The
n reactions can be composed to cover all metabolic reactions in the network or
only a specific subset of interest, such as the TCA cycle or the glycolysis path-
way. The method proceeds in two phases. First, the feasible flux range (vubi −vlbi )
for each reaction i is binned into b bins. Denote with vi = δj that the lower- and
upper flux bound for reaction i are constrained to the lower- and upper bound
of bin j. TFR(v|vi = δj) then denotes the total flux range given the tightened
bound on reaction i. TFR(v|vi = δj) is computed by adjusting the lower- and
upper bound of reaction i and propagating this constraint through the other re-
actions in the network (e.g. using FVA). Finally, this expression is normalized,
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Figure 3.1: a) A toy network with 3 metabolites, connected by 6 reactions. Flux
lower- and upper bounds are denoted between brackets. b) The TFR distribution
(relative to the original TFR) for each reaction.
such that TFR(v|vi = δj) denotes the TFR fraction remaining after constraining
reaction i.
In the second phase, a unique flux distribution can be chosen with respect
to the maximum metabolic flexibility paradigm. A first and straightforward ap-
proach is to discard all flux values that cause the TFR to drop below a certain
cutoff. This can then be used to further constrain the flux bounds such that the
space of possible flux distributions shrinks. This approach is illustrated for a toy
network (figure 3.1a). The network consists of three metabolites connected by
six reactions. Reaction v1 and v2 produce metabolite A, which is converted into
biomass either through intermediate metabolite B or C. Figure 3.1b illustrates
the TFR distribution (purple) for each reaction as a function of the constrained
flux through that reaction (here, for simplicity we set the lower- and upper flux
bound to the center of the bin). Notice that for instance for the uptake reac-
tions v1 and v2 a higher uptake rate corresponds to a higher TFR. This occurs
because reaction v3 and v4 can obtain a wide range of fluxes given enough in-
put through either v1 or v2. Similarly, when reaction v3 obtains the highest
rate of 10 mmol/gDW/h, there is only one feasible flux distribution and there-
fore TFR(v|v3 = [10,10]) is 0. Notice that when the TFR cutoff is set to 0.5, the
maximum flux through reaction v3 is approximately 5.0 mmol/gDW/h and the
minimal flux through the growth reaction (v6) should also be 5.0. Using this
approach, flux distributions that significantly violate the metabolic robustness
principle can be excluded. To obtain a unique flux distribution, for instance
pFBA can be applied to the network that satisfies a minimal predefined flexibil-
ity or robustness.
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3.2.2 Computing the flux distribution with maximum metabolic
flexibility (MMF)
A second option is to choose the flux distribution that maximizes the TFR under
the imposed mass-balance and flux capacity constraints directly. This can be
useful in the case that a clear biological objective such as growth is not present,
which is the case for instance in most mammalian cells. Because the TFR distri-
bution was computed for each reaction separately, selecting for each reaction the
flux value that maximizes the TFR yields a non-steady-state flux distribution pˆ.
This can be solved by selecting the steady-state flux distribution that minimizes
the overall Euclidean distance to the mode (peak) of each of the binned flux
ranges. However, for some reactions the TFR is hardly sensitive to the chosen
flux value (a uniform distribution), whereas for others there is a clear mode with
maximum TFR (S1 File). The peaked distributions provide a better estimate of
the real flux an organism can obtain and we therefore assign more weight to
these reactions. The flux distribution that globally maximizes the TFR can be
found by solving the following constrained weighted least-squares problem:
minv‖W v −W pˆ‖22 (3.2)
s.t.
Sv = 0
vlbi ≤ vi ≤ vubi ,∀i ∈ {1, 2, . . . , n}
Here, W is a diagonal matrix of weights and pˆ is the (unconstrained) flux
distribution that maximizes the TFR. The weight of a flux reflects how well it can
be predicted with the MMF method. Therefore, distributions with a clear mode
should receive more weight than uniform distributions. Shannon’s information
entropy is used to determine the weight of each reaction i:
Wi = log2−
b∑
j=1
TFRi,j log2(TFRi,j) (3.3)
Note that when the TFRi has maximum entropy (uniform distribution), the
weight i is minimal (0). The vector of weights ~W is normalized such that all
entries sum up to 1. Eq. 3.2 can be formulated as a quadratic program that
finds the flux distribution such that the network robustness or “flexibility” is
maximized under the constraints imposed.
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3.2.3 Using the TFR distribution to select flux measurements
MMF can be used to select or prioritize flux measurements. If measured flux
data is available, it can be used to reduce the flux capacity constraints (the lower-
and upper bounds). Furthermore, propagation (using FVA) of the new bounds
typically reduces the bounds of other reactions as well. The amount of reduction
caused depends mainly on three factors. First, the reduction of the measured
reaction depends on the experimental precision. More importantly, how this
reduction affects the feasible ranges of other reactions in the network depends
secondly on what the actual flux is that was measured and furthermore on how
that reaction is connected to the rest of the network (the network topology). For
instance, if a high excretion rate of ethanol was measured, then much of the car-
bon excreted cannot go to other pathways (under the steady-state assumption).
On the other hand, when a low ethanol excretion flux is detected it remains un-
known how for instance carbon is excreted in order to satisfy the steady-state
constraint. In other words, the organism might excrete other products such as
acetate, glycerol and lactate or dedicate much of this flux to growth. Thus, a high
excretion rate would typically provide a much larger reduction of the feasible
space than a low excretion rate.
The TFR distribution is helpful because it provides a reasonable estimate
of the flux through a reaction (supplementary file S1). Furthermore, we can
immediately see how much reduction of the TFR can be obtained at each pos-
sible measurement outcome. Using the maximum flexibility principle, fluxes
are selected where the mode of the TFR distribution is a global minimum. Any
measurement outcome will reduce the TFR to at least this value. When the mea-
sured flux deviates strongly from the expected value, the TFR reduction will be
even stronger.
3.2.4 Metabolic models and flux data
In a recent review about computational methods that integrate quantitative
“omics” (gene-expression) data, it was shown that pFBA in general provides
better quantitative flux estimates compared to most computational methods that
integrate omics data [135]. Although pFBA predicts some fluxes with high ac-
curacy, predicted rates for other reactions can be distant from the rates that
have been experimentally determined. We demonstrate the applicability of our
method using the same genome-scale metabolic models and experimentally veri-
fied fluxes as in [135]. In particular, we used the Escherichia coli iAF1260 [58] and
the Saccharomyces cerevisiae iMM904 [151] network reconstructions. The yeast
iTO977 network [164] used in [135] was replaced by the iMM904 model, be-
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cause the former did not yield a feasible growth rate when FBA was applied.
For the E. coli model, fluxes have been measured in batch culture by Holm et
al. [93] and in a chemostat environment by Ishii et al. [97]. The reaction rates
for S. cerevisiae have been measured at varying oxygen consumption rates by
Rintala and coworkers [188].
3.3 Results
Feasible flux distributions form a high-dimensional convex steady-state solution
space. The hypervolume of this space indicates how “many” (since the space
is continuous, there is actually an infinite number of solutions) alternative so-
lutions exist. Exact computation of this volume is infeasible for genome-scale
models [51, 114] and reliable estimation of this volume is extremely hard [22].
Summing the feasible ranges over all reactions is a somewhat crude, but useful
approximation.
It is known that organisms often do not grow at the theoretical optimal rate
computed by FBA [216], but at a suboptimal rate. This is especially the case
when nutrients are available in excess or the available oxygen is limited. The
exact deviation between the predicted and actual growth rate depends on the
experimental conditions. For the E. coli and yeast models we considered, the
measured growth rates are between 60% and 80% of the theoretical optimum
computed by FBA. Under this suboptimal growth rate, the space of alternative
flux distributions is considerably larger than when only distributions satisfying
optimal growth are considered (figure 3.2). The hypothesis that metabolism
in micro-organisms optimizes for growth allows FBA to effectively reduce the
feasible flux ranges to only 10% to 30% compared to those in a minimal glucose
medium without any maximization of growth. However, when the maximum
biomass output is constrained to the measured suboptimal growth rate, this
reduction is considerably less. Between 50% to even 70% of the original flux
ranges (without optimizing for growth) satisfy the measured suboptimal growth
rate. For organisms growing in a complex medium this reduction is even less
and thus a large space of flux distributions that agree with the measured growth
rate exist. Thus, there is need to further narrow down this space of suboptimal
growth solutions using a secondary objective. We applied MMF to maximize
the metabolic flexibility or robustness of the metabolic network.
3.3.1 Reducing the total flux range
By reducing the feasible ranges of the fluxes, better estimates can be made on
how flux is actually distributed through the cell. A computational approach
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Figure 3.2: TFR for various genome-scale metabolic reconstructions of E. coli and
S. cerevisiae. The TFR was computed while obtaining a minimum growth output
of 60, 80 or 100 percent of the maximum value computed by FBA.
suitable for reducing the space of (suboptimal) feasible solutions is uniform ran-
dom sampling [195, 177, 146]. By random sampling the feasible space, empirical
probability density functions (pdf) can be defined for every reaction in the net-
work. These can then be used to tighten the lower- and upper flux bounds of
each reaction by discarding flux values with very low probability. The MMF dis-
tribution can be used in a similar fashion by excluding reaction rates that cause
the TFR to drop below a certain cutoff. This procedure is illustrated for four
reactions in the E. coli genome-scale model (figure 3.3a; for the other reactions
and networks see supplementary file S1). The sampling distributions (red lines)
are narrow, meaning that many feasible flux values are actually never sampled
and are therefore unlikely to occur given the network stoichiometry and flux
capacity constraints. We also considered the MMF distribution and discarded
all flux values that caused the TFR to drop below 0.95 (dashed blue lines). Al-
though flux ranges based on the TFR distributions are wider, in contrast to the
sampling procedure, they often include the flux rates measured by C13 MFA
(orange squares).
In general, it is desirable to reduce the feasible space without excluding the
real (i.e. the measured) fluxes. Figure 3.3b-d compares the reduction of the so-
lution space with the fraction of measured fluxes that are outside the reduced
space; the mean error. Results are provided for scenario 1, where only the glu-
cose and oxygen uptake rates were constrained (figure 3.3b), when additionally
the biomass flux was constrained (scenario 2; figure 3.3c) and all measured ex-
change reactions were constrained (scenario 3; figure 3.3d). The same trend is
observed as in figure 3.3a; while the sampling method obtains a large reduc-
tion of the space, it also excludes most of the measured fluxes leading to a high
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Figure 3.3: Illustration of the purpose of MMF on four reaction in central car-
bon metabolism. (a) The fluxes estimated by pFBA (red) are distant from the
measured rates and are also outside the 0.95 TFR range. After applying MMF,
the fluxes estimated by pFBA are much closer to the measured rates. Notice
that the measured rates are within the 0.95 TFR range, but are generally not
captured by the ACHR sampling distribution. (b–d) TFR reduction vs error in
scenario 1-3 respectively. The MMF method provides less reduction of the flux
ranges, but also has a considerably smaller error rate. The MMF performs best,
when the growth rate (scenario 2) and the key exchange fluxes (scenario 3) are
constrained.
error rate. At a TFR cutoff of 0.95, the MMF method is more conservative com-
pared to sampling. A smaller reduction of the space is obtained, but most of
the measured reaction rates remain in the reduced space. When the cutoff is
increased to 0.99, the TFR reduction becomes similar to that achieved by the
sampling method (supplementary file S2). Notice that especially in the scenar-
ios for which MMF was designed (finding flux distributions in the suboptimal
space, i.e. where the growth rate is known), it achieves a smaller error rate than
the sampling approach (figure 3.3c-d). In the remainder of this paper, we favor
the smaller error over a large reduction and therefore use the cutoff of 0.95.
3.3.2 Quantitative flux estimation
A reduced solution space still does not provide a unique flux distribution. How-
ever, this can be obtained using either MMF to find the flux distribution that
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Figure 3.4: Flux prediction error for scenario 2. By first applying MMF, the
predictions made by pFBA (MMF + pFBA) improve. The error improves in
particular, when the biomass optimization paradigm may not hold (b and d).
Furthermore, global optimization of the flexibility works pretty well, except for
yeast growing under high oxygen conditions. In this case, yeast produces much
biomass and fluxes estimated by pFBA are more accurate. By first applying
ACHR, the feasible flux ranges are pruned to heavily, leading to worse flux
estimates.
globally maximizes the TFR or by using pFBA on a model with refined bounds.
The predictions made by pFBA improve when the MMF method was used to
preprocess the model and narrow the flux bounds (figure 3.4a). In this particu-
lar example, E. coliwas grown in chemostat culture at a dilution rate of 0.2/h [97]
and the model’s glucose and oxygen uptake as well as the biomass production
rates were constrained to those experimentally measured (scenario 2). In this
case, pFBA underestimates some of the major fluxes in glycolysis (fluxes cat-
alyzed by GAPD and enolase) and overestimates some of the reactions in the
TCA cycle (ICT lyase and malate synthase). By first tightening the flux lower-
and upper bounds, such that the TFR of each reaction is above 0.95 and then
rerunning pFBA, better estimates of the fluxes through these reactions (green
squares) are obtained. Similarly, by first applying MMF to find the bounds
that retain at least 0.95 of the original TFR, and then applying the global MMF
optimization procedure (MMF–2)in equations (3.2) and (3.2), we obtain a flux
distribution that is closer to the measured values than those computed using
pFBA alone.
Figure 3.4 shows the mean error for the aforementioned models in scenario 2
(see supplementary file S3 for all conditions). Notice that the quantitative fluxes
estimated by pFBA improve when MMF was applied in advance to refine the
flux ranges. Again, this holds in particular for the chemostat models, where the
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maximum growth assumption used by pFBA may not hold due to limited oxy-
gen availability (figure 3.4a and 3.4d). In the absence of oxygen, yeast uses the
fermentation pathways to produce biomass and excretes ethanol at a high rate.
It is known that the flux predictions made by FBA are incorrect in this case [216]
and refining the flux bounds with MMF helps to “guide” pFBA to a more ac-
curate flux distribution. Notice that the MMF–2 method works reasonably well
for most models, except for S. cerevisiae growing under aerobic (high oxygen)
conditions. The pFBA method, which assumes a maximization of the biomass
yield is clearly a better approach here. Although MMF–2 does not outperform
MMF+pFBA or pFBA alone, it can be used to estimate fluxes for models where
an optimization objective such as growth is not applicable.
3.3.3 Selecting measurements to optimally reduce the solution space
We applied the MMF method to select among the measured fluxes those that
are expected to maximally reduce the TFR. Selecting fluxes that have a large
impact on the TFR may help to reduce valuable experimental time and cost. We
iteratively selected one reaction and constrained the model with the measured
flux until seven fluxes were selected. Because adding an extra constraint always
reduces the TFR, we compared our method with two simple approaches. A
rather naive approach is to select reactions randomly from those that have avail-
able measurement data. The second approach always selects those reactions
that have the largest distance between their upper- and lower bound (called the
MaxSpan reactions). Although the flux range of these MaxSpan reactions can be
reduced considerably, they may or may not have a large constraining effect on
other flux ranges in the network
As a proof of concept, we looked specifically for reduction of the flux ranges
for reactions inside central metabolism. Since flux data for other pathways was
not available, little reduction can be expected within these pathways. The flux
ranges in the S. cerevisiae model are reduced faster when reactions selected by
MMF are constrained with measured fluxes compared to the other methods (fig-
ure 3.5a; see supplementary file S4 for all models and scenarios). As expected,
the larger reduction obtained after measurement of these reactions also results
in better prediction of the fluxes by pFBA (figure 3.5b; see supplementary file S5
for all models and scenarios). Notice that although the TFR decreases with each
flux measurement, this does not guarantee a better prediction of pFBA. The rea-
son that the error can increase is that the additional constraint causes pFBA to
perform a major flux rerouting, which is actually a worse estimate than the flux
routing before imposing the extra constraint. This behavior is shown for a sub-
set of the reactions (those in central metabolism) from the genome-scale model
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Figure 3.5: TFR reduction and pFBA improvement of MMF compared to random
and ‘MaxSpan’ selection on the S. cerevisiae iMM904 model (high oxygen). a)
The MMF method selects flux measurements that provide a larger reduction of
the flux ranges compared to the MaxSpan or random measurements. b) Fluxes
predicted by pFBA obtain the smallest errors when the reactions selected by
MMF are measured.
(figure 3.6). Some reactions in the glycolysis pathway have a large flux range
and pFBA actually underestimates the flux through these reactions (figure 3.6a).
MMF selects the reaction G3P → PEP for measurement. Due to the increased
flux through glycolysis, more pyruvate enters the mitochondria. Apparently,
the minimal sum of fluxes constraint drives a large portion of the flux through
a shortcut, which converts citrate into malate. As a consequence, reactions in
the right part of the TCA cycle have underestimated rates and the fluxes in the
left part are overestimated. A second measurement constrains the flux from
succinyl-coa to succinate, which results in a much more accurate prediction.
3.4 Discussion and conclusion
A major advantage of constraint-based metabolic modeling is that relatively few
constraints are required to predict quantitative traits such as a cell’s maximum
growth rate, or uptake and secretion rates of key metabolites. The main draw-
back is that the underdetermined nature of these networks, combined with a
limited set of available constraints makes it hard to compute or estimate many
flux distributions accurately. Computational methods such as FBA and pFBA
have been successfully applied to find the flux distributions that correspond
with a maximization of the growth rate. However, micro-organisms rarely grow
at this theoretical maximum rate, but – depending on the available substrates
and species – at rates typically between 60% to 90% of this optimum. Impor-
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Figure 3.6: Effect of flux selection by MMF for explained with a network recon-
struction of S. cerevisiae central metabolism. Red arrows denote overestimated
fluxes by pFBA, compared to the measured data. Blue arrows denote underes-
timated fluxes. Using subsequent measurements in glycolysis (g3p → pep) and
the TCA cycle (succinyl-coA → succinate), the pFBA estimates are much closer
to the measured fluxes.
tantly, even a small relaxation of the growth rate from 100% to 90% of the max-
imum computed by FBA, increases the amount of alternative optimal flux dis-
tributions and thus the network robustness considerably. The FBA solution to a
system that is constrained to have a maximum of say 90% depends mainly on the
linear programming algorithm used and has no biological relevance compared
to any other flux distribution within this suboptimal space. Using pFBA im-
proves the situation, because the shortest absolute flux path is chosen from the
optimal alternatives and thus thermodynamically infeasible cycles are avoided.
The MMF method can be viewed as a (computationally expensive) alternative to
minimizing the absolute sum of fluxes. Instead, a flux path is chosen that maxi-
mizes the “flexibility” or robustness of the network towards varying conditions
while maintaining a (sub)optimal growth rate. This robustness is believed to be
an evolutionary design principle of the metabolic networks of many organisms
and protects the cell against internal defects and varying environmental condi-
tions [100, 122]. The TFR summarizes the allowable flux ranges and thus can be
viewed as a measure of metabolic robustness. We rarely observed flux distribu-
tions that severely limit the TFR. By using this simple observation we were able
to refine the alternative suboptimal solution space found by FVA, by redefining
flux ranges such that they satisfy a predefined TFR (here 0.95 times the original
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TFR). Applying FBA or pFBA to this redefined space prevents that a flux route
is selected that severely limits the metabolic robustness of the organism.
We would like to discuss our comparison with the uniform sampling ap-
proach. First, uniform sampling of metabolic networks is often done by the
ACHR [113] method; a method that -contrary to the original Hit-and-Run method
[207]- has no theoretical guarantees to converge towards a uniform distribution.
The applicability of the ACHR method for large-scale metabolic networks has
recently been challenged [42, 187] and it is questionable to what extent the flux
distributions sampled from the steady-state solution space are truly a uniform
random sample. On the other hand, binning and propagating the flux values
as done in MMF, has some resemblance with belief propagation; a method that
has also been applied to metabolic networks [22, 144]. Constraining the flux
of one reaction and propagating this constraint through the network is exactly
what belief propagation does. Then, the flux distribution with maximum TFR is
a proxy to the one with maximum posterior belief. Thus, whether the reduced
error rate of MMF compared to sampling is really due to the optimization of
‘metabolic flexibility’ or is mainly due to the limitations of the ACHR method
remains unclear.
Our method can also be used on networks that are made tissue- or envi-
ronment specific with computational methods that integrate omics data with
genome-scale networks, such as iMAT [205], GIM3E [199] or EXAMO [191].
Despite the significant reduction that is often obtained by these methods, a large
space of solutions remains.
Finally MMF can aid in identifying the key intracellular reactions. Here,
to test the performance of the method, flux data measured by MFA was used,
since data obtained with other techniques is scarce at the moment. Before MMF
would be applicable as a measurement selection tool for MFA techniques, the
main obstacle that has to be solved is taking into account the intrinsic coupling
that exist between the tracers used and the pathways that are measured. That
is, reactions measured with MFA cannot be chosen one at a time and the choice
of isotopic label determines which reaction rates will be measured. A possible
solution would be to extend the algorithm to a greedy heuristic that tries to
select multiple consecutive measurements that best partition the flux space into
smaller subspaces. This would be useful to compute a priori which labeling
scheme provides most information about the network under study, especially
since the error rates can also be computed in advance [197]. Our method can also
be applied in association with Kinetic Flux Profiling (KFP) [241]. KFP is a mass
spectrometry based approach to measure individual fluxes through metabolic
networks by pulsechase feeding of heavy isotope (13C, 15N) labeled nutrients,
and does not require specific assumptions about the network.
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Taken together, we have presented a novel method that predicts metabolic
fluxes by adopting a maximum network flexibility paradigm. Our method can
be used to further narrow the solution space in genome-scale metabolic net-
works and thereby improve existing methods such as pFBA. Our method can
predict (intra)cellular fluxes in the absence of known cellular objectives and can
be used to find important hubs in the metabolic network that contribute most to
the large range of alternative distributions.
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Synthetic dosage lethality in the
human metabolic network
A synthetic dosage lethality (SDL) denotes a genetic interaction between two genes,
whereby the underexpression of gene A combined with the overexpression of gene B is
lethal. SDLs offer a promising way to kill cancer cells by inhibiting the activity of
SDL partners of activated oncogenes in tumors, which are often difficult to target di-
rectly. As experimental genome-wide SDL screens are still scarce, here we introduce
a network-level computational modeling framework that quantitatively predicts human
SDLs in metabolism. For each enzyme pair (A, B) we systematically knock out the flux
through A combined with a stepwise flux increase through B and search for pairs that
reduce cellular growth more than when either enzyme is perturbed individually. The
predictive signal of the emerging network of 12,000 SDLs is demonstrated in five differ-
ent ways. (i) It can be successfully used to predict gene essentiality in shRNA cancer
cell line screens. Moving to clinical tumors, we show that (ii) SDLs are significantly
underrepresented in tumors. Furthermore, breast cancer tumors with SDLs active (iii)
have smaller sizes and (iv) result in increased patient survival, indicating that activa-
tion of SDLs increases cancer vulnerability. Finally, (v) patient survival improves when
multiple SDLs are present, pointing to a cumulative effect. This study lays the basis for
quantitative identification of cancer SDLs in a model-based mechanistic manner. The ap-
proach presented can be used to identify SDLs in species and cell types in which ‘omics’
data necessary for data-driven identification are missing.
This chapter is based on Megchelenbrink W.L., Katzir, R. et al. (2015),
Synthetic dosage lethality in the human metabolic network is highly predictive of tumor growth and cancer
patient survival, published in Proceedings of the Academy of Sciences of the United States of America.
Supplementary material is online available at PNAS.
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4.1 Introduction
Synthetic lethality (SL) occurs when the combined loss of two nonessential genes
renders a lethal phenotype [86]. SLs have been studied by using experimen-
tal [37, 212] and computational approaches [210, 46, 203] to address various
questions of cell function and evolution. The potential of SLs for cancer therapy
has been recognized and accelerated the development of many SL screens [63,
68, 123, 134, 131]. (See refs. [108, 186, 29] for reviews of SLs applied in the con-
text of cancer research.) Less studied are the so-called synthetic dosage lethality
(SDL) interactions. An SDL is a genetic interaction between two genes whereby
the underexpression of gene A (A↓) together with the overexpression of gene B
(B↑) is lethal [121]. The observation that an interaction with an overexpressed
gene can be lethal makes it particularly interesting for targeting cancer cells
with (over) expressed oncogenes. This is because many oncogenes that drive
tumor growth are essential to cell function and thus difficult to target directly.
Targeting the oncogene’s SDL partner, which is a nonessential gene in normal
cells, may nevertheless kill cancer cells. That SDLs can have important implica-
tions for cancer research, for instance to aid in the design of new therapies, has
also been recognized [108, 16, 193, 208]. Moreover, it has been shown that the
overexpression of specific genes can be detrimental to cancer cell growth [228].
Recently, a data-mining approach was used that identifies SLs and SDLs by ana-
lyzing large volumes of cancer genomic data [105]. Here we aim to complement
data-driven computational efforts with a biological network model approach to
identify SDLs. This has recently become feasible in the realm of metabolism,
with the advent of genome-scale metabolic modeling. We introduce a method
that uses a constraint-based genome-scale model of metabolism (GSMM) [150,
198, 178, 218, 215] to predict metabolic SDLs. GSMMs have successfully resolved
a wide range of research questions in model organisms [178, 57, 160, 176, 153,
158] and have been the basis for many computational studies of cancer [63, 68,
104, 3, 102, 73]. Furthermore, they have contributed to a systematic understand-
ing of the underlying mechanisms leading to lethality and SL [212, 210, 46, 203,
63]. A major advantage of a model-based approach is that it can provide insights
into the underlying network mechanisms causing SDLs. Furthermore, the mod-
eling approach presented is general and can be used to identify SDLs in species
and cell types in which ‘omics’ data are missing. We introduce a computational
approach for identifying dosage lethality effects (IDLE) in metabolism. IDLE
predicts enzymatic SDLs from a GSMM with application to cancer. For each en-
zyme pair (A, B) in the human GSMM, we systematically knock out the enzyme
flux through A combined with a stepwise flux increase through enzyme B and
quantify the level of growth reduction. Pairs in which the growth is significantly
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more reduced than when either enzyme is perturbed individually are ranked as
SDLs (A↓, B↑) with a corresponding value of ‘strength’. We demonstrate the pre-
dictive power of our approach in five different ways: First, by analyzing genome-
wide experimental shRNA screens, we show that A↓ in predicted SDLs (A↓, B↑)
is indeed more likely essential in an overexpressed enzyme B↑ background than
when B is not overexpressed. When A is underexpressed and B is overexpressed
in a predicted SDL in a given tumor sample, we denote that SDL as ‘active’, that
is, bearing potential functional effects on the tumor growth and the patient’s sur-
vival. Second, we show that SDLs are less frequently active across patients with
cancer compared with randomly selected enzyme pairs, indicating that tumor
cells select against the presence of SDLs to avoid cell death. Third, we illustrate
that tumor size in patients with breast cancer (BC) with one or more active SDLs
is significantly smaller than in patients expressing randomly selected enzyme
pairs. Fourth, we show that the predicted impeding effect of active SDLs on
tumor growth correlates with a significantly longer patient survival time. These
results become even more pronounced when one includes only highly ranked
active SDLs (that show a stronger A↓, B↑ pattern at the transcriptional level),
illustrating that our method successfully identifies the clinical impact of SDLs.
Finally, we report that observed effects become stronger when more active SDLs
are present in a given tumor, pointing to the cumulative effect of active SDLs in
clinical tumors.
4.2 Results
4.2.1 Overview of the IDLE algorithm
The IDLE method (figure 4.1, 4.2 and supplementary material section 1) com-
putes the effect on cell growth when an enzyme B increases its activity (referred
to here as the reference GSMM) compared with its activity in a KO GSMM in
which, additionally, enzyme A is knocked out. The objective of IDLE is to find
enzyme pairs (A, B) in which this differential growth effect is marked, searching
over the space of all possible pairs. For a given pair (A, B), we define a refer-
ence WT GSMM and compute the maximum growth (biomass, µmax) with flux
balance analysis [224]. Similarly, µmax is computed for the KO GSMM, whereby
reaction A is knocked out. In both models, the maximum flux through B is com-
puted without any constraint on µ (i.e., the lower bound is zero; Figure 4.1 a
and b show the reference and KO GSMM, respectively). Now, the lower bound
of the biomass reaction is increased stepwise (by using n=10 steps) toward µmax
in both the reference (figure 4.1c) and KO (figure 4.1d) model. For each increase,
the maximal allowable flux through reaction B is computed again. The increas-
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Figure 4.1: Conceptual overview of the IDLE method. a) The maximum flux
through enzyme B is computed when there is no biomass pressure (i.e., the
flux lower bound is zero). b) This process is repeated for the KO model. c)
The biomass pressure is increased in a stepwise fashion and the maximum flux
through enzyme B is computed at each step. d) This is repeated for the KO
model. e) The maximum relative flux of B (VB,max) is plotted at each biomass
step (µmax) and the angle θ between the reference and KO vector is computed.
f) SDL pairs are ranked based on their growth impact, quantified by their angle
θ (see also 4.2).
ing growth pressure may affect the allowable flux through reaction B and, if so, it
must decrease. The basic idea behind IDLE is that this argument is reversible: if
the growth requirement constrains the maximum allowable flux through B, then
a further flux increase through B must decrease growth. This effect is quantified
and expressed as a vector (figure 4.1e). The angle θ between the reference and
KO vectors measures the difference between the effects on cellular growth of
overexpressing enzyme B in the WT (A, B↑) and after KO of enzyme A (A↓, B↑).
If growth reduction is stronger in the KO situation (A↓, B↑ ), then we define θ
positive and the enzymes (A, B) form an SDL. SDLs with the largest angle are
predicted to have the maximum effect and are termed ‘high-impact’ SDLs. We
can therefore rank-order SDLs based on the computed angle θ (figure 4.1f).
4.2.2 The metabolic SDL network
Our method discovered 12,447 SDL interactions (supplementary material; sec-
tion 2 and supplementary Dataset S1). Reassuringly, the ranked list of SDLs sig-
nificantly matches the top-ranked metabolic SDLs identified by the data mining
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Figure 4.2: The IDLE method. IDLE measures the ‘vulnerability’ of the growth
rate to a flux increase through enzyme B. This reference model m is compared
with a model m′ that computes this vulnerability when additionally enzyme A
is knocked out. This difference can be quantified as the angle θ between the
vectors in the m and m′ models. To accommodate for differences in flux scaling,
the computation is done using relative differences.
synthetic lethality identification pipeline (DAISY), an approach for data-driven
inference of genetic interactions in cancer that is based on the discovery of un-
derrepresented gene pairs in cancer genomic data [105] (Wilcoxon rank-sum p
< 0.0038). SDLs are asymmetrical by definition, i.e., A↓, B↑ denotes a different
interaction than A↑, B↓ and each may have a very different magnitude; in the
first interaction, enzyme A is the KO partner, whereas in the second interaction
it is the overexpressed partner. Surprisingly, we discovered that six enzymes are
major ‘master’ hubs, being the KO partners of many other overactivated B↑ in
the SDL network (supplementary figure S2). These major hubs (TPI, ENO, PGM,
PYK, PGK, and GAPD) all reside in the glycolysis pathway. Interestingly, when
examining the hub partners we observed that the B↑ partners are the same for
≈80% of the SDLs. The metabolic pathways that are enriched for these overex-
pressed partners are shown in supplementary table S3. To better understand the
putative mechanisms underlying the workings of these SDLs, we conducted a
further model-based analysis. First, we charted SL interactions of the six master
hubs, i.e., searched for genetic interacting pairs involving these six hub reactions
in which the growth reduction after their combined KO is larger compared with
that observed after the single KOs. We were surprised to see that although these
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SDL hub reactions are highly sensitive to a synthetic dosage load (each being
essential for ≈500 overexpressed partners), they have only very few SL partners
(a list of these reactions and their pathways is shown in supplementary table
S4). Examining the SDL partners of the six central glycolytic hubs, we find that
they are quite distributed across the metabolic network in ten different pathways
that are significantly enriched with the SDL partners (supplementary table S5).
When further investigating these SDLs, we discovered that glycogen production
is decreased by (on average) 60% when such SDLs are active compared with the
WT and KO conditions. Interestingly, it has recently been shown that glycogen
metabolism and its initial accumulation is a key pathway induced by hypoxia,
and its activity is necessary for optimal glucose utilization in tumors [55].
4.2.3 SDL is predictive of in vitro shRNA essentiality screens
We expect that a knockdown of enzyme A (A↓) will be lethal in a B↑ background
in the case of a SDL B(A↓, B↑). To study this, we exploited gene essential-
ity at a genome-wide scale in cancer cell lines by using experimental shRNA
screens [140] and matched it with gene-expression profiles [8]. In a typical
shRNA screen in a given cell line, each gene is individually knocked down
by targeting its mRNA (inhibiting and degrading it) by specific shRNAs that
bind to it. Then, the effect of each individual gene knockdown on cell growth is
measured, from which scores are calculated that indicate gene essentiality (a p
= 0.05 cutoff was used to consider a gene essential [140]). For each cancer cell
line, we divided SDLs into two groups: group 1 consists of SDLs in which at
least one of the B enzymes that form a SDL with enzyme A is overexpressed (B↑)
and group 2 consists of SDLs in which none of the B enzymes are overexpressed
(Materials and methods provides the definition of overexpression and supplemen-
tary material section 3 explains mapping genes to reactions). Then, the number
of essential and nonessential A enzymes observed experimentally in the shRNA
screen was compared between group 1 and group 2 in each cell line (one-tailed
Fisher exact test). Using a p = 0.05 cutoff, we counted the number of cell lines
in which enzymes A from group 1 are more frequently essential compared with
these enzymes in group 2. This procedure was also repeated 5,000 times for a set
of random enzyme pairs of equal size. As expected, the number of cell lines in
which essentiality of A in a B↑ background is enriched (group 1) is significantly
higher for SDL than for random pairs (empirical p ≤ 0.002).
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Figure 4.3: Percentage of active enzyme pairs (i.e., A, B) with A underexpressed
and B overexpressed. When the angle θ increases, the fraction of active SDLs
approaches zero. SDLs are significantly less frequently active than randomly
chosen enzyme pairs. For all cutoffs, the p-values obtain their maximum signif-
icance.
4.2.4 Cancer cells select against SDL
Cancer cells are expected to select against the negative effect that SDLs have on
(tumor) growth. Thus, when the enzyme pair (A, B) is a SDL, underexpression
of enzyme A and overexpression of enzyme B should occur less frequently than
for random enzyme pairs. We analyzed a gene expression dataset of 7,362 pa-
tients from the TCGA cohort [34] and determined for each gene whether it is
underexpressed (↓), overexpressed (↑), or unchanged compared with expression
levels in normal tissue samples [132] (supplementary material section 4). We
then computed for all SDLs the number of patients, Fsdl, with an active SDL (A↓,
B↑) relative to those patients having only enzyme A underexpressed (A↓, B) or
having only enzyme B overexpressed (A, B↑; supplementary material section 4).
This was repeated for 5,000 randomly constructed enzyme pair sets of equal size
(Frandom). As expected, Fsdl is significantly smaller than Frandom, illustrating that
an underexpression of A combined with an overexpression of B when A and B
have a SDL relation occurs significantly less frequently than when the enzyme
pair have no SDL relation (figure 4.3). In fact, when the angle θ increases, the
fraction of patients that have an active SDL approaches zero, testifying to the
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strong negative selection exerted on such SDLs.
4.2.5 SDL correlates with smaller BC tumor size
As SDLs negatively affect growth in cancer cell lines, we expect that the tumor
size will be smaller for patients with at least one active SDL compared with
those who do not. To address this, we used a dataset in which gene expres-
sion and matched tumor size data are available for 1,587 patients with BC [40].
We divided the patients in this heterogeneous dataset based on the estrogen
receptor (ER) sensitivity of their tumor (key properties of the data set are pro-
vided in supplementary material section 5). We analyzed whether the tumor
size of patients with an active SDL (A↓, B↑) is significantly smaller compared
with patients who have one of the single effects, meaning only an under- (A↓,
B) or overexpression (A, B↑) of enzyme A or B, respectively. To investigate A↓,
B↑ in relation to A↓, B, we separated patients into two groups: patients whose
tumor overexpresses enzyme B (Materials and methods provides the definition of
overexpression) with varying underexpression of enzyme A (σ between 0 and
3 given the underlying gene expression distribution) and patients whose tumor
does not overexpress enzyme B with varying underexpression of enzyme A.
When comparing A↓, B↑ with A, B↑, we also separated the patients into two
groups: patients who have enzyme A underexpressed (Materials and Methods
provides the definition of underexpression) with varying overexpression of en-
zyme B (σ between 0 and 3 given the underlying gene expression distribution)
and patients who have enzyme A not underexpressed with varying overexpres-
sion of enzyme B. Finally, we created random enzyme pairs (n=5,000) to serve as
control for testing the specific effects of the SDLs. Statistical significance for all
comparisons was computed with a signed Wilcoxon rank-sum test, analogous
to the signed Kaplan-Meier test as previously defined [105] (see supplementary
material section 6). As expected, we observed in ER+ BC that patients with (at
least one active) SDL have significantly smaller tumors compared with patients
with only overexpression of enzyme B (p < 4 × 10−8; figure 4.4). We found
for ER− disease that the tumor sizes in patients with SDL are also significantly
smaller compared with patients with only overexpression of enzyme B (p < 5 ×
105), as well compared with those with only underexpression of enzyme A (p
< 7 10−5). Moreover, smaller tumors are observed for patients with ER− and
ER+ disease with active SDLs compared with patients with randomly selected
enzyme pairs with the A↓, B↑ pattern active (p < 2 × 10−3).
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Figure 4.4: Median BC tumor size (in millimeters) for patients with ER+ disease.
Arrowheads denote the median tumor size for all patients with ER+ BC (22 mm).
The number of patients that express at least one enzyme pair are denoted inside
the figures. (a) Patients with at least one active SDL (A↓, B↑) with constant
overexpression of enzyme B. (b) Patients whose disease only underexpresses
enzyme A (A↓, B) of the SDL. (c) Patients with at least one active SDL (A↓, B↑)
with constant underexpression of enzyme A. (d) Patients whose disease only
overexpresses enzyme B of the SDL (A, B↑).
4.2.6 SDL correlates with increased cancer survival time
As SDLs decrease BC tumor size, we hypothesized that their presence also af-
fects patient survival. For the BC data, matched survival times were available
such that we could correlate them to the level of SDL activation [40]. We hence
performed a survival analysis analogous to the tumor size analysis described
earlier. The significance of the results obtained for SDL were compared with
the single effects and random pairs by a modified signed Kaplan-Meier test in-
troduced in a previous publication [105] (see supplementary material section
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6). As expected, we found that patients with ER+ BC with at least one active
SDL have significantly better survival times compared to patients with only an
underexpression of enzyme A (p < 4 × 10−3, figure 4.5a and b). Patients with
activated highly ranked SDLs show the longest ER+ BC survival times, as long
as a median of more than 12 years (figure 4.5a). In line with expectation, the
survival time of patients with active SDL is significantly better compared with
patients with only enzyme B overexpressed (p < 3 × 10−4; figure 4.5c and d).
Moreover, significantly longer survival is also observed for patients with SDLs
compared with those with random enzyme pairs with the A↓, B↑ pattern active
(p < 1 × 10−3). Supplementary material section 7 provides survival analysis of
ER− patients. As overexpression of enzyme B is generally not beneficial when
enzyme A is not underexpressed, we wondered whether underexpressing en-
zyme B alone would be beneficial. Supplementary figure S4 indicates that this is
not the case. In particular, severe underexpression of enzyme B correlates with
increased tumor sizes (supplementary figure S4a and S4c) and decreased sur-
vival times (supplementary figure S4b and S4d) in patients with ER+ and ER−
BC.
4.2.7 SDLs predicted by IDLE are not expected to be specific for BC
To examine their predictive power in another cancer type, we analyzed a large
cancer type-specific cohort of 921 patients diagnosed with serous epithelial ovar-
ian cancer (OC) [81] with matched survival times. Indeed, the same observations
were made as in the case of patients with ER+ BC, i.e., patients with OC with
at least one active SDL have significantly better survival times compared with
those with the single or random effects (p < 0.09 vs. A↓, B and p < 0.01 vs. all
others; supplementary figure S5). These results are even more apparent in the
relapse-free survival times (OC-RFS) of these patients (p < 0.02 vs. (A↓, B) and
p < 9 × 10−4 vs. all others; supplementary figure S6).
4.2.8 Cumulative effect of SDLs in a tumor correlates with better
survival
As SDL activity in a tumor correlates to survival prognosis, we asked if sur-
vival time would increase when patients have more SDLs active. We tested the
presence of such a cumulative effect in the two largest cancer subtypes: patients
with ER+ BC (n = 1,174) and those with serous epithelial OC (n=921). Patients
were categorized into three groups, those having one to three, four to eight,
or more than eight active SDLs in their expression profiles (over- and underex-
pression are defined in Materials and methods). The Kaplan-Meier survival curve
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Figure 4.5: Median ER+ BC survival time (in years). Arrowheads denote the
median survival for all patients with ER+ BC (7.4 y). The numbers of patients
whose disease expresses at least one enzyme pair are denoted inside the figures.
Note that the axis of figure a scales differently. a) Patients with at least one active
SDL (A↓, B↑ ) with constant overexpression of enzyme B. b) Patients whose
disease only underexpresses enzyme A (A↓, B ) of the SDL. c) Patients with at
least one active SDL (A↓, B↑) with constant underexpression of enzyme A. d)
Patients whose disease only overexpresses enzyme B of the SDL (A, B↑ ).
(figure 4.6) shows, as expected, better survival for patients with large numbers
of active SDLs compared with those with only a few active SDLs. Indeed, a
log-rank test [17] revealed significantly improved survival times in both cancer
types when the number of active SDLs increases (p < 8 × 10−3 for ER+ BC
and p < 2 × 10−3 for OC and OC-RFS). The largest cumulative effect in the
BC survival is related to SDLs being active with enzyme A as one of the major
glycolytic hubs. Interestingly, the observed cumulative effect in OC is already
present for patients who have four to eight active (figure 4.6b). The underacti-
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vated enzymes A in these SDLs are enriched for pathways that use glutamine
through glutamate metabolism, the TCA cycle and mitochondrial transport (p
< 0.001, hypergeometric test). It has recently been shown that severe types of
OC, such as the epithelial subtype we considered are driven by glutamine me-
tabolism, in contrast to BC tumors that depend on an overactivity of glycolytic
enzymes [237].
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Figure 4.6: Kaplan-Meier survival curves for patient groups that have one to
three, four to eight, or more than eight active SDLs. a) Survival times for the
patients with ER+ BC. b) Survival times for patients with serous epithelial OC.
4.3 Discussion
Here we introduced what is, to our knowledge, the first computational method
that captures enzymatic SDL effects in metabolic networks. Our method does
not only identify SDLs that are strictly lethal to the cell, but also those that
have a significant effect on tumor growth or proliferation in clinical settings (i.e.,
‘synthetic dosage sick’). We show that our method is able to assign a measure of
strength θ to each SDL, which correlates to its predictive power in an array of dif-
ferent tumor clinical attributes. It is therefore of interest to focus further research
toward therapeutic interventions on the basis of ‘high-impact’ pairs, which may
have the largest beneficial effect on killing cancer cells. We show that SDLs are
less frequently active than expected in cancer cells. This shows that rapidly ex-
panding cancer cells select against interactions that reduce their growth rate.
The activation of ‘high-impact’ SDLs is associated with smaller tumor sizes and
longer patient survival. The effect strongly depends on the extent to which SDLs
are activated, but most SDLs we found do not require a complete enzyme KO
to exert a functional predictive signal. Last, we demonstrated a cumulative ef-
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fect of SDL presence; the more SDLs active in a tumor sample, the better this is
for a patient’s prognosis. This observation may shed light on targeting cancers
that rely on glycolysis. Down-regulating glycolytic enzymes that are the major
hubs in the SDL network is hence expected to have a large growth-inhibitory
effect in tumor cells that overexpress many of the glycolytic SDL partners. As
glycolysis is usually less active in normal cells and SDL partners of glycolytic
hubs are less frequently overexpressed in normal cells compared with cancer
cells in the majority of tissue types (supplementary material section 2.2), target-
ing these glycolytic SDLs may be of therapeutic interest, especially when a large
number of their partners are overexpressed. The present study, being the first
of its kind of which we are aware, naturally focuses on harnessing the generic
human metabolic model to identify a common core of SDLs that may be shared
by many different cancer types. However, the IDLE approach is general and
could be extended in the future to identify cancer type-specific SDL interactions
more precisely by integrating patient- and tumor-specific omics data such as
gene expression or proteomics. The results of our metabolic network modeling
do not support the hypothesis that SDLs arise as a result of draining alterna-
tive compensatory pathways that compensate for the loss of the KO enzyme.
This is because we do not find that the flux in such backup reactions of the
major key glycolytic enzyme hubs is reduced following the overexpression of
their SDL partners. Intriguingly, we do find that disrupted glycogen metabo-
lism is predicted to be the major mechanism by which hundreds of SDLs of key
glycolytic enzymes exert their growth-inhibitory effects. Indeed, it has recently
been shown that glycogen metabolism and its initial accumulation is key for
optimal glucose utilization in tumors [55]. Thus, SDL relations do not arise via
simple proximal interactions, but are likely to be the result of complex stoichio-
metric network relations that withdraw flux from biomass production through
activation of other pathways.
Our results testify to the potential contribution of model-based approaches
to identify and uncover the mechanisms behind SDLs. Model-based SDL pre-
diction via IDLE is widely applicable and not limited to cancer. It could be
used to identify SDL networks in pathogenic bacteria or fungi, providing new
antibiotic therapeutic leads. Other possible applications include metabolic engi-
neering to increase the yield of valuable metabolic byproducts. Specifically, this
may be achieved by engineering a SDL effect to inhibit the production of unde-
sired byproducts, or inversely, neutralizing the SDL effect to force an increased
flux through desired pathways. Taken together, IDLE is expected to contribute
to various research fields ranging from medical sciences to biotechnology.
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4.4 Materials and methods
IDLE requires a GSMMwithmmetabolites, n reactions and a well-defined cellu-
lar objective function. We used the human metabolic network (recon1) [50], sup-
plemented with a biomass reaction to simulate growth. A rich environment was
simulated by allowing a maximum metabolite uptake rate of 5.0 mmol/gram
dry weight/h through all boundary reactions. The goal of IDLE is to find SDL
enzyme pairs (A, B) that severely interrupt cell growth when the flux through
enzyme A is decreased and the flux through B is increased (denoted as A↓, B↑).
As illustrated in figure 4.1 and supplementary material section 1, SDL is mea-
sured by an angle θ. Only those enzyme pairs with a significant difference
between the reference and KO were analyzed, i.e., all pairs with |θ| ≥ 2° were
selected, resulting in a list of 12,447 putative SDLs. Supplementary material
section 1 provides a detailed description of IDLE with an example.
In all analyses, we defined an enzyme/gene to be under- or overexpressed
when its expression was below or above 0.5σ to 1.0σ from the mean in the gene
expression distribution (see Results for references to gene expression datasets).
Detailed procedures of mapping gene expression to enzyme reaction level and
calculating the fraction of SDLs in cancer cells (Fsdl) and descriptions of tumor
size and patient survival statistics are provided in supplementary material sec-
tion 1.
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Predicting genetic interactions from
cancer genome evolution
Synthetic Lethal (SL) genetic interactions play a key role in various types of biological
research, ranging from understanding genotype-phenotype relationships to identifying
drug-targets against cancer. Despite recent advances in empirically measuring SL inter-
actions in human cells, the human genetic interaction map is far from complete. Here,
we present a novel approach to predict this map by exploiting patterns in cancer genome
evolution. First, we show that empirically determined SL interactions are reflected in
various gene presence, absence and duplication patterns in hundreds of cancer genomes.
The most evident pattern that we discovered is that when one member of an SL interac-
tion gene pair is lost, the other gene tends not to be lost, i.e. the absence of co-loss. This
observation is in line with expectation, because the loss of an SL interacting pair will
be lethal to the cancer cell. SL interactions are also reflected in gene expression profiles,
such as an under representation of cases where the genes in an SL pair are both under
expressed and an over representation of cases where one gene of an SL pair is under
expressed, while the other one is over expressed. We integrated the various previously
unknown cancer genome patterns and the gene expression patterns into a computational
model to identify SL pairs. This simple, genome-wide model achieves a high prediction
power (AUC = 0.75) for known genetic interactions. It allows us to present for the first
time a comprehensive genome-wide list of SL interactions with a high estimated predic-
tion precision, covering up to 591,000 gene pairs. This unique list can potentially be
used in various application areas ranging from biotechnology to medical genetics.
This chapter is based on Lu X., Megchelenbrink W.L. et al. (2015),
Predicting human genetic interactions from cancer genome evolution, published in PLOS ONE. Supple-
mentary material is online available at PLOS ONE.
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5.1 Introduction
A synthetic lethal (SL) genetic interaction is defined as a functional relationship
between two genes where the loss of either gene is viable but the loss of both is
lethal [85]. A comprehensive map of SL interactions sheds light on the relation-
ships between genotype and phenotype [92, 246, 18, 89], potentially advancing
the understanding of the mechanisms of complex human disease [56, 152], and
even providing therapeutic treatment strategies for human diseases such as can-
cer [26]. For instance, several studies have shown that inhibiting one gene in
an SL pair could be lethal to cancer cells in which the other gene of that pair is
mutated [6, 110, 145]. The underlying concept is that, in a cancer cell, a muta-
tion in one (A) of the two genes in an SL pair (A-B), which is not mutated in
the normal cell, allows for selectively killing tumor cells by inhibiting B. Despite
recent breakthroughs in technologies to identify SL interactions on a genome-
wide scale [189, 94, 37, 7], these interactions remain largely unknown in human,
underlining the need for predictive computational approaches.
Previous computational approaches have mostly been developed to predict
SL interactions in model microorganisms, such as Saccharomyces cerevisiae and
Caenorhabditis elegans [243, 235, 168]. However, genetic interactions are not
strongly conserved between species, for instance only 29% of genetic interac-
tions were found to be conserved between the fungi S.cerevisiae and Schizosac-
charomyces pombe [49] and the conservation of SL interactions between microor-
ganisms and human still has to be established. Recently, a study proposed to
use cancer genomic data [105] to identify SL interactions by using a ‘compensa-
tion’ pattern: one gene (A) is inactive while the other one (B) is highly active,
thereby selecting against the situation that both genes become lost and, as such,
causing a lethal phenotype. We recently showed another genomic pattern of
SL interacting gene pairs: SL interactions are reflected in present-day species
genomes and their ancestral genomes in a way that the combined loss of two
genes in an SL pair does not frequently occur across evolutionary history [131].
This raises the question whether we can use this ‘co-loss underrepresentation’
pattern to predict SL pairs from human cancer genomes (figure 5.1a). Here, we
used copy number variations, i.e. gene loss or gene gain, across hundreds of can-
cer genomes to ask i) are empirical SL interactions reflected in cancer genome
evolution and, if so, ii), which gain and loss patterns correlate most with SL
interactions, and iii) can they be captured into a simple computational model to
predict SL interactions genome widely?
By exploiting the availability of gene expression data for a large number of
cancer samples collected by the Cancer Genome Atlas (TCGA) 1 and recent em-
1The results shown here are in whole or part based upon data generated by the TCGA Research
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pirically measured SL interactions in human [123, 226], we found that genes
with SL interactions are more likely to have an expression pattern where one
gene is over-expressed while the other one is under-expressed, thereby confirm-
ing earlier observations [105]. Strikingly we observed that SL pairs are less likely
to be co-lost and co-under expressed than non-SL gene pairs. On the basis of
these findings, we present a simple ensemble-based computational model that
captures the genomic patterns to predict genome-wide SL pairs with high accu-
racy. We provide a unique and comprehensive map of the human SL interaction
network with a high estimated prediction precision of 67%, i.e., 14-fold higher
than expected from chance, covering 591,000 pairs. This map is expected to
be highly valuable in the light of understanding human disease and designing
therapeutic strategies.
5.2 Materials and methods
5.2.1 Data sources
We retrieved the experimentally measured SL pairs and non-SL pairs from two
studies [123, 226]. We collected 297 SL pairs and 6,358 non-SL pairs in total.
After excluding the pairs of which both genes are located on the same chromo-
some, we obtained 270 SL pairs and 5,660 non-SL pairs (supplementary material
table S1).
The CNV data was retrieved from the cBioPortal for Cancer Genomics [70].
The CNV signals in the database are generated as homozygous deletion, het-
erozygous deletion, normal copy, duplication and amplification. Using the cgdsr
R-package, we obtained the CNV data for 14136 tumor patients from 31 cancer
types.
RNAseq data were obtained from the Broad Institute’s Genome Data Ana-
lysis Center (GDAC) Firehose 2. The link for downloading the RNAseq data
is http://gdac.broadinstitute.org/runs/stddata__2014_03_16/data. For a
cancer study, we first downloaded the files named as RSEM genes normalized
data.Level 3, which contains the estimated expression levels for each gene in hu-
man genome from RNAseq data by using the RSEM package [128]. In total we
collected an expression profile for 7,362 tumor patients with coverage of 26 can-
cer types. Then, for each gene in a tumor, we computed the z-score and p-value
to infer its over- or under-expression relative to expression levels in normal tis-
sue. If at least 25 normal samples from the same tissue type as that of the cancer
Network: http://cancergenome.nih.gov
2Broad Institute TCGA Genome Data Analysis Center (2014): Analysis Overview for 16 March
2014. Broad Institute of MIT and Harvard
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are available, we used this as the comparison set. Otherwise, all normal tissue
samples, regardless of the tissue specificity, were used. The numbers of normal
samples for each type of tumor are listed in supplementary table S2. To adjust
for multiple hypothesis testing, we used the False Discovery Rate (Benjamini-
Hochberg) method to adjust p-values [13, 14] in R. A cutoff of the adjusted
p-value, 0.05, was applied to generate the over- or under-expression signal.
5.2.2 Extracting the pattern for SL pairs from genomic variations
The copy number variations can be, -2 = homozygous deletion, -1 = heterozy-
gous deletion, 0 = normal copy, 1 = duplication, and 2 = amplification. For a
gene pair (A, B), the co-loss event can be i) homCL: homozygous co-loss (-2, -2),
ii) hetCL: heterozygous co-loss (-1, -1) or iii) mixCL: mixed co-loss (-2, -1 or -1,
-2). For each co-loss event, we defined a fraction that quantifies the likelihood of
the co-loss event. For instance, for the homozygous co-loss event, we defined the
fraction for a gene pair A-B as f1 = nhomCL/nt, where nhomCL is the number
of patients with the homozygous co-loss of A-B and nt is the total number of
patients where A-B have a status as (-2, -2), (-2, 0) or (0,-2). We calculated the
f1 of a gene pair without including samples that have homozygous deletions of
more than 2000 genes (tail of the distribution in Figure A in S1 File). We noticed
that several tumor samples have a very high number of homozygous deletions
(supplementary figure S1A). Such samples can lead to an inflation of the co-loss
likelihood regardless of whether they have an SL interaction or not. Similarly,
we defined two fractions, f2 and f3, for heterozygous co-loss event and mixed co-
loss events correspondingly (Table 1 and figure 5.1). It should be noted that we
did not use an approach in which we, in order to quantify under representation
of co-loss events, compared the empirically observed co-loss rate of gene pair
A-B with the product of the single loss rates for genes A and B. This approach
assumes independence between the loss of randomly chosen genes, which is not
what we observe (supplementary figure S1A).
The variations in gene expression can be: -1 = under-expression, 0 = normal,
and 1 = over-expression. Here, we defined two fractions, f4 and f5 (table 5.1
and figure 5.1). f4 quantifies the likelihood of both genes in a pair (A, B) are
under-expressed. f5 is used to quantify how likely gene pair A-B has the ex-
pression up-down events, i.e., A is over expressed and B is under expressed or
vice versa.
Here, each defined fraction is a signal where SL pairs show difference from
non-SL pairs. For f1, f2, f3 and f4, we expected that SL pairs have smaller
values for these fractions than non-SL pairs. However, for f5 we expected that
SL pairs have larger values than non-SL pairs. To test these hypotheses, we com-
66
5.2. Materials and methods
SNP arrays: CNVs RNAseq: expression variations
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+
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+
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Figure 5.1: Patterns across cancer genomes reflecting selection against gene co-
inactivation and the workflow to predict SL interactions.
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Figure 5.1: Patterns across cancer genomes reflecting selection against gene co-
inactivation and the workflow to predict SL interactions. a) A SL interaction
SL1 between gene A and B can show a ‘compensation’ pattern across cancer
genomes in which it is more likely that when A is inactive (denoted by -1), B
is overactive (denoted by 1) to compensate the inactive A (genomes 110), com-
pared to when A is active (genomes 1130). SL interaction SL2 can show a ‘co-loss
underrepresentation’ in which a combined loss of A and B (denoted by -1 and
-1, genome 10) across cancer genomes is underrepresented compared to a loss
of either one of the two (genomes 29 and genome 1418). Note that SL1 can also
be identified via the co-loss underrepresentation pattern, but the SL2 can only
be identified via the co-loss underrepresentation pattern. b) The model requires
two types of data as input, i) CNVs measured by SNP arrays and ii) gene ex-
pression variations measured by RNAseq. In CNVs, the status of a gene can be
a homozygous deletion (two dashed lines), a heterozygous deletion (one dashed
and one solid line) or normal (two solid lines). For CNVs, we generated three
fractions to quantify the likelihood that a gene pair has a homozygous co-loss
(f1), a heterozygous co-loss (f2) or a mixed co-loss (f3) event. In gene expres-
sion variations, a gene can be under-expressed (one dash line), normal (one
solid line) or over-expressed (one bold line). For expression status, we gener-
ated two fractions, f4 and f5. f4 is the likelihood that both genes in a gene pair
are under-expressed. f5 is the likelihood that a gene pair has an expression up-
down event where one is over-expressed while the other one is under-expressed.
All these five fractions showed a distribution difference between SL and non-SL
pairs. By integrating these five fractions into a prediction model, we can identify
SL interactions that can be presented as a network.
pared the fractions in SL pairs with the fractions in non-SL pairs via one-sided
Wilcoxon rank tests in R. We carried out four comparisons of homozygous dele-
tion, heterozygous deletion, mixed deletion and co-underexpression to estimate
the difference of co-loss tendency between SL and non-SL pairs. In the analy-
sis of up-down compensation, we carried out two comparisons of expression
up-down or genomic up-down. Bonferroni correction was used to correct for 4
multiple comparisons in the analysis of co-loss tendency and 2 multiple com-
parisons in the analysis of up-down compensation (p-values are indicated with
Padj.).
To validate the robustness of the signals, we compared the fractions in SL
pairs to the fractions in random pairs. In each randomization, we first generated
300 random pairs from all human genes for which gene expression and CNV
were available and then compared the mean of the fractions in the random pairs
with the mean in SL pairs. We expected that the random pairs have a smaller
mean of f1, f2, f3 or f4 but a larger mean of f5 than SL pairs. To test the
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Table 5.1: Five fractions derived from genomic variations for SL interaction iden-
tification.
f1 = nhomCL/nt nhomCL =

A = −2
and
B = 2
nt =

A = −2 and B ∈ Z
or
A ∈ Z and B = −2
where Z = 0 or− 2
f2 = nhetCL/nt nhetCL =

A = −1
and
B = −1
nt =

A = −1 and B ∈ Z
or
A ∈ Z and B = −1
where Z = 0 or− 1
f3 = nmixCL/nt nmixCL =

A = −2
and
B = −1
nt =

A = −2 and B ∈ Z
or
A ∈ Z and B = −1
where Z = 0 or− 2
f4 = nco-under/nt nco−under =

A = −1
and
B = −1
nt =

A = −1 and B ∈ Z
or
A ∈ Z and B = −1
where Z = 0 or− 1
f5 = ncomp/nt ncomp =

A = −1
and
B = 1
nt =

A = −1 and B ∈ Z
or
A ∈ Z and B = −1
where Z = 1, 0 or− 1
hypotheses, we counted the randomizations (n1) where the difference of mean
between the random pairs and SL pairs is contradictory to the expectation. For
each comparison, we conducted 1000 randomizations and calculated the p-value
for each hypothesis test as p = (n1+1)/1001.
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5.2.3 Under-sampling
The training set is significantly skewed with only 4.6% of the pairs belonging to
the positive class (SL pairs) and the rest belonging to the negative class (non-SL
pairs). Such a skewed training set can affect the performance of most standard
classification algorithms [147]. Thus, we generated a more balanced training set
by randomly under-sampling the negative class so that the number of gene pairs
in it is equal to that of the positive class. The under-sampling is conducted with
ROSE package [133] in R and repeated 100 times. All the classifiers in the study
are trained on the balanced set.
5.2.4 Constructing the ensemble-based prediction model
We adopted an ensemble-based model to integrate the aforementioned five sig-
nals for predicting whether a gene pair has an SL interaction or not. The bal-
anced training set (described above) was used to train the ensemble-based pre-
diction model that combines multiple classifiers, namely AdaBoost, J48, Log-
itBoost, RandomForest, Logit, JRip and PART. The combination rule is simply
based on the mean function p(x) = 1N
∑N
i=1 pi(x) where x is a given gene pair
and pi(x) is the probability that x is predicted to be SL by classifier i. The prob-
abilities pi(x) from all classifiers, except for RandomForest, are obtained from
the ‘RWeka’ package [95]. The RandomForest classifier is implemented with the
‘randomForest’ package in R [129].
To quantify the performance of the ensemble-based model, we used a 10-fold
cross-validation framework on all empirically measured 270 SL pairs and 5,660
non-SL pairs. In each cross-validation, the ensemble-based model is trained on
nine of the randomly constructed 10 fractions and predictions are made for the
test samples in the remaining fraction. The performance of the model in each
cross-validation is evaluated by a ROC curve, the corresponding AUC score
and a precision-recall curve. Repeating this procedure ten times, a mean ROC
curve, a mean AUC score and a mean precision-recall curve are calculated as
the evaluation for the performance of the ensemble-based prediction model.
5.2.5 Constructing the genome-wide human SL interaction map
To predict SL interactions in human at a genome-wide scale, we first selected
15,620 genes that are measured for both CNV and mRNA variations in cancer
cells. As mentioned in the results section, due to the presence of arm-level
copy number variations, gene pairs on the same chromosome are more likely
to be co-lost regardless of the status of SL interaction. Thus, we applied our
model to approximately ≈115 million genes pairs that are located on different
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chromosomes. To construct a highly accurate SL interaction map, we predicted
a list of more than 591,000 SL interactions based on a probability score (p(x))
threshold of 0.81, which achieved a precision of 67% at a recall of 10%.
5.3 Results
5.3.1 SL interactions are reflected in cancer genome evolution
We first asked whether empirically observed SL interactions are reflected in gene
presence/absence and gene expression in cancer cells. To answer that, we used
two types of genome variation from the Cancer Genome Atlas (TCGA) i.e., i)
copy number variations (CNVs) and ii) gene expression variations. The TCGA
consortium measured 14,136 tumor samples for CNVs and 7362 tumor samples
for gene expression variations. To determine whether genes in cancer samples
are significantly over- or under-expressed, we determined their expression-levels
relative to normal samples of the same tissue type (Methods). We obtained
the empirical SL interactions from two recent studies [123, 226] that measured
SL interaction in colon tumor cell lines and have the highest genome coverage
among all the studies available. In total we collected 270 SL pairs and 5,660
non-SL pairs (supplementary table S1).
We first tested whether SL pairs are less likely to be co-lost in a genome than
non-SL pairs. A gene can either be homozygously or heterozygously deleted.
We first focused on homozygous losses in which both copies of a gene are lost.
We express the likelihood of homozygous co-loss of both genes in a gene pair by
the fraction f = n1/n2, where n1 is the number of tumor samples with a co-loss
of both genes and n2 is the number of tumor samples in which at least one gene
is lost (seeMethods and figure 5.1). Indeed, we found that SL pairs are less likely
to be homozygously co-lost than the non-SL pairs (0.00728 vs 0.0104, one-sided
Wilcoxon rank test, Padj. ≤ 0.008, figure 5.2a).
We performed several additional analyses to show that this result is valid
and robust. First, we showed that the difference in co-loss events is not caused
by the difference in single gene loss rates. Indeed the homozygous gene deletion
rate of the genes in SL pairs is not different from the deletion rate of the genes
in non-SL pairs (0.00402 vs 0.00406, two-sided Wilcoxon rank test, p ≤ 0.38).
Secondly, given the limited genome coverage of the known SL and non-SL pairs
available for our analysis, we also compared the likelihood of co-loss events of
SL pairs with random pairs from the human genome. We found a significant
difference in co-loss between SL pairs and random pairs (0.00728 vs 0.0128, 1000
randomizations, Padj. ≤ 0.012, figure 5.2a). This shows that the difference in the
likelihood of co-loss events between the SL pairs and the random gene pairs is
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Figure 5.2: SL pairs are reflected in copy number variations. SL pairs are less
likely to have a) homozygous co-loss events, b) heterozygous co-loss events and
c) mixed co-loss events than non-SL pairs or random pairs. The fractions for
these three types of co-loss events are described as f1, f2, f3 in Methods and
figure 5.1. Each dot is the fraction for a given pair and the horizontal bar rep-
resents the mean of the fractions. P-values for the comparison between SL and
non-SL pairs were calculated using one-sided Wilcoxon rank test. P-values for
the comparison between SL and random pairs were calculated from 1000 ran-
domizations. P-values were adjusted for multiple comparisons using the Bon-
ferroni correction (see details in Methods).
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a consistent signal across the human genome. The difference between SL pairs
and random pairs is larger than the difference between SL pairs and non-SL
pairs (figure 5.2a). This is likely due to the fact that the genes included in the
experiments tend to be biased towards those that are frequently lost, i.e. the
homozygous deletion rate of genes in SL/non-SL pairs is higher than that in
random pairs (0.0049 vs 0.0042, one-sided Wilcoxon rank test, p ≤ 0.04). It
should furthermore be noted that we require the gene pairs included in the
analysis to be composed of genes on different chromosomes. The reason for this
is that the presence of arm-level copy number variations will always cause a high
probability of co-loss for the gene pairs on the same chromosome regardless of
whether they have an SL interaction or not.
Besides a homozygous co-loss, with both genes homozygously deleted, there
is also the possibility of a heterozygous co-loss, where both genes are heterozy-
gously deleted and a mixed co-loss where one gene is homozygously deleted
and the other is heterozygously deleted. For the heterozygous co-loss and for the
mixed co-loss event we carried out the same analysis as done above for the ho-
mozygous co-losses. For both types of co-loss events, we found a significant and
robust signal, i.e., the SL pairs are less likely to be co-lost than the non-SL pairs
(for heterozygous co-loss 0.1935 vs 0.216, one-sided Wilcoxon rank test, Padj. ≤
1.08e-08, figure 5.2b; for mixed co-loss 0.189 vs 0.2008, one-sided Wilcoxon rank
test, Padj. ≤ 0.02, figure 5.2c). As was the case for the homozygous co-losses,
both signals are consistent when SL pairs are compared with random gene pairs
(for heterozygous co-loss 0.1925 vs 0.218, Padj. ≤ 0.004, figure 5.2b; for mixed
co-loss 0.189 vs 0.210, Padj. ≤ 0.032, figure 5.2c).
We next examined gene expression levels, where we expected to find a sim-
ilar signal to the one we found at the level of gene absence/presence, since the
under-expression of one gene can also result in the loss of its activity. Indeed, we
found that SL pairs are less likely to be both under-expressed than non-SL pairs
(0.0443 vs 0.0586, one-sided Wilcoxon rank test, Padj. ≤ 2.39e-10, Fig 3A). Only
pairs composed of genes on different chromosomes are included in the analysis.
Again the signal is consistent when SL pairs are compared with random gene
pairs (0.0443 vs 0.0570, Padj. ≤ 0.004, figure 5.3a).
Previous studies [44, 109] have shown another pattern in genes in SL pairs
at the transcription level. In this pattern one gene of an SL interacting pair
is over-expressed while its partner is under-expressed. Thus, we expected that
compared with non-SL pairs, SL pairs would have higher probabilities to have an
expression pattern where one gene is over-expressed while the other is under-
expressed. We refer to this as expression up-down. The probability of this
expression pattern is quantified by the fraction f = n1/n2, where n1 is the num-
ber of tumor samples that have the pattern and the n2 is the number of tumor
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Figure 5.3: SL pairs are reflected in gene expression variations. a) SL pairs are
less likely to be co-underexpressed relative to the control i.e., non-SL or random
pairs. The fraction for co-underexpression events is described as f4 in methods
and figure 5.1. b) SL pairs are more likely to have expression up-down events
where one gene is over-expressed while the other in under-expressed. The frac-
tion for such pattern is described as f5 in Methods and figure 5.1. Each dot is
the fraction for a given pair and the horizontal bar represents the mean of the
fractions. P-values for the comparison between SL and non-SL pairs were calcu-
lated with a one-sided Wilcoxon rank test. P-values for the comparison between
SL and random pairs were calculated from 1000 randomizations. P-values were
adjusted for multiple comparisons using the Bonferroni correction (for details
see Methods).
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samples that have an under-expression of at least one of the genes (see Meth-
ods and figure 5.1 for details). As expected, we found that SL pairs are more
likely to have this expression pattern than non-SL pairs (0.250 vs 0.211, one-
sided Wilcoxon rank test, Padj. ≤ 2.10e-04, figure 5.3b). Again, we validated the
consistency of the signal by comparing the likelihood of this expression pattern
in the SL pairs against its likelihood in random pairs (0.250 vs 0.146, 1000 ran-
domizations, Padj. ≤ 0.002, figure 5.3b). We note that the difference between
SL pairs and random pairs is higher than that between SL pairs and non-SL
pairs. This is possibly due to the fact that the genes included in the experiments
were biased towards those that are more likely to be over-expressed when one
is mutated, i.e., the over-expression of genes in non-SL pairs is higher than that
of random genes (0.0957 vs 0.0789, one-sided Wilcoxon rank test, p ≤ 1.08e-06).
We also analyzed a genomic pattern at the gene presence/absence level by cal-
culating the probability for each gene pair to have a CNV pattern where one
gene is duplicated or amplified while the other one is homozygously or het-
erozygously deleted, referred to as genomic up-down in the remainder of the
text. We found that SL pairs indeed have a higher probability to have the ge-
nomic up-down combination at the DNA level than non-SL pairs (0.300 vs 0.274,
one-sided Wilcoxon rank test, Padj. ≤ 1.65e-07), but this is not significant when
we compared the SL pairs to random gene pairs.
In total, we found five patterns in the CNVs and gene expression variations
in cancer cells, all of which showed that synthetic lethal interactions are reflected
in cancer genome evolution. These five patterns fall into two categories: i) genes
in SL pairs are more likely to be over-expressed when their interaction partner
is under-expressed and ii) genes in SL pairs are less likely to be co-lost either at
the DNA level or at the gene expression level.
5.3.2 An ensemble-based model for predicting SL interactions
We next asked whether these five genomic patterns are strong enough to reliably
predict SL pairs in human on a genome-wide scale. To do that we developed
an ensemble-based model that integrates the five patterns. It should be noted
that we did not include the genomic up-down pattern found in CNVs since
SL pairs are not significantly different from random pairs. An ensemble-based
model is a classifier that combines the prediction results from multiple classi-
fiers, such as decision trees and logistic regression. It is known that such an
ensemble-based model can improve performance relative to a single classifica-
tion procedure [190], especially for complex problems such as SL prediction
involving noisy inputs [48].
We used the empirically measured 270 SL pairs and 5,660 non-SL pairs as
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described in the previous analysis. To construct the prediction model, we first
needed to handle the imbalance of sample size between the negative class, i.e.
non-SL pairs, and the positive class, i.e. SL pairs. The skewed distribution of the
classes can affect the performance of prediction models [147]. To solve this is-
sue, we randomly under-sampled the negative class (non-SL pairs, 95.4% of the
training set) to produce a set of negative samples of the same size as the positive
class (SL pairs, 4.6% of the training set). This balanced combination of two sets
is used to train an ensemble-based model for SL prediction. Note that the under-
sampling is only applied to the training set. In total we selected seven different
single classifiers as the base for the ensemble model: AdaBoost [67], J48 [179],
LogitBoost [69], RandomForest [23], Logit [124], JRip [36] and PART [66], which
are either robust against noisy data or over-fitting. After being trained with the
balanced set, each single classifier generates a probability that a gene pair has
an SL interaction. Then we integrated all seven probabilities from these single
classifiers by calculating the mean of the seven probabilities and used that as the
final predicted probability.
To assess the performance of the ensemble-based prediction model, we used
a 10-fold cross-validation on all the empirically measured 270 SL pairs and 5,660
non-SL pairs. The plot of sensitivity (i.e., true positive rate) versus false positive
rate of the ensemble-based model shows that our model achieves an area under
ROC curve (AUC) of 0.75 (standard error = 0.016, figure 5.4b). It should be noted
that this high AUC is only achieved when combining all patterns (Fig 4A). We
also found that the ensemble-based model achieved the highest AUC compared
to all seven single classifiers (figure 5.4b). In order to predict a genome-wide
SL interaction map, we estimated the average precision and recall values from
the 10-fold cross-validation (figure 5.4c). We then applied the model to all gene
pairs on the genome. Among ≈115 million pairs for which gene expression
and CNV data were available, we predicted more than 591,000 SL interactions
based on a probability score threshold of 0.81 (figure 5.4c), which corresponds
to an estimated precision of 67% based on our training set, i.e., 14-fold higher
than expected from chance (supplementary dataset S1). Note that the model
achieves a similar precision (60% at p = 0.81) when using an independent set of
experimentally measured SLs (supplementary figure S1C).
5.4 Discussion
In this study we present a novel computational model that identifies SL inter-
actions from cancer genomic data on a genome-wide scale. To develop such
a model, we first systematically explored how SL interactions are reflected in
cancer genomes and their gene expression levels. We found that compared
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Figure 5.4: Receiver operating characteristic (ROC) curves. a) The ensemble-
based prediction model based on all five combined patterns has an area under
curve (AUC) of 0.75 (blue line), which is estimated by 10-fold cross validation.
Ensemble-based prediction models based on the non-combined individual pat-
terns, i.e., co-loss in CNVs, co-underexpression and expression up-down, are
shown in red, green and purple respectively and have lower AUCs. Standard
error bars are added to each ROC. b) The ensemble-based prediction model (the
blue ROC curve) has a better performance than all the seven single. c) The pre-
cision and recall curve is estimated from 10-fold cross validation. Standard error
bars are added. The curve is colored according to the cutoff of probability. The
color panel of the probability is plotted at the right side. The cutoffs of proba-
bility scores (p(x)), 0.81, are printed at the corresponding curve positions. The
grey line represents the prediction precision by chance alone.
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with non-SL pairs, genes in SL pairs are significantly less likely to be co-lost
in a cancer genome, both at the level of gene expression and at the level of
copy number variation. Moreover, SL pairs are more likely to have an expres-
sion up-down pattern where one gene is over-expressed while the other one is
under-expressed, which is consistent with another recent study [105]. Based on
these results, we constructed an ensemble-based model to predict SL interactions
via integrating these unique patterns in cancer genome variations, achieving a
high prediction performance (AUC = 0.75). Our work presents a direct way
to predict SL interactions from cancer genomic data, in contrast to most exist-
ing computational models, which identify SL interactions either specific for the
model organisms yeast and C. elegans [243, 235, 168], or predict SL pairs in hu-
man in an indirect way by mapping SL interactions from yeast to human via
orthology [45]. A strategy that uses human genomes by exploring the ‘com-
pensation’ pattern also requires, as an additional criterion, that the genes are
generally co-expressed [105]. As SLs have the characteristic that only one of the
two genes is strictly needed, co-expression is not crucial. As such, co-expression
as an additional criterion limits the coverage of SL interactions encoded in the
genome, which is reflected in the total number of predicted SL pairs by Jerby-
Arnon L. et al. (2,816 with accuracy of 0.779) [105]. In contrast, our approach,
which does not rely on co-expression, predicts many more SL interactions with
a comparable accuracy (591,000 with an estimated accuracy of 0.75).
Future work should focus on the following issues to improve the perfor-
mance of the model. First, given the genomic and micro-environment hetero-
geneity among different types of tumors [28, 106], the empirically detected SL
interactions included in our analysis might be only specific to colon cancer in
which the experiments were carried out. As genetic interactions were found
to be growth condition specific [84], it might be that two genes are co-lost in
certain tumors simply because the functions of these SL pairs are not essential
for that particular cancer type. Such discordance of tissue types might have
dampened the effect size we discovered. To improve this, one can focus on
gene-expression and CNVs that are taken from the same tumor type as the em-
pirical SLs. A model can then be constructed to predict tumor type specific SLs,
which is valuable to overcome the challenges posed by inter-tumor heterogene-
ity in cancer treatments. Secondly, our model only considered gain or loss of
gene function caused by CNVs and variations in gene expression. There are
other mutations that can result in gain or loss of gene functions, such as muta-
tions of miRNA [130, 169] and epigenetic mutations [98, 91]. When knowledge
becomes available on how these other types of genomic variations affect gene
function and genetic interactions, these mutations could also be taken into ac-
count. Thirdly, our model achieves a good prediction performance by a 10-fold
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cross validation. However, we note that the model is trained on a relative small
number of available SL and nonSL pairs, which constraints a precise estimation
of the model performance for genome-wide prediction. The performance can
be better estimated in the future when more empirically measured SLs become
available. Finally, it still remains to be seen to what extent these predicted SL
interactions from cancer genomes are relevant to understand other diseases. For
diseases where CNV or gene expression data are available, one can prioritize
disease-associated SL interactions from our prediction list by selecting pairs that
are co-lost in the disease.
Taken together, we systematically investigated and showed that SL interac-
tions are reflected in genome evolution of cancer in various forms. Based on the
unique patterns discovered in cancer genomics, we proposed a simple approach
to identify SL, which strongly improves existing frameworks. We generated a
unique SL interaction network in human at the genome-scale covering up to
591,000 pairs with a high estimated precision. In the light of medical genet-
ics, this list is highly valuable in the search for anti-cancer drug targets and in
understanding human diseases.
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Chapter 6
Weighted co-expression predicts new
genes for molecular systems
We have developed the Weighted Gene Expression Tool and database (WeGET) for the
prediction of new genes of a molecular system by correlated gene expression. WeGET
utilizes a compendium of 465 human and 560 murine gene expression datasets that have
been collected from multiple tissues under a wide range of experimental conditions. It
exploits this abundance of expression data by assigning a high weight to datasets in
which the known genes of a molecular system are harmoniously up- and downregulated.
WeGET ranks new candidate genes by calculating their weighted co-expression with
that system. A weighted rank is calculated for human genes and their mouse orthologs.
Then, an integrated gene rank and p-value is computed using a rank-order statistic. We
applied our method to predict novel genes that have a high degree of co-expression with
Gene Ontology terms and pathways from KEGG and Reactome. For each query set we
provide a list of predicted novel genes, computed weights for transcription datasets used
and cell and tissue types that contributed to the final predictions. The performance for
each query set is assessed by 10-fold cross-validation. Finally, users can use the WeGET
to predict novel genes that co-express with a custom query set.
6.1 Introduction
Ever since the publication of the first gene expression arrays, the correlated ex-
pression of genes involved in a related molecular process has been used to pre-
dict functional relations between gene pairs [35]. Large amounts of microarray
This chapter is based on Szklarczyk R., Megchelenbrink W.L. et al. (2015),
WeGET: predicting new genes for molecular systems by weighted co-expression, published in Nucleic acids
research. Supplementary material is online available at Nucleic acids research.
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and RNA-seq transcript expression, measured under a plethora of conditions
enable mining for concordantly expressed genes. Indeed, this concept has been
successfully employed in databases such as COEXPRESSdb, GeneFriends, Gen-
eMANIA and STARNET 2 [107, 159, 41, 245]. Nevertheless, relative to other
types of genomics data, co-expression has lower sensitivity and selectivity [157].
To improve the quality of the predictions, various strategies have been applied,
like exploiting the conservation of co-expression between species [227], combin-
ing many gene expression datasets [125, 244] or biclustering datasets to identify
groups of genes that co-express within a subset of the experiments (see [137]
for a review). Expression screening, an extension of biclustering methods [10],
weighs gene expression datasets based on the co-expression of genes within a
molecular system and uses those weights to predict new genes involved in that
system. It has been successfully applied to predict new mitochondrial proteins
essential for the organelle [10] and to discover new players in heme biosyn-
thesis [156]. The principle behind this method is appealing: it systematically
exploits the available gene expression data and, via its weighting scheme, im-
plicitly solves the question facing many researchers: which gene expression data
to use to predict new genes for a pathway? Nevertheless, it is computationally
costly, as the weighting has to be recalculated for each pathway separately and
additional cross validation requires multiple runs per pathway.We have there-
fore developed and implemented a fast expression screening algorithm that in-
cludes a dataset weighting and allows for the rapid computation of genes that
co-regulate with a query gene set. Our algorithm was employed to compile
a weighted co-expression database for all Gene Ontology (GO) terms and hu-
man pathways annotated in the KEGG and Reactome databases. Furthermore,
we provide information regarding the original experimental setup of the highly
weighted datasets. In particular, WeGet reports the cell and tissue types in which
the query genes are consistently up- and downregulated with each other. Finally,
the robustness of the predicted results is assessed by 10-fold cross-validation and
reported as the receiver operating characteristic (ROC) curve.
We compared WeGET with five popular web tools and databases that predict
novel genes based on their co-expression with specified query gene sets, using
two query gene sets published by Baughman et al. [10] and show that indeed,
weighting the datasets results in improved precision, in particular at low recall
rates (the top 100 genes). The complete WeGET database, together with a custom
query submission system, is available through the WeGET website.
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6.2 The WeGET analysis pipeline
WeGET uses a compendium of 465 human and 560 murine gene expression
datasets ranging from 6 to 192 samples per dataset. In total, approximately
30,000 samples from multiple mammalian platforms were collected from the
Gene Expression Omnibus (GEO) [9].
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Figure 6.1: The WeGET computational pipeline used to create the database. a)
Determining the dataset weight Wdataset. The transcriptome measurements are
converted into a correlation matrix. The average correlation with the query set
(Sgene) is used for gene ranking and the dataset weight calculation Wdataset.
b) Data integration across datasets, platforms and species. Gene scores Sgene
from all datasets are combined taking into account the precomputed weights.
Subsequently different transcriptome platforms and species data are integrated
to arrive at the final ranking. The process is repeated after excluding each query
gene to construct a receiver operating characteristic (ROC) curve that visualizes
predictive power of the method for a specific query set of genes.
The WeGET computational pipeline starts with selecting the normalized ex-
pression values for all probes associated with the query genes. For genes with
multiple probes, the probe with the highest average Pearson correlation coeffi-
cient with all other query probes is selected. Subsequently, the pipeline calcu-
83
Chapter 6. Weighted co-expression predicts new genes for molecular systems
lates the average Pearson correlation between each gene and the set of query
genes in every dataset (figure 6.1). Then, all probes are ranked based on their
average correlation with the query probes and mapped back to their associated
gene. Each gene i obtains a score si depending on the fraction of the query set
that has been ranked above that gene. These calculations are then repeated four
times for the same query set and gene expression dataset, where the expression
values have been randomly permuted between the genes in every measurement.
This step estimates the number of genes that are expected to highly correlate
with the query set in a random model. To calculate the dataset weight, an
N100 value is calculated that is the fraction of query genes found among the
top 100 genes with highest average Pearson correlation. The ratio between the
N100 from the original dataset and the average N100 value for the random-
ized datasets constitutes the weight of the experiments. A species score is the
weighted average of all its datasets. The final ranked gene list is obtained by in-
tegrating the ranked human and mouse list (mouse genes that are unambiguous
human one-to-one orthologs). This is performed using the ‘RobustRankAggreg’
R-package [118] that computes the final gene rankings using a rank-order statis-
tic [1, 209].
Thus for each set of expression data the pipeline measures whether genes in
a given pathway co-express better than expected and uses that to assign weights
to that expression dataset. These weights are subsequently used in determining
the (weighted) co-expression of all genes with that pathway. The source of the
variation in the weights between the datasets can be technical, e.g. variation in
the probes that have been used, or biological, e.g. variation in the tissues in
which gene expression has been measured. The important assumption behind
the method is that new genes for a pathway are significantly co-expressed with
the majority of the genes of a pathway that they belong to, rather than only
with some of its members. This, in turn, depends on the pathway definition.
To aid in finding the genes from a pathway that co-express with each other, the
results include a visualization of co-expression between query genes displayed
as a network. This allows the user to select a subset of co-expressed genes from
that pathway to repeat the procedure.
6.3 WeGET validation and comparison to other co-expression
databases
To assess and compare the predictive power of different co-expression methods
(supplementary table S1), we used two query gene sets [10]: 19 query genes in
the cholesterol biosynthesis pathway and 76 genes involved in oxidative phos-
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phorylation (OXPHOS). We manually performed leave-one-out or 10-fold cross
validation by multiple submissions (see supplementary methods for details). We
took into account the top 100 ranked genes as a likely use case scenario. Fig-
ure 6.2 shows the WeGET results for the cholesterol biosynthesis pathway and
OXPHOS system compared to other online tools employing the co-expression
analysis. Baughman et al. [10] carried out one-time computations for choles-
terol and OXPHOS datasets. WeGet webserver achieves identical (cholesterol)
or marginally better performance (OXPHOS, 86.4% sensitivity at 99.8% speci-
ficity, compared to 85% and 99.4%, respectively, supplementary figure S1).
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Figure 6.2: ROC performance curves for online co-expression tools (see supple-
mentary table S1). Performance measured by multiple cross-validation runs is
indicated by the area under the curve (AUC) for the top 100 genes corresponding
to a typical use case scenario. a) Results for 19 genes in the cholesterol pathway
using leave-one-out cross-validation. b) Results for 10-fold cross-validation in
the oxidative phosphorylation (OXPHOS) query set.
6.4 The WeGET database and web access
Figure 6.3 depicts the architecture of the WeGET database. Human pathways
and their associated genes from GO and KEGG are stored in a central database.
The WeGET parallel algorithm that calculates each dataset on a separate thread
precomputes the co-expressed genes and dataset weights for all pathways using
the transcriptome compendium. The results are presented to the user using
the WeGET webtool (implemented in Python Flask) and can additionally be
downloaded.
On the WeGET website, pathways are shown in a data grid (figure 6.4),
which can be sorted and searched. Detailed information (figure 6.5), such
as the best scoring genes, dataset weights, cell and tissue types in which the
genes highly co-express (see also supplementary figures S2 and S3) and cross-
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WeGET DB (MySQL)
GO
Micro-array
datasetsKEGG
WeGET application (C#)
Scheduler (RabbitMQ)
WeGET webtool (Python)
Custom gene set Precomputed gene sets
Figure 6.3: The WeGET system architecture. Results for predefined pathways
(GO, KEGG and Reactome) are precomputed and exposed through the WeGET
webtool. Custom defined gene sets can be analyzed by submitting the gene ids
or gene symbols to the webserver.
validation results are shown when a row entry is selected. A pathway can be
accessed directly as http://weget.cmbi.umcn.nl/pathwaydb/identifier where “path-
waydb” denotes the pathway database (one of: GO, KEGG or Reactome) and
identifier the category identification (e.g. http://weget.cmbi.umcn.nl/GO/GO:
0000398). User queries (different than the predefined sets) can be entered us-
ing the “Custom pathway” tab, specifying genes as Entrez ID or HUGO gene
symbol. The query is then scheduled for analysis. After the analysis, the user
receives an email with results, including the cross-validation and a network that
displays the co-regulation of the query genes within the datasets (see below)
in a spreadsheet. The website provides an opportunity to learn more about the
experimental conditions in which the concordant expression of the query molec-
ular system has been observed. The tab “Dataset Weights”, accessible for each
precomputed query set lists GEO datasets with a concordant expression patterns
of the query system, indicating congruent coexpression of the gene components
of the molecular system. The dataset identifier is directly hyperlinked with the
GEO entry description (both online and in Excel output file) such that users can
read details of the experiment that lead to harmonious expression of the query
set.
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Figure 6.4: The GO data grid. Users can browse or search the list of Gene
Ontology (GO) terms. When a row is clicked, detailed information is provided
(see Figure 6.5). KEGG and Reactome pathways can be accessed in a similar
fashion.
6.5 Evaluation of WeGET results for a query gene set
The robustness of the results is tested by k-fold cross-validation and graphi-
cally displayed with a ROC curve. The curve illustrates the performance of the
WeGET method, by plotting the true positive rate (successfully cross-validated
query genes) versus all human genes (figure 6.2). The curve is plotted for ev-
ery molecular system stored in the database (GO, KEGG and Reactome path-
ways) separately. The area under the curve (AUC) is a measure of the prediction
quality and robustness for that pathway. The average AUC computed for all
pathways is around 0.7. Well-studied and clearly defined cellular components
such as mitochondria and biological processes such as cilium movement and as-
sembly have a higher AUC (average 0.83 and 0.84, respectively) reflecting their
concomitant expression patterns. For pathways with less than 50 genes we use
leave-one-out cross-validation, for larger pathways 10-fold cross-validation is
carried out. Finally, the cohesion of the query gene set is displayed as a net-
work using a node-force algorithm (figure 6.1). Query genes that consistently
co-express perform a large attractive force and therefore cluster together. In con-
trast, genes that show little evidence of co-regulation exhibit a smaller force and
do not cluster with the other query genes. Using this visualization, the user
can resubmit the query gene set to omit genes that do not show evidence of
co-regulation.
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Figure 6.5: Detailed information for a precomputed term/pathway. The query
genes, co-expressed genes, dataset weights and cross-validation results are
shown.
6.6 Using WeGET to predict genes involved in neuropathic
pain
Previous studies indicate that mutations in genes coding for voltage-gated so-
dium channels and related processes may impair the nociceptive pathway and
influence response to pain stimuli [87]. From the literature we collected genes
implicated in neuropathic pain (Table 1) and used the WeGET database to pre-
dict novel candidate genes for this pathway. Table 2 shows genes co-expressing
with the neuropathic pain molecular system as calculated by WeGET. Next to
sodium channels and its regulators (PRMT8, UNC80 rank 41 and 74, respec-
tively) also genes of the voltage-gated potassium system are strongly repre-
sented among top coexpressing genes (MAP1A, PPP2R2C, KCNH3, KCNQ2
rank 6, 7, 66 and 87, respectively) consistent with their involvement in nocicep-
tive processing [219], their expression in dorsal root ganglion neurons analogous
to voltage-gated sodium channels [173] and with recently discovered genetic
variants that modulate neuropathic pain [38]. The PIEZO2 gene, a nociceptive
component mechanically activated in nerve endings [43] ranks 74th among all
genes. Additional poorly characterized genes such as SERP2, TMEM130 and
CCDC155 (ranks 5, 9 and 20, respectively) are also present among genes co-
expressing with the system and constitute novel candidate genes for nociceptive
pathway. Figure 6.6a shows the higher performance of WeGET integration of
all datasets (cross-validated AUC=0.82) compared to integration of all datasets
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with equal weights (average coexpression across all experiments, AUC=0.71)
and a high weight individual dataset GDS1634 of dorsal root ganglia neurons
(AUC=0.68). Weights assigned to GEO datasets reveal a high contribution of
transcriptome measurements related to neurons: a murine nodose and dorsal
root ganglia study (GDS1634, weight 3.0) (22), gene expression in human neu-
rofibrillary tangles (GDS2795, weight 2.5) and DNA methylation effect on neural
stem cells (GDS538, weight 3.0). The peripheral roles of DPYSL2 (trafficking sub-
set, table 6.1), MSN and NEDD4L proteins (peripheral subclass) are visualized
in the query gene network (figure 6.6b). Currently we screen patients with a fa-
milial form of neuropathic pain for genetic variants that may impact the function
of the candidate genes.
No. Gene Symbol Sub-system No. Gene Symbol Sub-system
1 ACTG1 CORE 11 DPYSL2 TAG
2 ANK3 CORE 12 KCNK3 TAG
3 SCN10A CORE 13 NRCAM TAG
4 SCN11A CORE 14 ANXA2 TAG
5 SCN1B CORE 15 PRKACA TAG
6 SCN2B CORE 16 PRKCB TAG
7 SCN3A CORE 17 SYN2 TAG
8 SCN3B CORE 18 TNR TAG
9 SCN8A CORE 19 MSN PI
10 SPTBN4 CORE 20 NEDD4L PI
Table 6.1: Genes implicated in neuropathic pain collected from the litera-
ture. Core molecular sub-system associated with voltage-gated sodium channels
(CORE), trafficking-associated genes (TAG) and the peripheral involvement (PI)
classes are indicated [175, 53, 220].
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Figure 6.6: Visualization of performance of the WeGET results for neuropathic
pain genes. a) ROC curves for the neuropathic pain query set (table 6.1).
The x-axis represents the fraction of human genes, the y-axis the fraction of
the neuropathic pain molecular system. Shown are ROC curves for final re-
sults (blue), the cross-validation (CV) of integrated datasets (green), the average
co-expression across all datasets (integration with equal contribution of each
dataset) with CV (red) and results of co-expression within a single high-weight
dataset (GDS1634, a nodose and dorsal root ganglia comparison (cyan)) b) Net-
work visualization of the co-expression allows identification of genes less co-
expressed with the core of the query gene set.
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Rank P-value Entrez ID Symbol Description
01 0.00000 6854 SYN2 synapsin II
02 0.00005 6327 SCN2B sodium channel, voltage-gated, type II, . . .
03 0.00010 23705 CADM1 cell adhesion molecule 1
04 0.00018 60 ACTB actin, beta
05 0.00018 730102 LOC730102 quinone oxidoreductase-like protein 2 . . .
06 0.00020 7532 YWHAG tyrosine 3-monooxygenase
07 0.00025 283209 PGM2L1 phosphoglucomutase 2-like 1
08 0.00030 64207 IRF2BPL interferon regulatory factor 2 binding . . .
09 0.00037 71 ACTG1 actin gamma 1
10 0.00040 288 ANK3 ankyrin 3, node of Ranvier (ankyrin G)
12 0.00049 8455 ATRN attractin
12 0.00050 5579 PRKCB protein kinase C, beta
13 0.00054 3785 KCNQ2 voltage gated KQT-like subfamily Q
14 0.00054 3745 KCNB1 voltage gated Shab related subfamily B
15 0.00055 6191 RPS4X ribosomal protein S4, X-linked
16 0.00064 84502 JPH4 junctophilin 4
17 0.00064 6907 TBL1X transducin (beta)-like 1X-linked
18 0.00066 2917 GRM7 glutamate receptor, metabotropic 7
19 0.00076 221336 BEND6 BEN domain containing 6
20 0.00081 26508 HEYL hes-related family bHLH transcription factor
21 0.00083 6235 RPS29 ribosomal protein S29
22 0.00088 2597 GAPDH glyceraldehyde-3-phosphate dehydrogenase
23 0.00097 84677 DSCR8 Down syndrome critical region 8
24 0.00101 8825 LIN7A lin-7 homolog A (C. elegans)
25 0.00101 6134 RPL10 ribosomal protein L10
26 0.00108 4155 MBP myelin basic protein
27 0.00111 11280 SCN11A sodium channel, voltage gated . . .
28 0.00114 3778 KCNMA1 calcium activated large conductance subfam . . .
29 0.00115 399947 C11orf87 chromosome 11 open reading frame 87
30 0.00115 6171 RPL41 ribosomal protein L41
31 0.00117 63895 PIEZO2 piezo-type mechanosensitive ion channel . . .
32 0.00122 222865 TMEM130 transmembrane protein 130
33 0.00125 2828 GPR4 G protein-coupled receptor 4
34 0.00126 23201 FAM168A family with sequence similarity 168 . . .
35 0.00129 57181 SLC39A10 solute carrier family 39 (zinc transp.) . . .
36 0.00129 1816 DRD5 dopamine receptor D5
37 0.00132 9378 NRXN1 neurexin 1
38 0.00135 4130 MAP1A microtubule associated protein 1A
39 0.00138 7314 UBB ubiquitin B
40 0.00148 302 ANXA2 annexin A2
Table 6.2: Results from custom molecular system as received by the user. Top
40 genes prioritized for their involvement in neuropathic pain are shown. Genes
that were part of the query set are shown in bold font face.
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Chapter 7
Discussion
In this thesis, three main themes were considered. First, constraint-based modeling
of metabolic networks was discussed in chapter two and three, with focus on the
space of feasible flux paths. In chapter 4, a new algorithm was introduced to
infer SDL interactions from a genome-scale metabolic network. This chapter
bridges metabolic modeling and another important topic of this thesis; inference
of synthetic genetic interactions pairs. Whereas the SDL in chapter 4 denotes a
lethal interaction between an over- and underexpressed (or lost) gene, the fifth
chapter considers an interaction involving two lost genes. In this case, we do not
use a metabolic model, but an ensemble based classifier that considers synthetic
lethal (SL) interactions spanning the whole human genome. In both chapters,
the possibility to exploit S(D)Ls to target cancer cells was explored. Finally, in
chapter 6 a new webtool was introduced to identify novel genes for a molecular
function or pathway given a set of query genes representative for that system.
There, we used gene co-expression computed in a large set of micro-arrays;
an idea that has been exploited in many research papers before. The more
interesting idea in this chapter is how to automatically select relevant data sets and
features from the vast amount of (public) high-throughput data given a small set of
representative members of that cellular system. For each of these three themes,
the main results of this thesis and future perspectives are discussed.
7.1 Constraint-based modeling of metabolic networks
7.1.1 Sampling the solution space
In constraint-based modeling of metabolism, two main types of constraints are
imposed. First, a steady-state assumption dictates that there is no built-up
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of metabolic mass in the network. Second, the direction and magnitude of
metabolic flux are constrained by limitations on flux capacity and directional-
ity. All flux distributions that satisfy these constraints form the convex space of
steady-state flux distributions. Sampling flux distributions (i.e. n-dimensional
points) from this space in an unbiased manner (uniformly distributed over the
whole space) is difficult for two main reasons.
First, metabolic networks are large and heavily underdetermined. For exam-
ple, the latest reconstruction of human metabolism [218] has m=5,063 metabo-
lites, n=7,440 reactions and a nullspace with k=2,774 dimensions. Therefore,
this system of linear equations has 2,774 degrees of freedom and thus a solu-
tion space with equal dimensions. In order to provide a good estimate of the
feasible flux distributions, a large number of samples need to be drawn from
this huge space in an unbiased manner. The second difficulty is caused by the
large variability in constrained flux ranges. By consensus, unknown reaction
rates are typically constrained to ± 1000 mmol/gDW/h. However, the range
between the lower- and upper bound of measured reactions is typically a small
fraction of that. After propagating all constraints in the network, one often faces
the situation where the ratio between the largest and smallest flux range is in
the order of 105 or worse. As a consequence, the ratio between the longest and
smallest axis of the solution space has a similar magnitude. For this reason,
ordinary Hit-and-Run [15], which takes a direction uniform on the boundary
of the k-dimensional sphere is inapplicable, even for small scale networks. The
smallest axis of the space limits the allowable step size so much that the larger
axes are in practice never fully explored, which biases the sampler to a subspace
of the feasible solution space. Resorting to Artificial Centering Hit-and-Run
(ACHR) [113] greatly alleviates this problem, but does not seem to be a satisfac-
tory solution for sampling the ever increasing genome-scale metabolic networks.
In the next paragraphs, I will discuss some alternatives and recent developments
that may be better suited to the largest metabolic networks.
Taken together, although the new sampling tool described in chapter 2 signif-
icantly improved sampling time and ‘uniformity’, it is still not an ideal solution
for deriving the ‘most likely’ flux distributions in the largest metabolic network
reconstructions. Fortunately, alternative methods and new developments exist,
which I will briefly discuss now.
Alternatives for ACHR sampling
It is clear that efficient and uniform sampling from a metabolic network is a
challenging task. Hit-and-run is an example of a Markov Chain Monte Carlo
(MCMC) sampler and therefore possesses attractive convergence properties, but
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does not mix well in the odd-shaped solution space of metabolic networks. Ar-
tificial Centering Hit-and-Run (ACHR) [113] mixes much better, but is not a
MCMC method and therefore loses these theoretical convergence guarantees.
MCMC sampling with non-uniform direction choice Recently, a new method
was introduced that seems to combine the best of both worlds in a two phase
procedure. First, the shape of the solution space is estimated and this infor-
mation is used to bias the sampling direction [42] towards the elongated axes
during the second phase. Because the sampling direction does not depend on
previous iterates, the resulting algorithm is still an instance of a MCMC sam-
pler. Results show that it indeed converges nicely, but does that mean that the
samples are indeed uniformly distributed? Showing that samples indeed have
a uniform distribution is straightforward for basic and well-known geometric
shapes, but not trivial for the unknown shapes of metabolic networks. In the
end, if that uniform distribution was known, we would not need these sampling
techniques. How to deal with this problem?
Belief- and expectation propagation An alternative technique for sampling
from the solution-space is (loopy) belief propagation (BP) [171, 170], which has
indeed been applied to metabolic networks [22]. In a nutshell, BP starts with
choosing flux values for the uptake fluxes. These values are ‘propagated’ to
reactions sharing the metabolite that was taken up and for these reactions the
possible flux values are computed. By using this local propagation step through-
out the network, an empirical flux distribution for each of the reactions can be
obtained. In particular, when the network has no cycles, this propagation al-
gorithm is highly efficient and produces exact results. In the case of metabolic
networks, where cycles often exists, the propagation steps can be repeated until
the flux values converge. In most cases, the algorithm still produces reliable
results in a reasonable amount of time. The fact that computations are local not
only makes BP very efficient, but also makes it much easier to deal with the
heterogeneous axes of the solution space. Expectation propagation (EP) [148] is
a similar technique, often applied in Bayesian inference. Remarkably, BP and EP
do not seem to be widely adopted by the metabolic community, possibly due to
a lack of available toolboxes tailored to metabolic modeling.
7.1.2 Reducing the feasible flux space
Discovering the biologically relevant flux distributions from the wide range of
possibilities is a central problem in constraint-based metabolic modeling. Where
Flux Balance Analysis (FBA) [163] and many other optimization techniques are
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rooted in maximizing the growth rate or yield in unicellular organisms, they can-
not easily be applied to complex, multicellular organisms. A notable exception
is the modeling of cancer metabolism, where tumor growth is an objective with
strong clinical relevance that can easily be optimized in network simulations.
In the context of mitochondrial disease, we wanted to know how metabolic
fluxes are routed in healthy and diseased subjects. In particular, metabolic mod-
eling was used to prioritize flux measurements; a challenging task for a couple
of reasons. First, most metabolic fluxes cannot be measured with current exper-
imental techniques. Exchange fluxes (uptake from, or secretion to the growth
medium) and reaction rates for which the metabolites can be isotopically la-
beled are the main exceptions. The latter is usually applied by using C13 carbon
labeling, [231, 242] which enables the quantification of reaction rates in central
carbon metabolism. Combined, the methods are able to uncover the fluxes in
central metabolism and those exchanging metabolites through the cell bound-
ary. Although that is an important part of the metabolic network, only a couple
dozen fluxes are revealed in the ideal case. This severely limits the amount of
data available for building and validating models. Second, by tracing the iso-
topic labeling of carbon metabolites in central metabolism, a whole pathway of
fluxes is measured. In our experiments we have neglected this fact, because
proper experimental design of isotopic labeling is a complex research field by
itself. Rather then focusing on one experimental design, we aimed to develop
a general method, focusing on reduction of the steady-state flux space. Third,
there is no clear quantitative relation between flux and gene- or protein expres-
sion [4]. Reactions whose enzyme coding genes are not expressed usually do
not carry flux, but the reaction rate is often unknown when the genes are ex-
pressed. Thus, gene expression can mainly be used to exclude the measurement
of fluxes for non-expressed enzymes. Fourth, the size of the solution space after
flux measurement not only depends on which reaction’s rate is measured, but
to a high degree also on the actual outcome of the measurement. In many cases,
a flux that is relatively high constrains the other fluxes more than a low flux.
The exact impact depends on many things; network topology and measurement
precision amongst others. This last fact we tried to exploit by estimating the
most likely reaction rates.
It has been shown that bacteria that are believed to optimize for growth yield,
do this at a suboptimal rate [60, 201]. It is hypothesized that the reason for this
behavior is a robustness principle. Dedicating the complete metabolic machin-
ery to optimal growth in one nutrient environment severely affects the capabil-
ity to quickly adapt to other environments. A slight relaxation of the maximum
growth rate on the other hand, greatly improves the adaptation capability and
therefore the metabolic robustness of the organism [201]. This robustness prin-
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ciple is a uniform design principle of metabolic networks [100, 183]. However,
robustness on the topology level of the network can still be superseded at the
metabolic flux level. This seems unlikely and therefore the basic idea behind our
algorithm is to discard flux distributions that severely affect the robustness of
metabolic systems. We applied this principle in chapter 3 to predict intracellular
flux rates, reduce the steady-state solution space and prioritize measurements.
7.1.3 Future directions
One of the main limitations in metabolic modeling is that metabolic flux mea-
surement techniques are currently not available at the genome scale. To circum-
vent this problem, researchers resort to indirect evidence of metabolic activity.
Traditionally, this was mainly gene expression data, but advances in proteomics
and metabolomics allow the measurement and integration of increasingly larger
amounts of proteins and metabolites. With ongoing developments in many of
the high-throughput omics techniques, there is a rapid growth in the number
and types of available molecular datasets. A natural consequence of these de-
velopments, is the desire to unravel how data from various cellular processes fit
together. Therefore, there is demand for computational methods that can inte-
grate data from various experiment types to obtain a systematic understanding
of the cellular machinery. This trend is already visible in metabolic modeling,
where next generation models include gene regulatory processes [31] and data
on protein structure [32] and concentrations [126, 161]. It is likely that in the fu-
ture other processes such as signaling, cell cycle specific modifications or epige-
netic dynamics can be included. Eventually, it is likely that metabolic modeling
gradually shifts to whole cell modeling.
An integrated cellular model, with data from different, but related molecular
processes could be captured in a layered constraint-based setting (figure 7.1).
The benefit of such a model is that lower layers (e.g. epigenetic marks or pro-
teomics data) can propagate constraints up to higher level processes and vice
versa. An interesting use case for such an integrated modeling approach would
be capturing the early differentiation dynamics in pluripotent mouse embryonic
stem cells (mESC). It has been observed that cultured pluripotent mESC, apart
from strong genetic and epigenetic dynamics also show significant metabolic al-
terations [142]. How this is established is largely unknown, which makes them
an ideal candidate for such an integrative modeling approach.
Dealing with increasingly larger networks One might expect that with the
introduction of the second genome-scale reconstruction of human metabolism
[218], metabolic networks will not get larger or more complex. This seems to be
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Figure 7.1: Simplified integrated model of regulation and metabolism. a) The
metabolic layer is connected by the enzymes that are build from proteins trans-
lated from RNA. b) The translated proteins determine which metabolic states
are feasible. In turn, they provide information about the transcription layer be-
low. c) Transcription is determined by active promoters and enhancers. The
epigenetic machinery determines which genes are transcribed and which are
not. Any layer provides feasible states for the layer above. In addition, observed
layers provide information about the regulation patterns that must be present in
the lower layers.
a mistake; next-generation models that incorporate protein structure (GEM-PRO
models) or protein expression (ME models) exist [161]. Other models integrate
regulatory mechanisms [31]. With the ambition to build genome-scale ‘whole-
cell’ models, it seems we are far from reaching a maximum in model size or
complexity. It is unlikely that current sampling techniques are suitable for these
large scale models. One reason for the large size of metabolic models is that
they are general and aim to capture all feasible metabolic states in any tissue.
For many applications, a tissue specific model is more desirable and in such a
case often only a part of the model is required. A possible solution is using an
algorithm [103] that discards metabolites and reactions irrelevant to the cell- or
tissue type under study. Another possibility is to reduce or partition large scale
models [182], such that they can be analyzed with current computational tools.
Integration of experimental data On the one hand, many methods exist that
incorporate experimental data into genome-scale constraints. On the other hand,
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sampling methods and also propagation methods aim to obtain an unbiased flux
sample. It seems natural to also integrate ‘omics’ data into sampling techniques,
to obtain samples that are more likely given the experimental data. Using for
instance gene- or protein expression to bias the direction of the sampler such
that it preferentially explores higher flux regions for highly expressed genes or
proteins seems perfectly feasible. Similar incorporation of prior data can be used
with BP or EP techniques. This is an easy way to perform (semi) probabilistic
inference in constraint-based metabolic models.
7.2 Inferring gene pairs causing a synthetic (dosage) lethality
Metabolic networks have previously been used to compute synthetic lethal (SL)
interactions [240, 63] in various model organisms [203, 210] and cancer. Recently,
the detrimental effects of certain dosage reactions on cancer cells have also been
discovered [228] using metabolic modeling. However, a method to compute
synthetic dosage lethality (SDL) from a genome-scale metabolic network had not
been published before. The fact that one of the genes within a SDL gene pair
is overexpressed makes them particularly attractive for possible applications in
cancer research.
Our method scores SDL pairs based on their predicted impact on cell growth.
This score proved to be predictive, in particular for measured tumor sizes and
patient survival in breast- and ovarian cancer patients. Moreover, we showed
that SDLs have a cumulative effect; expressing more SDL pairs is in general
beneficial for a patient’s tumor growth and survival prognosis. By studying the
SDL interaction network, we discovered that the vast majority of SDL pairs have
a downregulated enzyme in the glycolysis pathway. Indeed, many cancer cells
depend heavily on glycolysis [72, 71, 55] and we observed that the largest effect
of the SDL is due to the knock-out enzyme in this pathway. Nevertheless, a sig-
nificantly larger effect was found when additional ‘dosage’ enzymes were over-
expressed. Such dosage reactions are generally not simple proximal enzymes,
but can be in a distinct part of the metabolic network in which metabolites are
drained from biomass. The SDL effect can therefore be seen as a competition
between reactions in the supply of and demand for metabolites. Lowering the
glycolytic activity limits the supply of metabolites that sustain tumor growth.
The effect is increased when other reactions drain these metabolites before they
can be used for growth. In essence, our method computes which combination
of a lowered flux (limited supply) and increased flux (competitive demand) has
the largest effect on the availability of metabolites required for tumor growth.
By combining clinical data with tumor gene-expression profiles, we were able to
verify our model predictions.
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Our method is not limited to cancer, but can in principle also be used to
identify SDL networks in pathogenic bacteria or fungi, providing new antibiotic
therapeutic leads. Other possible applications include metabolic engineering to
increase the yield of valuable metabolic byproducts. This can for instance be
achieved by engineering SDLs in order to inhibit the production of undesired
byproducts, or inversely, neutralizing the SDL effect to force an increased flux
through desired pathways.
7.2.1 Synthetic lethality
A novel computational approach that identifies SL interactions from cancer ge-
nomic data on a genome-wide scale was presented in chapter 5. First, cancer
genomes were systematically explored to identify predictive patterns of SL in-
teractions. Compared with non-SL gene pairs, SL pairs were observed to be
significantly less often co-lost in a cancer genome, both in gene expression and
in copy number variation analysis. Furthermore, SL pairs are more likely to ex-
press a compensation pattern (called up-down SL pairs), where one gene in the
SL pair is over-expressed to compensate for the under expression of the other
gene. In total, five such predictive signals in cancer genome variations and ex-
pression data were detected and integrated in an ensemble-based model. This
model achieved high predictive performance (AUROC 0.75) on validation sets
of known SL pairs.
7.2.2 Future directions
The SL and SDL interactions discovered are not specific for any tumor type. In
the case of SDLs, a general model of human metabolism was used. Further-
more, in the metabolic models, predictions were done on the metabolic flux
level, whereas validations were performed mainly on the RNA expression level.
Although we were able to reveal general patterns by applying our method to
large numbers of patients and genomic data, it is far from clear how such pre-
dictions can be utilized for individual patients who often require personalized
cancer therapy. This also holds for the SL pairs derived in chapter 5. An inter-
esting approach would be to integrate omics data with the metabolic network,
in order to create models that are specific to each cancer (sub)type. Then, dif-
ferential analysis between the models and comparison with healthy tissue can
reveal vulnerabilities that are either specific to, or shared amongst different can-
cer types. Ideally, these vulnerabilities can be ranked and top candidates would
be validated in vitro.
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Clearly, the central role of glycolysis in the metabolism of both cancerous
and healthy tissue poses a difficulty in drug design. Since glycolysis is also vi-
tal for healthy cells, therapeutic strategies should aim to target specifically the
glycolytic pathways in cancer cells. Interestingly, compounds that suppress key
glycolytic enzymes only in cancer cells have already been successfully identi-
fied [30, 62], showing that the SL and SDL mechanism can indeed be applied
in practice. Whether stimulation of dosage reactions can be achieved in practice
and how that would affect healthy cells is at this moment unclear.
Another important point is that cancer is not limited to metabolism and most
of our observations are probably caused by (epi)genetic defects upstream of the
altered metabolic pathways. A growing tumor cell obviously requires metabo-
lites and metabolic flux, but these events need to be regulated. Once more,
given the abundance of (epi)genetic data, an integrated approach as depicted
in figure 7.1 would be beneficial to get a better understanding of SL and SDL
interactions and the mechanisms explaining their cause and effect.
For the SL interactions, we used publicly available copy number variation
and gene-expression data from colon cancer patients. In this case, the predicted
interactions where not limited to metabolism but genome-wide. A disadvan-
tage of this approach is that it is harder to gain systematic insights, since no
mechanistic model was used to derive the SLs. Furthermore, SL interactions
were derived from colon cancer tissue and in unclear to what extent predicted
interactions hold for other cancer types. Finally, both the SDL and SL study
identified a large number of lethal interactions. Although that provides ample
choice for further study, one would ideally narrow this set of interactions to a
small set of high confidence pairs, to be validated in an experimental setup.
An interesting possibility would be to study the glycolytic shift observed in
many cancer types (known as the Warburg effect) using an integrated systems
biology approach, such as illustrated in figure 7.1. Evidence collected from
different layers could then be used to better understand this effect, in order to
design more effective experimental perturbations.
In summary, SL and SDL approaches, whether derived from a mechanis-
tic model or inferred from data provides important opportunities to selectively
target cancer cells or pathogens. In general, the cellular complexity of these
diseases cannot be fully understood with a relatively coarse-grained metabolic
model. Tailoring the model to a particular cancer (sub)type is important to in-
crease its predictive capabilities. Furthermore, a complex disease such as cancer
cannot be completely understood by only looking at metabolism. Therefore, it is
important that other processes such as gene regulation are also captured, ideally
in an integrated cellular model.
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7.3 Automated dataset weighting and feature extraction from
high-throughput data
In chapter 6, a webtool was introduced that searches novel genes co-regulating
with a set of query genes known to be involved in a certain molecular system.
The WeGET webtool ranks genes based on their weighted co-expression with
the query genes within a large compendium of micro-arrays. Mining micro-
array datasets using co-expression; a so called ‘guilt by association’ strategy has
been applied in numerous papers [234, 47, 78]. What makes our application
interesting is that it automatically weights the most relevant datasets based on
the congruent expression of the query genes. If the expression of query genes is
jointly activated or repressed in a certain dataset, that dataset might be more rel-
evant than one without a clear co-expression pattern between the query genes.
In chapter 6, we only used micro-array data, but the same principle can be
applied to other ‘omics’ data types, ideally combining multiple data types of
interest.
7.3.1 Future directions
New high-throughput sequencing and mass-spectrometry techniques provide
massive amounts of novel data. This data can in principle be used to gain better
understanding of any query system. More importantly, since the amount of data
provided by these techniques is so large, obtaining the relevant genes, proteins
or other features from an experiment often depends on arbitrary cutoffs, such
as fold changes or read counts. A system that automatically crawls a large
number of similar data sets and selects the most interesting ones based on some
relevance criterion is an attractive way to rapidly obtain a set of key players in
the system with higher confidence.
As long as a good measure of relevancy can be defined, such a strategy can
be applied to any type of data to find the key genes, proteins, metabolites or
epigenetic marks relevant to a query set. Moreover, this data can be integrated
such that search results are not limited to co-expressing genes. For instance,
when one is interested in gene regulation, the search result could also provide
relevant proteins (transcription factors), chromatin interactions, epigenetic alter-
ations and DNA binding motifs. Third, this data can provide an integrated view
of the query system. In the ideal case, a systems biology approach shows not
only which components are associated with the query system, but also provides
systematic insights into their relation.
Taken together, the automated selection of relevant data and extraction of the
most important features opens important possibilities in the analysis of high-
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throughput ‘omics’ data. On the one hand, this data can be used to obtain a
better and preferably systematic picture of the query system. On the other hand,
such a tool could prove to be advantageous in rapidly obtaining key insights in
high-throughput experiments.
7.4 Combining model-driven and data-driven approaches
In this thesis, two approaches for analyzing biological systems have been used.
First, existing models can provide novel systematic insights and ‘mapping’ new
data on established models is often used to better understand the mechanics of
a biological system. Second, if such a model does not exist, relationships can
also be derived directly from the data. Surely, both approaches are not mu-
tually exclusive. Models can be created, refined, extended or integrated using
new data. Furthermore, where currently the availability of data mostly drives
the construction of mechanistic models, the reverse is also possible. Mechanistic
models can provide interesting leads for follow-up experiments that could not
have been easily discovered by ‘simple’ analysis of the data. Ideally, experimen-
tal and computational approaches are combined in a systems biology project,
where model-driven discovery is combined with wetlab experiments and vali-
dation in an iterative fashion. This trend is already visible and an increasing
number of labs appreciate the power and benefits of this combined approach.
By exchanging the models and the data through public repositories, we will ul-
timately advance to an integral cellular model, with significant implications, for
example in our combat against complex diseases.
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Summary
Metabolism is the process in which a cell or organism takes up nutrients from
its environment and converts them to molecules that facilitate the cellular mech-
anisms required to sustain life. This conversion process is performed by a large
number of metabolic reactions. The metabolites produced by one reaction are of-
ten the inputs for others. Most metabolic reactions do not occur spontaneously,
but require proteins (or protein complexes) called enzymes, which catalyze the
reaction. The ‘recipe’ for making these proteins is stored in the genes on our
DNA. In particular, a gene is a long sequence of only four possible nucleotides
(abbreviated A, C, T or G) and the specific order of these nucleotides determines
the protein it encodes. Before the protein is made, the gene needs to be tran-
scribed to RNA (a sort of ‘temporary copy’ of the recipe). The RNA molecule
is finally translated into amino-acids that make up the protein. When the cell is
actively creating many of these RNA copies, we call the gene expressed and it
often indicates that the cell is producing much of this protein. Thus, by regulat-
ing the rate of gene transcription and translation, a cell controls which proteins
and enzymes are present. Using this mechanism for hundreds or even thou-
sands of genes, a cell regulates (switches on or off) the metabolic pathways that
are available.
For most of the metabolic reactions, the metabolites consumed and produces
are known. This also holds for most of the enzymes catalyzing the reactions
and gene(s) required to produce these enzymes. Therefore, metabolism can be
modeled as a network, with connections between reactions sharing metabolites.
However, also the connections between reactions, enzymes and genes can be
stored in such a network. This network representation of metabolism is conve-
nient, because it allows us to use computational methods and mathematical tools
such as graph theory and optimization techniques to analyze their behavior. For
example, we can determine which pathways are ‘blocked’, because the enzyme
coding genes for many of the reactions in that pathway are not expressed.
Reaction rates or metabolic flux (the reactions ‘speed’) and metabolite con-
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centrations depend on many things, can change rapidly over time and may differ
between organisms. Measurement of all parameters required to create a detailed
model of how metabolic flux and metabolite concentrations change over time
is currently infeasible for a metabolic network that spans all known metabolic
reactions. A widely used alternative is COnstraint-Based Reconstruction and A-
nalysis (COBRA) of metabolism. The idea of COBRA is to explicitly incorporate
physical, biochemical and genetic limitations of the cell in order to model which
metabolic states can be reached. Metabolic states of interest are for example a
cells growth rate, the production rate of certain metabolites such as (bio)ethanol
or which nutrients must be available in order for the cell to survive.
COBRA assumes two basic types of constraints. First, a steady-state con-
straint dictates that any metabolite that is produced by a reaction inside the
cell must immediately be consumed by another reaction. Though this is strictly
not the case, the time scale on which metabolic events occur is typically much
smaller than for the processes regulating them (activation of the genes and build-
ing of the enzymes). Therefore this is a useful simplification. A second type of
constraint limits a reactions capacity (its maximum flux) and the directionality.
A flux path that satisfies these constraints is called feasible. Together, all feasible
flux paths form a space (think of it as a box) and the volume of this space re-
flects the amount of feasible flux paths in the space. The volume also reflects our
uncertainty about the metabolic pathways used by the cell, since a large volume
means that many alternative flux pathway exist. It is possible and often desir-
able to add more constraints to further narrow the space of feasible metabolic
states, or more informally, to shrink the box. Such constraints can be the result
of metabolic flux measurements, integration of protein- or RNA expression or
for example by only considering the flux paths that maximize the tumor growth
rate in cancer cells.
In constraint-based modeling of metabolism, the space of feasible flux paths
is of central interest. Its volume reflects the capabilities of the cell under the
constraints imposed. In practice, there are never enough constraints to pinpoint
the exact flux path utilized by the cell.
The first part of this thesis consists of three chapters dealing with metabolic
modeling and this space of feasible flux paths. An introductory chapter briefly
explains how models are created and used in molecular biology, with a focus
on metabolic modeling in particular. In chapter 2, a method is described that
samples valid metabolic states from the space of feasible steady-state distribu-
tions. Though the volume of the flux space was mentioned above, this word is
actually reserved for spaces with three dimensions. The space of feasible flux
paths actually consists of hundreds of dimensions, even for a relatively sim-
ple organism such as bakers yeast. Sampling efficiently from this large space
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requires optimized computational methods. An important application of sam-
pling is to find which flux paths are often used compared to others. Though
useful, sampling from large metabolic spaces can also lead to undesired bias
and therefore sampling results have to be considered with care. In chapter 3,
an optimization method is introduced which finds the flux paths that severely
reduce the metabolic robustness of the cell. Robustness is important for a cell in
order to adapt to changing environmental conditions. We show that this method
can also be used to prioritize experimental measurements of metabolic fluxes in
order to reduce the flux space. In chapter 4, metabolic modeling is combined
with a new algorithm to detect so called synthetic dosage lethalities (SDLs), with
potential to target tumor cells. Briefly, the method finds specific combinations
of one inactive (or at least reduced in activity) and one overactive reaction that
reduce the production of metabolites required for a tumor to grow. One can
think of this as a supply and demand problem. The pinched reaction limits the
supply of metabolites needed by the tumor and indeed by itself already reduces
its growth. The overactive reaction competes with the tumor for its scarce con-
struction material and therefore amplifies this effect. Cancer patients with many
of these SDLs indeed have reduced tumor sizes and longer survival times com-
pared to patients who do not have these SDLs. Such discoveries can be beneficial
to test the potential of new anti-cancer drugs in an early stage using computer
simulation or explore new possibilities to target tumor cells.
The seconds part of the thesis studies genetic interactions causing cell death
and the automated discovery of gene sets involved in specific cellular processes.
One such genetic interaction is the synthetic lethality (SL), which is similar to
the SDL described above. In this case, the combined inactivation of two specific
genes is lethal to the cell, whereas the inactivation of only one of the genes is
not. SLs also have particularly interesting applications in cancer cells where ge-
netic mutations occur frequently. When a cancer cell has lost one of the genes
(say gene A) for which a SL partner gene is known (gene B), this provides a
good opportunity to silence gene B. Besides its lethal effect on the cancer cell,
healthy cells will survive the deletion of gene B, since they do not have the muta-
tion that inactivated gene A. Because human DNA contains thousands of genes,
it is practically impossible to screen for all possible combinations of genes in
an experimental setup. But, given that large amounts of genetic data obtained
from healthy and cancerous tissue are available, we can screen for promising
candidates using computer models and simulation. Chapter 5 deals with the
computational screening for SL gene pairs. In this chapter we tried to answer
two important questions. First, how do you recognize patterns of promising
SL candidates in all this genomic data? Moreover, how can we integrate these
patterns to come up with a ranked list of the most promising SL candidates?
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Importantly, the SL genes found are still candidates. To really say that they in-
teract, such SL combinations have to be tested experimentally. However, we can
show that SL interactions that have been tested experimentally are frequently
found near the top of our list and thus that such a method can indeed be very
valuable in selecting candidates that are more promising compared to others.
Chapter 6 deals with a similar topic for finding genes that are involved in
certain cellular functions. One can for instance think of genes involved in a
disease, but the method is equally valid for genes playing important roles in
normal cellular functions. For many functions and diseases, a number of the
genes involved is known, but this information is often incomplete. Can we use
our knowledge of the known genes to find novel genes that may also play a
role in the cellular function or disease? Again, we can try to exploit the huge
amounts of public genetic data that is available. One data source that is often
used is gene expression data. Genes that play an important role in a certain cel-
lular process, disease or tissue are often co-expressed. This means that the cell
activates and deactivates these genes at the same time, such that the enzymes
required for the cellular process or disease are available at the same time. Im-
portantly, cellular processes taking part in certain brain cells may not take place
in muscle cells. Similarly, a set of genes that are important in breast cancer, may
not be active at all in lung cancer. Therefore, it is critical that the data source
used matches the system of interest as close as possible. In this chapter, we
describe a tool that finds the most important data sets for the molecular system
specified and weights them accordingly. Then, the more important data sets are
used to find novel genes that may also be important for the system we study.
Such a tool provides a very easy and cheap way to screen for novel genes that
can then be tested experimentally. It also provides an easy means to check the
potential of novel candidates found by another (computational) method.
Our cells (and those of any other complex species) contains large amount of
genes, proteins and many other cellular compounds that interact in a complex
temporal and spatial manner. Modern methods can measure thousands of genes
or proteins in a single experiment. Often, such experiments are performed to
compare different cell types or to follow a cellular process over time. One can
imagine the amounts of data that are obtained in such an experiment and the
combinatorial explosion of all the possible genes and proteins that may or may
not be important in this process. Computational analysis is needed to discover
which genes, proteins or reactions are important and how they interact to fulfill
the cellular task. For the latter, it is important to build computer models that
mimic their behavior, to unravel how all the small parts work together and try
to predict the consequences of perturbations. Such predictions can be tested
to refine our models. New experimental techniques are introduced every year,
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enabling us to look at new aspects of the complex functioning of the cell in
greater detail. There is a great number of interesting opportunities to study this
and I will discuss some of them in the concluding chapter. Using computers
to analyze and model this complex behavior has greatly advanced the field of
molecular biology and our understanding of disease and will continue to do so
in the future.
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Samenvatting
Metabolisme is het proces waarin een cel of organisme voedingstoffen opneemt
uit zijn omgeving en omzet in moleculen die de cellulaire processen mogelijk
maken. Dit afbreken en omzetten van moleculen wordt uitgevoerd door een
groot aantal metabole reacties. De moleculen (metabolieten) die worden gepro-
duceerd door de ene reactie worden vaak weer afgebroken en omgezet in andere
moleculen door de volgende reactie. De meeste metabole reacties vinden echter
niet of nauwelijks spontaan plaats, maar vereisen enzymen (eitwitten of eitwit-
complexen) die de reactie versnellen. Het ‘recept’ om eiwitten te maken ligt
opgeslagen in de genen op ons DNA. Ons DNA bestaat voor een groot deel
uit vier soorten zogenaamde nucleotiden (afgekort A, C, T en G). Een gen is
een langgerekt stuk DNA van duizenden nucleotiden, die door hun specifieke
volgorde coderen voor een specifiek eiwit. Voordat dit eiwit gemaakt kan wor-
den moet het DNA ‘afgelezen’ worden. Dit aflezen gebeurt door het gen om te
zetten naar RNA; een soort tijdelijke kopie van het gen. Hierna wordt het RNA
vertaald naar een keten van aminozuren die het eitwit vormen. Op het moment
dat de cel veel van deze RNA kopiee¨n van het gen maakt noemen we dat gen
actief. Dit is vaak een indicatie dat relatief veel van het eiwit wordt gemaakt.
De cel kan deze activiteit van aflezen en kopie¨ren naar RNA (transcriptie) en
omzetten naar eiwit (translatie) reguleren en hiermee dus bepalen welke enzy-
men op een bepaald moment aanwezig zijn. Door gelijktijdige regulatie van
honderden of zelfs duizenden genen bepaalt een cel welke metabole reacties en
paden beschikbaar zijn.
Veel van de reacties en metabolieten in onze cellen en die van veel andere
organismen zijn bekend. De enzymen die deze reacties catalyseren, evenals de
genen die betrokken zijn bij de productie van deze enzymen zijn ook bekend.
We kunnen metabolisme daarom modelleren als een groot netwerk van metabo-
lieten die de input of output zijn van verscheidene metabole reacties. Van deze
reacties modelleren we welke enzymen de reactie catalyseren en tenslotte welke
genen verantwoordelijk zijn voor het maken van deze enzymen. Zo’n netwerk
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model is handig voor de visualisatie van metabolisme, maar vooral omdat er uit-
gebreide wiskundige technieken en methoden beschikbaar zijn om netwerken te
analyseren. Een voorbeeld is om te kijken welke metabole paden niet beschik-
baar zijn, omdat de onderliggende enzymen niet actief zijn. Een andere veel-
gebruikte toepassing is het berekenen van de maximale celgroei gegeven de
beschikbare voedingstoffen.
Reactiesnelheden (ook wel metabole flux genoemd) en de concentraties van
metabolieten en eiwitten worden bepaald door vele factoren, kunnen zeer snel
veranderen en verschillen vaak tussen organismen. Het meten van al deze fac-
toren is op dit moment vrijwel onmogelijk wanneer alle reacties en moleculen
die betrokken zijn bij het metabolisme worden beschouwd. Een veelgebruikt
alternatief is de metabole capaciteiten van een cel te bepalen door haar fysieke,
biochemische en genetische beperkingen in acht te nemen. Voorbeelden hiervan
zijn de maximale groeisnelheid van een bacterie wanneer er wel of juist geen
zuurstof aanwezig is, of de reacties die actief moeten zijn om zoveel mogelijk
glucose om te zetten in bioethanol.
Twee soorten beperkingen worden altijd toegepast. Allereerst wordt aange-
nomen dat ieder metaboliet geproduceerd in de cel direct weer wordt omgezet
in een ander metaboliet. In de cel vindt dus geen opslag van metabolieten
plaats. Hoewel deze aanname een versimpeling van de werkelijkheid is kan
die in het algemeen worden toegepast omdat de tijdspanne waarop metabole
reacties plaatsvinden vele malen kleiner is dan die van de processen die het
metabolisme reguleren. De tweede beperking stelt een grens aan de snelheid en
de richting (de reactie zet metaboliet A om in B en niet andersom) waarmee die
kan plaatsvinden. Een aaneenschakeling van reacties (met hun reactiesnelheid)
dat aan deze twee voorwaarden voldoet wordt een geldig(e) fluxpad of fluxdis-
tributie genoemd. Alle geldige fluxpaden samen vormen een ruimte (een soort
doos) en het volume van deze ruimte is een maat voor de metabole capaciteiten
van de cel. Dit volume is echter ook een maat voor onze metabole kennis van de
cel. De metabole capaciteiten van de cel zijn in werkelijkheid vaak kleiner dan in
ons model, alleen weten we niet welke reacties wel of niet plaatsvinden en met
welke snelheid. Wellicht de grootste uitdaging van deze manier van modelleren
is om de capaciteiten van de cel in ons netwerk zo precies mogelijk te definie¨ren,
zonder daarbij de daadwerkelijke capaciteiten te verliezen. We bereiken dit over
het algemeen door voorwaarden of beperkingen in de vorm van extra aannames
of metingen toe te voegen. Een voorbeeld van zo’n aanname is dat metabole
reacties actief zijn wanneer hun enzymen actief. Die enzymen zijn op hun beurt
weer actief als hun coderende genen actief zijn. Het is mogelijk de activiteit van
vele genen gelijktijdig te meten en met de genoemde aannames kan men dan de
onderliggende activiteit van het metabole netwerk afleiden.
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Het eerste deel van dit proefschrift bestaat uit vier hoofdstukken waarin
het metabole netwerk en haar capaciteiten centraal staan. Dit deel begint met
een introductie over de constructie en analyse van modellen in de moleculai-
re biologie, met speciale aandacht voor metabole netwerken. In hoofdstuk 2
wordt een methode beschreven waarin samples worden genomen uit de ruimte
van geldige fluxpaden. Hierboven wordt gesproken over het volume van deze
ruimte, maar dat woord verwijst eigenlijk naar objecten met drie dimensies.
De ruimte van geldige fluxpaden heeft vaak honderden dimensies, zelfs voor
een relatief eenvoudig organisme zoals bakkersgist. Efficie¨nt een groot aantal
samples nemen uit deze gehele ruimte vereist geoptimaliseerde computerpro-
gramma’s. Een belangrijke toepassing van sampelen is om te bepalen welke
fluxpaden waarschijnlijker zijn dan anderen. Hoofdstuk 3 behandelt een me-
thode die fluxpaden vindt die de robuustheid van het metabole netwerk ernstig
verminderen. Robuustheid is zeer belangrijk voor een cel om snel in te kun-
nen spelen op veranderende omstandigheden. Vaak kunnen de fluxpaden die
de robuustheid van de cel aantasten buiten beschouwing worden gelaten, om-
dat deze in werkelijkheid vrijwel nooit gebruikt worden. Ook kan de methode
gebruikt worden om te bepalen welke experimenten de meeste informatie ver-
schaffen over de genoemde ruimte van fluxpaden, opdat deze zoveel mogelijk
verkleind kan worden.
Hoofdstuk 4 gaat over een nieuwe methode om zogenaamde celdood door
synthethische overdosering (CSO) te bepalen aan de hand van het metabole
netwerk. Deze CSO is een combinatie van een sterk verlaagde reactiesnelheid
van reactie A en een verhoogde snelheid van reactie B die dodelijk is voor een
cel. CSO’s vinden een interessante toepassing in de bestrijding van kanker-
cellen, die vaak gekenmerkt worden door sterk verhoogde activiteit in bepaalde
metabole reacties. Men kan deze CSO beschouwen als een vraag- en aanbod
probleem. De levering van bouwstoffen aan de tumor wordt verminderd door
reactie A te blokkeren. Reactie B gebruikt ook de bouwstoffen die A levert
en concurreert dus met de tumor. Door de levering van moleculen door A te
beperken worden deze schaars en een verhoogde activiteit van reactie B zorgt
(nog sterker) dat vrijwel geen moleculen aan de tumor geleverd worden, waar-
door deze cellen sterven. Kankerpatie¨nten met veel van deze CSO bleken zoals
verwacht kleinere tumoren en een langere overlevingstijd te hebben. Methoden
zoals deze kunnen gebruikt worden om snel en goedkoop kansrijke combinaties
van enzymen of genen op te sporen. Ook kan men met behulp van deze metho-
de ook voor andere combinaties van genen of enzymen snel bepalen wat hun
effect is op de berekende tumorgroei.
Het tweede deel van dit proefschrift bestudeert genetische interacties die tot
celdood leiden en combinaties van genen die juist belangrijk zijn voor specifieke
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processen in de cel. Een interessante genetische interactie is de zogenaamde
synthethische lethaliteit (SL). In dit geval leidt de gezamenlijke blokkering van
twee genen of enzymen tot celdood, maar het blokkeren van slechts een van
hen niet. Ook voor SL’s geldt dat er mogelijk interessante toepassingen bestaan
in kankeronderzoek. Omdat veel kankercellen mutaties ondergaan is het mo-
gelijk dat bepaalde genen in de kankercel verloren zijn gegaan (bijvoorbeeld
gen A). Dit gen kan redundant zijn als er een gen B is met een gelijke func-
tie. Het uitschakelen van gen B kan nu de kankercel doden, omdat deze niet
terug kan vallen op gen A. Een normale cel kan dit wel en dit principe maakt
SL’s buitengewoon interessant om tumorcellen heel specifiek te bestrijden. Ons
DNA bevat duizenden genen en het is vrijwel onmogelijk om voor alle com-
binaties experimenteel vast te stellen of ze een SL vormen. Gelukkig zijn er
grote hoeveelheden moleculaire data verzameld van tumor- en gezonde cellen.
Dit maakt het mogelijk om computerprogramma’s te ontwikkelen die kansrijke
combinaties van genen selecteren. Dit screenen van grote hoeveelheden data
om SL combinaties te vinden is het onderwerp van hoofdstuk 5. We proberen
hier twee belangrijke vragen te beantwoorden. Allereerst, welke patronen in de
data kernmerken deze SL’s? Ten tweede, hoe kunnen we deze patronen com-
bineren in een computerprogramma dat geheel automatisch een lijst geeft van
de meest kansrijke combinaties? Het programma op zichzelf kan geen uitsluit-
sel geven over de gevonden combinaties; deze moeten nog getest worden in
het laboratorium. Het voordeel van een goed programma is dat de ‘kansrijke’
SL’s inderdaad veel vaker daadwerkelijk een SL blijken te zijn dan wanneer zo’n
programma niet wordt gebruikt. Hierdoor kan dus veel gerichter onderzoek
worden gedaan, waardoor tijd en kosten bespaard kunnen worden.
Hoofdstuk 6 gaat over het vinden van genen die betrokken zijn bij een
bepaalde celfunctie. Men kan hierbij denken aan genen die geassocieerd worden
met een bepaalde ziekte, maar ook aan genen die belangrijk zijn voor reguliere
celfuncties. Voor veel functies en ziektes is een deel van deze genen bekend,
maar voor lang niet allemaal, of het is niet bekend of deze set compleet is.
Kunnen we de genen die reeds bekend zijn gebruiken om andere genen, die
mogelijk ook betrokken zijn bij de celfunctie of ziekte op te sporen? Wederom
kunnen we de grote hoeveelheid genetische data gebruiken. In het bijzonder
kijken we hier naar genexpressie; informatie over de mate waarin genen actief
zijn. Genen die betrokken zijn bij een gezamenlijke functie komen vaak gelijk-
tijdig tot expressie (co-expressie). Deze processen zijn echter celtype specifiek.
Processen die zich in hersencellen afspelen, vinden vaak niet plaats in hartcellen
en genen die betrokken zijn bij borstkanker zijn wellicht totaal niet betrokken
bij longkanker. Het is daarom belangrijk dat de gen-expressie data die men ge-
bruikt om co-expressie te bepalen zo goed mogelijk matchen met het celtype
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en het proces waarin men geı¨nteresseerd is. Het is vrijwel onmogelijk om dit
handmatig te matchen voor honderden datasets en duizenden mogelijke pro-
cessen waarin men geı¨nteresseerd kan zijn. In dit hoofdstuk wordt een methode
beschreven die automatisch goed matchende datasets zwaarder weegt en op die
manier vaak meer relevante resultaten oplevert.
Onze cellen (en die van ieder ander complex organisme) bevatten grote hoe-
veelheden genen, eiwitten en heel veel andere componenten die op een com-
plexe manier interacteren in de tijd en ruimte. Met moderne technieken kunnen
duizenden genen, eiwitten of andere componenten gelijktijdig gemeten worden
in een enkel experiment. Zulke experimenten worden vaak herhaald voor ver-
schillende celtypen of op verschillende tijdstippen om de ontwikkeling van de
cel te volgen. Men kan zich de enorme hoeveelheid data voorstellen die hierbij
gegenereerd wordt. Bioinformatica en het modelleren van biologische systemen
zijn belangrijk om een beter begrip te krijgen van de cel en haar functie. Jaarlijks
worden er nieuwe en verbeterde technieken geı¨ntroduceerd die ons een stapje
verder brengen in het begrip van de complexiteit van de cel. Computermodellen
die deze complexiteit kunnen nabootsen en de consequenties van veranderingen
of experimentele ingrepen correct voorspellen zijn zeer belangrijk voor een beter
begrip van gezonde en zieke cellen. Dit brengt nieuwe uitdagingen en mogelijk-
heden met zich mee, die kort in het concluderende hoofdstuk aan bod komen.
Bioinformatica en systeembiologie hebben een belangrijke bijdrage geleverd aan
de moleculaire biologie en zullen dit blijven doen in de toekomst.
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suggestions during my pleasant stay.
Moleculaire Biologie
Op dit moment werk ik met veel plezier als postdoc op de afdeling moleculaire
biologie. De woorden ‘post’ en ‘doc’ laten zich natuurlijk wat moeilijk verenigen
met het feit dat ik nu het dankwoord van mijn proefschrift schrijf. Omdat het
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